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Chronic obstructive pulmonary disease (COPD) is a common reason for seeking medi-
cal care; it is a disabling chronic disease which affects 210 million people worldwide.1 
According to the Global Burden of Disease Study, COPD was the third leading cause of 
death in 2010.2 Prevalence estimates show considerable variability across populations, 
suggesting that risk factors can affect populations differently.3 In 2011, there were 
360.000 patients with a diagnosis of COPD in the Netherlands.4 Unfortunately, COPD is 
largely underdiagnosed worldwide independent of overall prevalence, with a propor-
tion of underdiagnosis ranging from 72% in Spain to 93% in Montevideo (Uruguay) in 
population-based studies.5-9 In the Netherlands, the prevalence of undetected COPD 
was estimated as 29% in patients older than 50 years with persistent cough.10
COPD is a preventable disease: there are primary (smoking cessation, adequate treat-
ment of asthma), secondary (early detection of disease and modification of risk factor 
exposure) and tertiary (prevention of complications) prevention strategies available.3 
Although COPD is not fully reversible, it is a treatable disorder. However, individuals with 
similar smoking and exposure histories vary greatly in severity of symptoms and their 
response to treatment.3;11;12 Frequent comorbidities add to this: depression, osteopenia 
and cardiovascular disease are often seen, making optimal treatment even more com-
plicated.3 In all patients, smoking cessation could prevent further progression of the 
disease.13 Nonetheless, it is discouraging that a substantial percentage of patients with 
moderate to severe COPD continue to smoke, ranging from 36% to 52% in recent large 
clinical trials of patients with moderate to severe COPD.14-19 
People with early or undiagnosed COPD are most likely to encounter the health care 
system in the primary care setting.20 Consequently, accurate knowledge of diagnosis 
and the prevalence of COPD in this setting are critical to planning and implementing 
strategies for the management of the disease.20 A recent study in Canada concluded one 
of every five adults over 40 years who visited a general practitioner for any reason in com-
bination with a smoking history of at least 20 pack-years, met the spirometric criteria of 
COPD.20 Although more than three-quarters of the patients with COPD reported at least 
one respiratory symptom, two-thirds were unaware of their diagnosis.20 Furthermore, 
once diagnosed, patients greatly underestimate the severity of their disease, as they 
often regard their disease as mild to moderate while suffering from relatively severe 
dyspnoea and disability.
As a consequence of underreported symptoms, disappointing effects of medical 
treatment and a lack of knowledge about the (heterogeneity of the) disease, doctors 
found themselves in a somewhat frustrating position.21 They have to recognize COPD 
treatment is not about cure rather than optimal care for patients, which mainly consists 
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of improving one’s quality of life, daily functioning and provide patients with essential 
tools to learn to live with the disease. 
So, from these perspectives, what is optimal management for COPD patients? The stud-
ies presented in this thesis explore optimal COPD care, as well as the potential role of 
integrated disease management for COPD patients, specifically in primary care. 
OPTIMAL MEDICAL TREATMENT
Firstly, when it comes to medical treatment for COPD patients, the evidence published 
in guidelines is a reflection of large pharmaceutically sponsored trial results, aimed at 
evaluating the effect of inhalation medication therapies.22;23 These trials, usually de-
signed (often by the industry) to maximize significant effects, applied strict inclusion 
criteria for patients. Often, only those patients were eligible who fulfilled the criterion of 
severe lung function loss, a high exacerbation rate and possessed both time and motiva-
tion to participate in a trial. Patients with comorbidities are excluded from these studies. 
Pharmaceutical companies sometimes generalize the results of their studies to all COPD 
patients, but do the results hold true for less severe patients in primary care? Which 
part of our primary care population would actually be eligible for inclusion in such a 
trial? In Chapter 2, we investigate the external validity of the company sponsored COPD 
trials published in the last decade, by using a large combined international primary care 
dataset, comparing patient characteristics of primary care patients to patients included 
in trials.
PULMONARY REHABILITATION
Besides smoking cessation, the most effective treatment for COPD patients is pulmo-
nary rehabilitation (PR), which is a comprehensive intervention based on a thorough 
patient assessment followed by patient-tailored therapies including exercise training, 
education, and behaviour change, designed to improve the physical and psychological 
condition and to promote the long-term adherence to health-enhancing behaviours.24 
PR has been proven to be effective in all patients in whom respiratory symptoms cause 
diminished quality of life and a reduced exercise tolerance.25;26 Unfortunately, the use 
of PR is limited worldwide, due to low accessibility and availability27-30, high costs31, and 
lack of motivation of patients to integrate learned skills into daily life after the program 
has been finished.32 
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INTEGRATED DISEASE MANAGEMENT 
In recent years, attention has shifted from questions regarding the effectiveness of PR 
for those who successfully attend and complete a programme, to meeting challenges 
for the delivery of PR to the wider population with COPD, including patients in primary 
care. As a result, there is considerable interest in developing and testing alternative 
models of delivery of PR to improve general health, knowledge of the disease and self-
care.33 Following this interest, the concept of integrated disease management (IDM) was 
introduced in the last decade. For example, if PR programs could be tailored to fit into 
general practice in an integrated disease management model, would it then be possible 
to extend the benefits to a larger part of the population? Would it then be possible to let 
milder, primary care COPD patients benefit of these adapted PR programs? In Chapter 
3, we further elaborate on this hypothesis and focus on key aspects of PR programs 
tailored for primary care, providing a framework for further research on the effective-
ness of such primary care integrated disease management programmes.34 
Currently, there is no consensus on a definition of IDM, although it is usually described 
as a group of coherent, multidisciplinary interventions for chronic diseases.35 The World 
Health Organization defines integrated care as “a concept bringing together inputs, 
delivery, management and organization of services related to diagnosis, treatment, care, 
rehabilitation and health promotion”. There is great overlap in literature on the use of 
terminology of pulmonary rehabilitation, self-management and IDM.36;37 For example, 
some of the extended ‘self-management’ programmes exceed the level of support that 
many comprehensive PR programmes offer.38;39 A model (Figure 1) presented by Wagg 
might offer clarification of the used terms and the underlying relationships between 
self-management, pulmonary rehabilitation and IDM.37 In this model, IDM can be seen as 
the extension of ongoing support after a program has been finished, including different 
elements of care, such as education, action plans, self-management and PR. Moreover, 
although not apparent in this figure, IDM consists usually of other components of care, 
such as dietary interventions, optimal medication, psychosocial support or smoking 
cessation. 
The aim of optimal IDM is to improve quality of life and exercise tolerance, and to pre-
vent exacerbation related hospital admissions. Several systematic reviews have been 
published that evaluated the effectiveness of IDM; however, these were either out-of-
date, assessed not all important clinical outcomes, or were unable to perform meta-
analyses.40-43 Therefore, we systematically and comprehensively evaluate all randomized 
clinical trials between 1990 and 2012 that published the effects of IDM in COPD patients 
on these outcomes, using the rigid systematic approach of the Cochrane collaboration. 
This Cochrane systematic review is described in Chapter 4.
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IDM is delivered in a team setting, in which doctors, nurses, physiotherapists, occupa-
tional therapists, pharmacists, dieticians, social workers and mental health specialists 
can be involved and contribute within their field of expertise. Since ten years, several 
of such community and hospital-based multidisciplinary teams (MDTs) have evolved 
within the UK, mostly on healthcare members’ own initiatives. Currently, there is no re-
search published on the perception and satisfaction of these healthcare providers work-
ing in a team setting for COPD patients. Do they think it is useful, and which patients 
are usually discussed during their meetings? What do they think is the purpose of the 
meetings, and do they have suggestions for improvement? How do they feel outcomes 
of a successful team can be measured? Insight in the perceptions of these experienced 
and well-developed teams is presented in Chapter 5, and can be used to inform other 







































































Figure 1. The spectrum of self-management, pulmonary rehabilitation and integrated disease 
management programmes for COPD (adapted from Wagg44)
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EXACERBATION SELF-MANAGEMENT AND ACTION PLANS
An important aspect of IDM COPD programmes is implementing self-management 
strategies. Self-management is intended to help patients acquire and practice the 
skills they need to carry out medical regimens, to change their health behaviour and to 
provide emotional support, resulting in adjustment of their roles for optimal function 
and control of their disease.45 Self-management suits the concept of integrated and 
collaborative care very well, in which well-informed patients actively participate in the 
decision making processes regarding their chronic disease.46 While doctors are experts 
about diseases, patients are experts about their own lives. Once physicians recognize 
patients as individual self-experts, they can add their medical knowledge to what pa-
tients feel about their own lives to create a tailor-made plan that will help patients to 
achieve personal goals47, for instance recognizing exacerbations at an early stage. None-
theless, the term self-management in the literature is widely used for a whole range of 
different interventions. In general, collaborative care is defined by a patient-physician 
relationship in which physicians and patients make health care decisions together. The 
term self-management refers to the realm of patient education and includes a plan that 
provides patients with problem-solving skills to enhance their lives.46 Bourbeau and 
colleagues were the first to demonstrate beneficial effects of a COPD self-management 
programme in a widely cited Canadian trial.48 This led to numerous attempts to replicate 
these findings worldwide; however, this led to a contradictory body of literature: some 
trials demonstrated reductions in hospital admissions and improvements in quality of 
life49;50, while other trials revealed absence of these effects51-53, or even showed increased 
mortality rates in the self-management group.54 The contrast in findings is further dis-
cussed in Chapter 6, where we focus on the characteristics of both the positive as the 
negative trials. Which factors are associated with success and which with failure? For 
what group of patients is self-management actually successful? 
INTEGRATED DISEASE MANAGEMENT PROGRAMS IN PRIMARY CARE
After addressing these theoretical concepts and the potential of primary care IDM 
programmes, followed by the evidence of IDM and self-management programmes in 
general, the effectiveness of IDM programmes in primary care is further explored in the 
last part of this thesis. 
Firstly, we describe the long term results of a controlled clinical trial and implementation 
study conducted in the Netherlands, which is presented in Chapter 7: Sustained effects 
of integrated COPD management on health status and exercise capacity in primary care 
patients. 
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There is a lack of well-conducted randomized clinical trials evaluating an IDM approach 
delivered in primary care, with a long-term follow-up. Therefore, we conducted  a 
pragmatic cluster randomized trial (the RECODE trial) to evaluate the clinical and cost-
effectiveness of IDM for COPD patients in primary care. This trial was specifically designed 
to allow for subgroup analysis, and therefore we included a large and broad range of 
heterogeneous COPD patients, ranging from mild to very severe patients. We aimed to 
answer the question whether it was possible to define subgroups in the population that 
determine clinical outcomes, such as disease specific quality of life or exacerbations. 
The design and baseline results of this study are described in Chapter 8, and the clinical 
results are described in Chapter 9.
In Chapter 10: General discussion, the components of optimal COPD management are 
further explored and the current state-of-the-art of IDM is summarised, based on the 
thesis chapters and current literature. The implications for practice, based on the results 
presented in this thesis and the recommendations for further research, are proposed in 
this Chapter as well. 
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Primary care and COPD management

Chapter 2
Primary care COPD patients compared with large 
pharmaceutically-sponsored COPD studies: an UNLOCK 
validation study
Annemarije L. Kruis, Björn Ställberg, Rupert C.M. Jones,  Ioanna G. Tsiligianni, 





Guideline recommendations for chronic obstructive pulmonary disease (COPD) are 
based on the results of large pharmaceutically-sponsored COPD studies (LPCS). There is 
a paucity of data on disease characteristics at the primary care level, while the majority 
of COPD patients are treated in primary care. 
Objective
We aimed to evaluate the external validity of six LPCS (ISOLDE, TRISTAN, TORCH, UPLIFT, 
ECLIPSE, POET-COPD) on which current guidelines are based, in relation to primary care 
COPD patients, in order to inform future clinical practice guidelines and trials.
Methods
Baseline data of seven primary care databases (n=3508) from Europe were compared 
to baseline data of the LPCS.  In addition, we examined the proportion of primary care 
patients eligible to participate in the LPCS, based on inclusion criteria.
Results
Overall, patients included in the LPCS were younger (mean difference (MD)-2.4; p=0.03), 
predominantly male (MD 12.4; p=0.1) with worse lung function (FEV1% MD -16.4; 
p<0.01) and worse quality of life scores (SGRQ MD 15.8; p=0.01). There were large differ-
ences in GOLD stage distribution compared to primary care patients. Mean exacerba-
tion rates were higher in LPCS, with an overrepresentation of patients with ≥1 and ≥2 
exacerbations, although results were not statistically significant. Our findings add to the 
literature, as we revealed hitherto unknown GOLD I exacerbation characteristics, show-
ing 34% of mild patients had ≥1 exacerbations per year and 12% had ≥2 exacerbations 
per year. The proportion of primary care patients eligible for inclusion in LPCS ranged 
from 17% (TRISTAN) to 42% (ECLIPSE, UPLIFT). 
Conclusion
Primary care COPD patients stand out from patients enrolled in LPCS in terms of gender, 
lung function, quality of life and exacerbations. More research is needed to determine 
the effect of pharmacological treatment in mild to moderate patients. We encourage 
future guideline makers to involve primary care populations in their recommendations.
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INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is one of the most complex diseases seen 
by respiratory physicians and general practitioners (GPs). Patients suffer from fluctuat-
ing episodes of exacerbations and airway symptoms which are difficult to control and 
may not sufficiently respond to inhalation therapy. 
In the last 30 years, more than 50 (inter)national guidelines on the management of 
COPD have been published worldwide.1 However, despite international dissemination 
and intensive promotion, guidelines are not widely adopted in daily practice.2 Recently, 
two surveys revealed that COPD management by GPs was well below guideline-recom-
mended levels, with many GPs having very limited knowledge of COPD and its manage-
ment.3;4 Furthermore, about 25% of the GPs reported to be unfamiliar with GOLD and 
one-third with ATS/ERS guidelines.4 Overall, non-guideline-informed management was 
a consequence of no availability, no confidence in gauging pharmacologic response, 
or because the GPs considered the guidelines too long, not relevant, or expressed no 
agreement with guidelines.3;4
Recommendations in guidelines are usually based on the strongest category of 
evidence: (meta-analyses of ) randomized clinical trials (RCTs). These RCTs, particularly 
in medication studies, included large and selected COPD populations to ensure that the 
effect of the studied treatment is not concealed by confounding factors.5 Furthermore, 
mild COPD patients are often neglected in these trials, as inclusion criteria are restricted 
to values of predicted forced-expiratory volume in 1 second (FEV1% predicted) below 
70%. Moreover, selected patients are generally those with sufficient motivation and 
time to participate in a trial, and most likely to comply with medication and regular 
appointments. It is questionable whether the results of such RCTs can be extrapolated 
to all patients with COPD.5;6 However, reliable judgments about the external validity of 
RCTs are essential if treatments are to be used correctly in as many patients as possible 
in routine clinical practice.7 Recent GOLD guidelines acknowledge this limited generaliz-
ability in COPD studies and state some considerations related to the results of these 
trials.8
However, there still remains a paucity of data in the literature regarding COPD patient 
characteristics at the primary care level, and therefore it still remains unknown if there 
is overlap in disease characteristics of populations included in large RCT’s compared to 
the population seen in primary care.  For example, exacerbation prevalence data in mild 
COPD patients remains still unknown, and exacerbation prevalence data in the other 
GOLD stages are solely based on the results of large trials.8
To this end, the aim of this study was to evaluate the external validity of six large 
pharmaceutically sponsored COPD studies.9-14 We aimed to provide insight into disease 
characteristics of COPD patients in primary care, in order to inform future guidelines and 
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trialists. A secondary aim was to describe the proportion of primary care COPD patients 




Seven primary care databases from the UK, the Netherlands, Sweden and Greece were 
combined to create an extensive dataset of primary care COPD patients in the UNLOCK 
study.15 All individual datasets included baseline data collected as part of on-going real-
life cohort studies or pragmatic clinical trials in primary care. Inclusion criteria consisted 
of spirometrically validated COPD patients according to GOLD guidelines8; all studies 
applied few/limited or no exclusion criteria. Additional information on the methodology 
of the relevant studies is reported in the references. The UK dataset was a cohort study 
including 375 COPD diagnosed patients gathered to derive and validate a multicom-
ponent assessment tool of COPD severity (the DOSE index); exclusion criteria consisted 
of serious co-morbidity affecting the patient’s ability to take part or to perform spi-
rometry.16 The Netherlands had four primary care datasets: two studies (one controlled 
clinical trial, Bocholtz study; n=15417 and one cluster RCT, RECODE trial (Netherlands 
Trial Register (NTR) number 2268); n=108618] aimed to evaluate the long-term effects of 
a multidisciplinary disease management program on quality of life.  Both these studies 
included COPD patients and had limited exclusion criteria (terminal disease, immobility, 
substance abuse and inability to fill in questionnaires). The third dataset included 51 
COPD diagnosed patients with a smoking history of > 10 years enrolled in a pilot for a 
RCT (The MARCH study; NTR number 2643) assessing the effect of health status guided 
care compared to GOLD guideline guided care in the primary care setting.19 Exclusion 
criteria were patients with a myocardial infarction < 3 months ago, history of asthma/al-
lergic rhinitis before age 40 years, oxygen use, dementia, or unstable or life-threatening 
comorbid condition. The fourth dataset comprised 1736 patients who were diagnosed 
and followed-up by the Asthma/COPD service in the Netherlands. This consultation 
service (including medical history, health status, lung function test and inhalation 
technique evaluation) is used by GPs for patients with (a suspicion of ) asthma or COPD. 
For this latter study, only COPD patients were included and no exclusion criteria were 
applied. The Greek cohort study was designed to explore issues on quality of life, physi-
cal activity and dyspnea and included 109 primary care COPD patients with a smoking 
history of > 10 years; exclusion criteria were history of asthma, unstable cardiovascular 
disease, or any other respiratory disease other than COPD.20 The dataset from Sweden 
The external validity of large COPD studies 27
included a cohort study (PRAXIS-study) of 775 primary care COPD patients aged 45-75 
years, randomly selected from the medical records of 56 primary healthcare centres; 
there were no exclusion criteria.21;22
Ethical approval
The UK dataset was obtained with the aim to collect anonymised data on COPD patients. 
The South West Multicentre Research Ethics Committee confirmed that as a service 
evaluation, formal research ethics approval was not required for the audit. Patients were 
informed about the study and confidentiality issues. Patient consent was obtained to 
collect and analyse the data using an electronic consent form approved by the NHS 
information security and registration authority.16 In the Dutch Bocholtz clinical trial, the 
regional Medical Ethics Committee of the Atrium Medical Centre, Heerlen, approved the 
study protocol. All patients gave written informed consent.17 The Medical Ethics Com-
mittee of the Leiden University Medical Centre approved the Dutch RECODE trial, and 
all patients gave written informed consent.18 Data from the Bocholtz and RECODE study 
is hosted at the department of Public Health and Primary Care at the Leiden University 
Medical Centre. The MARCH study was approved by the Medical Ethical Committee of 
the University Medical Centre Groningen, and data is hosted at the University Medical 
Centre Groningen. All patients gave written informed consent.19 The fourth Dutch study 
consisted of observational, anonymised data from the large Asthma/COPD service in the 
Netherlands. The privacy regulation of the study was registered at the Dutch Data Pro-
tection Authority. According to current Dutch legislation, neither informed consent nor 
approval is required from a medical ethics committee for observational studies using 
anonymised data records.23 The Greek study was approved by the local medical ethics 
committee of the University Hospital of Heraklion, Crete, Greece and all patients gave 
written informed consent. The data is hosted at the department of Thoracic Medicine in 
the University Hospital of Heraklion, Crete, Greece.20 The Swedish study was approved 
by the Regional Ethical Review Board of Uppsala University, Uppsala, Sweden (Dnr 
2004:M-445, Dnr 2010/090 and Dnr 2012/252). Written consent to use the information 
for future analysis was obtained for all participating patients in 2005. The data is hosted 
in the University of Uppsala, Sweden, at the department of Medical Sciences: Respira-
tory Medicine & Allergology.21;22 The first and last author received all anonymised study 
datasets and combined these in one dataset.  
Large pharmaceutically sponsored COPD studies (LPCS)
We compared the patient characteristics of the UNLOCK datasets with baseline data 
(if available) from six large pharmaceutically sponsored COPD studies (hereafter called 
the LPCS). These studies were published in the year 2000 or later: the ISOLDE9;24;25, 
TRISTAN10, TORCH11;26-29, UPLIFT12;30, ECLIPSE13;31;32 and POET-COPD14 studies. In addition 
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to five large trials, we decided to include the ECLIPSE cohort study as well, because this 
is an important observational study often cited in guidelines, especially with regard to 
exacerbation frequency patterns. 
Outcomes
Measurements
Measurements included age, gender, smoking status, pack years, body mass index (BMI), 
lung function, dyspnea, health-related quality of life, and exacerbations. For smoking 
status, participants were categorized as never, ex- and current smokers and, if available, 
the number of pack years was calculated. BMI was calculated using (weight (kg)/(height 
(m))2. In all patients, spirometry was performed according to international guidelines.8 
We grouped patients into GOLD stage categories based on their post-bronchodilator 
FEV1% predicted as follows: stage I corresponds to post-bronchodilator FEV1 ≥ 80% 
predicted, stage II to post-bronchodilator FEV1 50% to < 80% predicted, stage III cor-
responds to 30% to <50% predicted, and stage IV corresponds to ≤ 30% predicted.8
Definition of exacerbations
The definition of exacerbation used in the UNLOCK, ISOLDE9, TRISTAN10, TORCH29 and 
ECLIPSE32 studies was based on worsening of symptoms and the decision by a patient’s 
clinician (or by study personnel) to prescribe antibiotics or systemic corticosteroids, 
alone or in combination. In the UPLIFT30 and POET-COPD14 studies, an exacerbation was 
defined as an increase in or the onset of more than one respiratory symptom (cough, 
sputum, sputum purulence, wheezing, or dyspnea) lasting 3 days or more and requiring 
treatment with an antibiotic or a systemic corticosteroid. The mean exacerbation rate 
per person per year was calculated and subsequently distributed per GOLD stage.  We 
also calculated the proportion of patients with at least one or two exacerbations per 
year and compared these to baseline values of the LPCS. If baseline data were missing, 
we contacted the authors of the studies to request more information. When we received 
no response or baseline data was not available, we used placebo-limb data of the LPCS. 
Additionally, we used recent data of the GOLD 2013 guidelines8, in which reference 
values of exacerbation rates distributed per GOLD stage are stated. 
Dyspnea and health-related quality of life questionnaires
Dyspnea was measured with the Medical Research Council (MRC) dyspnea score.33 We 
used the St Georges Respiratory Questionnaire (SGRQ) which is designed to measure 
health- related quality of life in patients with asthma and COPD.34 The Clinical COPD 
Questionnaire (CCQ) was also used: this is a disease-specific 10-item questionnaire that 
calculates an overall score and three domain scores: symptoms, functional state and 
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emotional state; patients are required to respond to each item on a 7-point scale with 0 
representing the best possible score and 6 representing the worst possible score.35
Data acquisition
Data on age, gender, lung function and GOLD stage were available for all patients. The 
UNLOCK datasets had additional data on the following subsets: current smoke status 
(98%), CCQ (98%), number of exacerbations (79%), BMI (61%), MRC dyspnea score (41%), 
SGRQ (32%) and pack years (25%). Mean exacerbation rates in the UNLOCK study were 
calculated using the number of exacerbations per patient in the year prior to inclusion 
in the study, divided by the total number of patients in the dataset, which provided data 
on the number of exacerbations.
Data analysis
All analyses were performed with SPSS software, version 21. There were seven UNLOCK 
datasets. We calculated proportions for frequencies, and means for continuous variables, 
for every individual UNLOCK dataset. We used the means of the LPCS reported in the 
original publications as a comparison. Using independent sample t-tests, we tested the 
means of the seven (or less, in case of subsets of data) UNLOCK studies to the means of 
the six LPCS and reported mean differences, 95% confidence intervals (CI) and p-values. 
We performed a sensitivity analysis on primary care patients with GOLD stage II or 
above, in order to compare whether patients enrolled in trials were similar to the more 
severe patients in the primary care setting. 
Furthermore, step-by-step we applied the inclusion criteria of the trials9;10;14;29;30;32 to the 




The UNLOCK datasets included a total of 4286 patients diagnosed with COPD by a GP 
or respiratory physician. After exclusion of patients with missing lung function data 
(N=524; 12%) and a ratio of FEV1/FVC of ≥ 0.7 (N=254; 7%), baseline characteristics of 
the remaining 3508 primary care COPD patients were compared with those of the LPCS. 
Results of baseline characteristics of the individual UNLOCK datasets and the LPCS are 
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Overall means of the UNLOCK and LPCS studies
The overall means of the UNLOCK studies and the LPCS, including the results of the in-
dependent sample t-tests, are reported in Table 2. Compared with the UNLOCK studies, 
the LPCS included a statistically significant (mean difference (MD) -2.4; p=0.03) younger 
population with a higher proportion of males (MD 12.4; p=0.1) and significant lower 
FEV1% predicted values (MD -16.4; p<0.01) and lower FEV1/FVC values (MD -9.2; p<0.01). 
There were large differences in GOLD distribution between the UNLOCK studies and the 
LPCS. There was total absence of GOLD I in the LPCS, whilst in the UNLOCK studies, mild 
and moderate patients (GOLD I and II) comprised 74% of the total COPD population. In the 
LPCS, the proportion of GOLD III patients were more than doubled compared to the UN-
LOCK population (44.5% versus 21%, MD 23.5; p<0.01). In addition, primary care patients 
in the UNLOCK studies had significantly better health-related quality of life (measured with 
the SGRQ) compared with LPCS (MD 15.8; p=0.01). In the TORCH and ECLIPSE studies, the 
proportion of patients with an MRC score >2 was measured, and in ECLIPSE the mean MRC 






Mean difference between 
UNLOCK – LPCS (95% CI)
p-value
Patients (N) 3508 23860
Age, years 66.1 (2.3) 63.7 (0.9) -2.4 (-4.6 — -0.3) 0.03*
Male, % 60.9 (16.7) 73.3 (4.1) 12.4 (-3.1—27.9) 0.1
Current smokers, % 42.9 (9.5) 40.7 (8.6) -2.2 (-13.2—8.8) 0.67
Pack years 43.6 (13.5) 44.9 (4.03) 1.3 (-15.2—17.8) 0.84
BMI, kg/m2 26.3 (0.5) 25.6 (0.9) -0.7 (-2 —0.6) 0.23
Postbronchodilator FEV1, % predicted 63.8 (8.7) 47.4 (2.4) -16.4 (-24—-8.2) <0.01*
FEV1:FVC, % 55.7 (0.7) 46.5 (4.0) -9.2 (-14.1 —-4.2) <0.01*
GOLD distribution  
Mild GOLD I 20.7 (13.2) - - -
Moderate GOLD II 53.3 (6.2) 45 (6.3) -8.3 (-16.6—0.1) 0.05
Severe GOLD III 21 (10.1) 44.5 (3.1) 23.5 (13.9—33.1) <0.01*
Very severe GOLD IV 5.8 (5.2) 11.5 (3.5) 5.7 (-0.71—12) 0.08
Patient-reported outcomes  
SGRQ 32.6 (6.2) 48.4 (1.9) 15.8 (6.3—25.4) 0.01*
CCQ (mean) 1.6 (0.3) - - -
MRC (mean) 2.1 (0.8) 2.7 (1.1) 0.6 (-1.5—2.7) 0.5
MRC score > 2 (%) 32.3 (17) 51.5 (2.1) 19.2 (1.3—37) 0.04*
Data are overall mean values (SD), in which every dataset or study contributed equally to the overall means. “-“ indicates 
data not available. 95% CI: 95% confidence interval. Abbreviations: BMI: body mass index; FEV1: forced expiratory volume 
in 1 second; GOLD: Global initiative for chronic Obstructive Lung Disease; SGRQ: St Georges Respiratory Questionnaire; 
CCQ: Clinical COPD Questionnaire; MRC: Medical Research Counsil 
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scores were reported as well. Overall mean MRC scores were similar in the UNLOCK studies 
compared to ECLIPSE: 2.1 (0.8) and 2.7 (1.1), respectively. However, overall 51.5% of the 
patients in the ECLIPSE and TORCH studies had an MRC score >2, meaning walking slower 
than most people on the level, whereas in the UNLOCK studies this overall proportion was 
32.3%, this mean difference was statistically significant (p=0.04). 
Exacerbation data
Individual datasets
UNLOCK studies reporting exacerbation data were compared with baseline data of the 
ISOLDE, TRISTAN, TORCH, UPLIFT and ECLIPSE studies (Table 3). There was heterogeneity 
between UNLOCK studies, with studies from the Netherlands reporting lower exacerba-
tion rates compared to the UK study. 
Overall means of the UNLOCK and LPCS studies
The UNLOCK studies reported a lower mean exacerbation rate per year compared to the 
LPCS (MD 0.3; p=0.31), as well as a lower proportion of patients with ≥ 1 (MD 15; p=0.21) 
or ≥ 2 exacerbations (MD 8; p=0.24); Table 4. 
Table 3. Exacerbation data of the UNLOCK studies, compared with exacerbation data of the large 



















Patients (N) 86 375 1665 902 370 * 361 * 6112 5992 2138
Mean exacerbation 
rate p/year
1.05 (1.3) 1.32 (1.6) 0.72 (1.1) 0.54 (1.19) 1.90 
(2.63)*
1.30 * 1.0 (1.3) 0.85 
(0.02)*
0.9 (1.2)
≥1 in preceding 
year, % (n/N)




63* - 57 68* 47
≥2 in preceding 
year, % (n/N)
29 (25/85) 33 (124/374) 19 
(312/1661)
11 (72/636) - - 32 - 29
Data are baseline data and mean values (SD), unless stated otherwise. *indicates data from placebo group; “-“ indicates 
data not available.
Table 4. Mean exacerbation data of the UNLOCK studies, compared with mean exacerbation data of the 










Patients (N) 3028 14973
Mean exacerbation rate p/year 0.9 (3.5) 1.2 (0.4) 0.3 (-0.3—0.9) 0.31
Mean % of patients with ≥1 exacerbation in 
preceding year
44 (14.4) 59 (9) 15 (-12—42) 0.21
Mean % of patients with ≥2 in preceding year 22 (10) 30 (2.1) 8 (-9—25) 0.24
Data are overall mean values (SD), in which every dataset or study contributed equally to the overall means. 95% CI: 95% 
confidence interval















































































































































































































































































































































































































































































































































































































































































































































































































Exacerbation data distributed per GOLD stage
Exacerbation characteristics distributed per GOLD stage are shown in Table 5 (individual 
datasets) and Table 6 (overall means). When the severity of COPD increased (as measured 
with GOLD), the proportion of COPD patients with at least one or two exacerbations also 
increased, the exception being patients in GOLD stage IV in UNLOCK patients, which had 
a lower proportion compared to GOLD III on all these variables. Furthermore, differences 
between GOLD stages in patients with ≥ 1 or ≥ 2 exacerbation in the UNLOCK studies 
were not as high as reported in the LPCS (Table 6). 
Sensitivity analysis
We performed a sensitivity analysis on the UNLOCK datasets including only patients 
with GOLD stage II or above, in order to compare whether patients enrolled in the trials 
are similar to the more severe patients in primary care. There was no difference between 
the sensitivity analysis (Supporting Information Table 1) and Tables 2 and 4. 
Table 6. Exacerbation characteristics distributed per GOLD stages: means of the large COPD studies, 









Patients (N) 3028 14973
≥1 exacerbations p/year distributed per GOLD stage
GOLD I, % (n/N) 34.3 (11.7) - -
GOLD II, % (n/N) 43 (14.1) 58.3 (17) 15.3 (-18.6—49.2) 0.28
GOLD III, % (n/N) 58.3 (17.5) 69 (16.1) 10.7 (-22.8—44.3) 0.33
GOLD IV, % (n/N) 54.3 (14.1) 71.7 (11.2) 17.4 (-7.3—42.1) 0.13
≥2 exacerbations p/y distributed per GOLD stage
GOLD I, % (n/N) 12 (2.0) - -
GOLD II, % (n/N) 21.3 (9.6) 22 15.3 (-18.6—49.2) 0.28
GOLD III, % (n/N) 32 (13.9) 33 10.7 (-22.8—44.3) 0.33
GOLD IV, % (n/N) 27.8 (9.7) 47 17.4 (-7.3—42.1) 0.13
Exacerbation rate distributed per GOLD stage
GOLD I 0.55 (1) - -
GOLD II 0.81 (0.3) 0.84 (1) 0.03 (-0.5—0.5) 0.85
GOLD III 1.25 (0.4) 1.27 (0.4) 0.02 (-0.7—0.7) 0.95
GOLD IV 1.13 (0.5) 1.55 (0.4) 0.42 (-0.32—1.16) 0.22
Data are overall mean values (SD), in which every dataset or study contributed equally to the overall means. “-“ indicates 
data not available. 95%CI : 95% confidence interval. Abbreviations: GOLD: Global initiative for chronic Obstructive Lung 
Disease
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Selection for large COPD studies 
The proportion of patients from primary care that would be eligible to be included in the 
LPCS ranged from 17% (TRISTAN trial) to 42% (ECLIPSE and UPLIFT study) (Table 7). The 
LPCS inclusion criteria of at least one exacerbation in the preceding year and an FEV1 of 
< 60% predicted, excluded the largest proportion of primary care patients, as only 44% 
(≥ 1 exacerbation in previous year) and 39.3% (FEV1≤ 60% predicted) of the patients, 
respectively, fulfilled these criteria.  
Table 7. Percentage of patients remaining after introduction of different selection criteria used in six large 
COPD studies
Inclusion criteria ISOLDE 2000 TRISTAN 2003 TORCH 2007 UPLIFT 2008 ECLIPSE 2010 POET-COPD 
2011
Age 40-75 years - 40-80 years ≥ 40 years 40-75 years ≥ 40 years
% of patients in 
primary care
77.2 89.9 99.7 77.2 99.7
FER ≤ 70% ≤ 70% ≤ 70% ≤ 70% ≤ 70% ≤  70%
% of patients in 
primary care
93.2 93.2 93.2 93.2 93.2 93.2
FEV1 < 85% 25-70% < 60% ≤ 70% < 80% ≤ 70%
% of patients in 
primary care
83.4 57.9 39.3 59.3 76.5 59.3
Reversibility ≤ 10% ≤ 10% ≤ 10% - - -












% of patients in 
primary care
82.3 82.3 82.3 82.3
Pack years - ≥ 10 pack years ≥ 10 pack 
years
≥ 10 pack 
years
≥ 10 pack 
years
≥ 10 pack years
% of patients in 
primary care
93 93 93 93 93
Exacerbation - ≥ 1 exacerbation 
in previous year
- - - ≥ 1 exacerbation 
in previous year
% of patients in 
primary care
44 44
Total % of patients 
in primary care
39 17 20 42 42 23
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DISCUSSION
This is the first study using a large international COPD primary care dataset from Europe 
to compare disease characteristics of primary care COPD patients with disease charac-
teristics of COPD populations included in large pharmaceutically-sponsored COPD stud-
ies (the LPCS). We demonstrated there were clear differences in gender, age, distribution 
of GOLD stages, quality of life scores and exacerbation characteristics between COPD 
patients seen in primary care and included in the LPCS. As a result, the majority (58-83%) 
of COPD patients in primary care would not serve as a candidate for inclusion in these 
LPCS. 
The present study provides insight into the disease characteristics of COPD in primary 
care, including the milder affected patients. According to GOLD guidelines8, prevalence 
data on exacerbation rates in GOLD I were currently lacking in literature, whereas data 
on GOLD II-IV stages were based on selected COPD populations of the LPCS and were not 
validated in primary care. In the ECLIPSE study, Hurst et al. showed that the best predic-
tor of exacerbations (across all GOLD stages) was an exacerbation history.13 Interestingly, 
we determined that 12% of GOLD I patients in primary care were frequent exacerbators 
(≥ 2 exacerbations per year).  Furthermore, we demonstrated 34% of GOLD I patients ex-
acerbated at least once yearly. Since moderate COPD is more prevalent than very severe 
COPD, the overall burden of exacerbations in terms of FEV1 decline, and the costs may 
be greater with milder disease.13 On the other hand, physicians should be aware that the 
majority of mild COPD patients are often symptom free and often remain undiagnosed, 
as earlier demonstrated in the international BOLD and PLATINO studies.36;37 It could be 
important to intervene at an early stage of the disease38, but pharmacological interven-
tion should in general be reserved for symptomatic patients or frequent exacerbators, 
whilst asymptomatic GOLD I patients can be offered non-pharmacological strategies, 
such as smoking cessation, aimed at preventing further worsening of the disease. 
Interestingly, we demonstrated the majority of COPD patients in primary care would 
not serve as a candidate for inclusion in large pharmaceutically sponsored studies. As a 
result, primary care physicians are left to treat patients based on results derived from tri-
als that their patients would not have been eligible to join. The economic impact of this 
low external validity potentially leads to considerable avoidable costs. Over-prescribing 
of inhaled steroids in primary care is described in various countries.16;39-42 One recent 
UK primary care study concluded 38% of patients were over-treated regarding their 
GOLD stage, with considerable potential for harm and a mean extra per patient cost of 
£553.56/year.41 This is in line with results of a Spanish primary care study, in which 18.2% 
of patients received inhalation therapy not meeting criteria for its use as recommended 
in guidelines, which was associated with lower physical health status and higher annual 
costs.42 The revised GOLD 2013 guidelines acknowledge the lack of evidence concern-
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ing anti-inflammatory and bronchodilator medications in patients with GOLD stage I 
and II.8 Subsequent post-hoc analysis of the TORCH trial concluded that a combination 
of salmeterol and fluticasone propionate reduced exacerbations and FEV1 decline in 
patients with a FEV1 of 50-60% predicted.28 However, that study was not specifically 
powered to show differences between GOLD stages and, as inclusion was restricted to 
FEV1 of 60%, many GOLD II patients were not included. Subgroup analysis of UPLIFT 
showed promising results of tiotropium in GOLD II patients on FEV1 decline12, but inclu-
sion was limited to patients with FEV1<70%, leading to incomplete representation of 
GOLD II. More research is needed to determine the effect of inhalation therapies in mild 
to moderate COPD patients, and we strongly encourage guideline makers to base their 
recommendations on primary care studies as well. 
Our population based data reflect the recent tendency towards an increasing preva-
lence of COPD in women, drawing a different picture of the current COPD patient than 
the one represented in the LPCS. In fact, underrepresentation of women in large medical 
trials is not uncommon, resulting in a call in Nature for other journals, funding agencies 
and researchers to give women parity with men.43 As the prevalence of COPD in women 
is rising, we advise future trialists to include not only milder COPD patients, but also 
more female participants, in order to study whether biological differences affect the way 
women respond to medications and therapeutic strategies.
Two studies published in 2005 and 2007 evaluated the external validity in COPD patients 
using smaller datasets.5;6 Although their results are in line with our conclusions, there 
are some important differences. Herland et al. used a population of mixed obstructive 
lung disease and concluded that only 17% of these patients were eligible for inclusion 
in a typical COPD RCT; included COPD patients (n=366) were not classified according to 
GOLD criteria, but were graded using a 10-cm free-graded visual analogue scale which 
had to differentiate between asthma, COPD and mixed obstructive lung disease.5 In the 
study of Travers et al., only 0-9% of COPD patients were eligible for inclusion based on 
the very strict criteria of trials conducted between 1994 and 2003.6 It is likely that in 
more recent years less strict inclusion criteria were used for participation in a trial. 
This study has several limitations that should be addressed. First, the current analysis of 
primary care COPD patients was restricted to seven datasets from four different coun-
tries in Europe; as a consequence, our data will probably not be representative for all 
primary care populations worldwide. Second, as there are differences in COPD patients 
between countries, there was considerable heterogeneity between populations in the 
different databases, with for example patients from the UK having more exacerbations 
per year and worse quality of life scores compared to Dutch patients. Although it would 
be interesting to further evaluate these differences between countries, the present 
study does not allow drawing firm conclusions about these differences. Perhaps this 
study will provide an useful starting point for further validation in a larger, more diverse 
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population of COPD patients across a multitude of different countries. Third, all indi-
vidual datasets included baseline data collected in different designs of studies ranging 
from pragmatic clinical trials to real-life cohort studies. Irrespective of these varying 
designs, all studies had few or no exclusion criteria, making the dataset a reasonably 
representative sample of primary care populations in these countries. Fourth, as data 
were accessed retrospectively from different types of studies, some data were available 
on subsets of outcomes. As a result of heterogeneity and a low number of studies used 
for independent sample t-tests, on some outcomes mean differences were large and 
represented important findings, whilst showing no statistically significance. Therefore, 
the statistical tests performed in this study should be interpreted with caution. However, 
our aim was to provide illustrative findings rather than to be conclusive, and we assumed 
that our findings are based on a representative sample of primary care patients. In addi-
tion, we feel we provided an overall dataset large enough to make reliable comparisons 
with the LPCS, as we evaluated a similar number of included patients. Finally, another 
limitation is that, for comparison purposes, the present study compared primary care 
data to six LPCS. Although many other large COPD studies have been published over the 
years, we chose to evaluate the studies most frequently referred to in the guidelines, and 
published in the last decade. 
CONCLUSION
This study provides an informative insight into COPD patient characteristics in primary 
care. Overall, compared to primary care patients, patients in large pharmaceutically 
sponsored trials were younger, predominantly male with worse lung function and worse 
quality of life scores. Our findings add to the literature, as we revealed hitherto unknown 
GOLD I exacerbation characteristics, showing 34% of mild patients had ≥1 exacerbations 
per year and 12% had ≥ 2 exacerbations per year.  Additionally, the majority of patients 
seen in primary care would not be eligible to be included a large pharmaceutically 
sponsored trial.  Therefore, more research is needed to determine the effect of pharma-
cological treatment in mild to moderate patients. Furthermore, we encourage future 
guideline makers to involve primary care populations in their recommendations as well. 
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Table S1. Sensitivity analysis on UNLOCK patients with GOLD stage II or above; comparison with large 





Mean difference between 
UNLOCK – LPCS (95% CI)
p-value
Patients (N) 3508 23860
Age, years 66.3 (2.3) 63.7 (0.9) -2.6 (-4.8—-0.4) 0.03*
Male, % 59.6 (16.2) 73.3 (4.1) 13.7 (-1.3—28.8) 0.07
Current smokers, % 42.4 (9.1) 40.7 (8.6) -1.7 (4.9—-12.5) 0.73
Pack years 43.6 (13.5) 44.9 (4) 1.3 (-15.2—17.8) 0.84
BMI, kg/m2 26.2 (0.5) 25.6 (0.9) -0.6 (-2—0.7) 0.28
Postbronchodilator FEV1, % predicted 57 (5.4) 47.4 (2.4) -9.6 (-14.8— -4.4) <0.01*
FEV1:FVC, % 53.5 (1.6) 46.5 (4) -7 (-11.9—-2.1) 0.01*
GOLD distribution
Moderate GOLD II 68.7 (12.5) 45 (6.3) -23.7 (-36—11.3) <0.01*
Severe GOLD III 25.6 (44.5) 44.5 (3.1) 18.9 (9.5—28.2) <0.01*
Very severe GOLD IV 6.6 (5) 11.5 (3.5) 4.9 (-1.4—11.1) 0.11
Patient-reported outcomes
SGRQ 35.1 (5.8) 48.4 (1.9) 13.3 (4.5—22.2) 0.02*
CCQ (mean) 1.7 (0.3) -
MRC (mean) 2.1 (0.8) 2.7 0.6 (-1.8—3) 0.54
MRC score > 2 (%) 32.3 (18.9) 51.5 (2.1) 19.2 (-4.11—42.4) 0.09
Exacerbation-related outcomes
Mean exacerbation rate p/yr 1.0 (0.3) 1.2 (0.4) 0.2 (-0.4—0.8) 0.39
≥1 exacerbation in preceding yr 48 (14) 58.8 (9) 10.7 (-10.6—32) 0.25
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ABSTRACT
Chronic obstructive pulmonary disease (COPD) represents a major and progressive 
cause of morbidity and mortality worldwide, resulting in an important financial and 
health burden in coming decades. Pulmonary rehabilitation (PR) has been proven to 
be the most effective treatment in all patients in whom respiratory symptoms are as-
sociated with diminished functional capacity or reduced quality of life. Nevertheless, 
despite wide recommendation and proven efficacy, the use of PR is limited in daily 
practice. Reasons for these include low accessibility and availability, high costs, and lack 
of motivation to continue a healthy life style after treatment. By contrast, it has been 
demonstrated that primary care patients can be reactivated by formulating personal 
targets and designing individualized treatment plans in collaboration with their gen-
eral practitioner or practice nurse. Based on these personal plans and targets, specific 
education must be provided and development of self management skills should be 
actively encouraged. Ideally, elements of pulmonary rehabilitation are tailored into a 
comprehensive primary care integrated disease management program. In that way, the 
benefits of PR can be extended to a substantially larger part of the COPD population, to 
reach even those with milder stages of disease. Favorable long-term effects on exercise 
tolerance and quality of life in a number of studies have  been demonstrated in recent 
years, but broad introduction in the primary care setting still needs further justification 
in the form of a proper (cost) effectiveness analysis.
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BACKGROUND
COPD is a smoke-related disease, characterized by largely irreversible airflow obstruc-
tion. Patients suffer from variable grades of impaired quality of life and the disease is 
often complicated by co-morbidities, making it one of the more complex chronic dis-
eases seen by general practitioners. 
Because of the complexity of the disease, diagnostic problems are common: symptoms 
are not always recognised by patients and health care workers, and patients greatly 
underestimate the severity of their disease.1 Moreover, when diagnosed, patients fre-
quently receive insufficient treatment.2
COPD forms a major cause of chronic morbidity and mortality worldwide and, according 
to the WHO, will be the third leading cause of death in 2030.3 Given the rise in incidence, 
COPD constitutes an important financial and health burden in coming decades. 
The most effective non-pharmacological and pharmacological treatment, besides smok-
ing cessation, is pulmonary rehabilitation (PR), which has been widely recommended.4;5 
PR refers to an integrated, multidisciplinary treatment of COPD, aiming at reducing 
dyspnoea and symptoms. Integrated into the treatment of the patient, PR is designed to 
optimize functional status, increase participation and reduce healthcare costs. Ideally, 
PR programs are individually tailored and designed to promote education and self-
management skills in combination with personal exercise training.4 Beneficial effects 
are well established in severe to very severe patients6, and significant improvements 
in exercise capacity, dyspnoea and health-related quality of life have been reported.7-10 
Nevertheless, despite proven efficacy and wide recommendation4;5;11;12, PR is still not 
available in the vast majority of cases. 
CAPACITY PROBLEMS 
Even though the benefits of PR are widely established, daily use is limited. There are 
several reasons for this. 
First, access is poor and services are frequently unavailable for patients who would 
benefit from PR programs.13 Overall, admission to a program is only considered for a 
small proportion of the COPD population, usually the most severely affected patients. 
A disequilibrium between demand and supply of PR services is the result, and conse-
quently, health care workers are confronted with capacity problems.13 As a striking ex-
ample, it was concluded in a UK survey that only 1% of the COPD population had access 
to a PR program.14 These results are confirmed in a more recent Canadian study, where 
it was found that only 1.2% of the COPD population was able to follow a PR program.15 
Availability of PR programs at hospital settings differs considerably among countries. 
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A survey across North America, Europe and Japan in 1999 indicated that PR programs 
were available at 56% of hospitals in North America and 74% in Europe, but at only 20% 
of hospitals in Tokyo.16
Second, due to its highly specialized setting, PR programs are costly (but cost-effective) 
interventions: each rehabilitation program (maximum of 20 patients) has been calcu-
lated to cost £12.120, equalling approximately €14.280 per patient.17 As a result of these 
high costs, services have often been available for those patients in whom quality of life 
has already deteriorated to a large extent only, and prognosis is dire. 
Generally speaking, it is considered a “last-ditch” effort for patients with only the most 
severe forms of COPD.18 This is in contrast with the American Thoracic Society/European 
Respiratory Society (ATS/ERS) Statement on Pulmonary Rehabilitation and recent GOLD 
Guidelines, that actually recommend PR for all patients in whom respiratory symptoms 
are associated with diminished functional capacity or reduced quality of life.4;19 This 
recommendation is backed up by results of earlier studies, where PR has been proven 
to be effective, regardless of disease severity.20;21 In fact, especially improvements in 
milder stages of disease could slow down disease progression considerably. In addition, 
exercise training on its own, which forms one of the major component of PR, has shown 
improvements in fitness of mild to moderate COPD patients.22
A third problem with PR is the fact that it usually consists of a separate program running 
parallel to standard care. Furthermore, it is only administered during a limited period of 
time. Patients are frequently not motivated to continue a more active and healthy life 
style after returning home, and benefits usually dissolve over time. Ideally, when the 
general practitioner and/or practice nurse would be involved in the PR program, they 
could partake in counteracting this imminent lack of motivation, and could support 
the patient in maintaining physical exercise training on a daily basis. In reality, primary 
physicians are rarely involved in rehabilitative efforts, and as a result, largely unable 
to support program methods or integrate the program into their plans of continuous 
care.23 What is needed for a successful long term effective intervention, accessible for 
all eligible patients in primary care, is to integrate the tools of PR into standard care, as 
was also suggested before by other authors18;23;24, which will likely lead to substantial 
cost reduction. Our case would gain strength when it would no longer be doubted that 
home-based or outreaching PR programs can in fact be as efficacious as more traditional 
inpatient programs, and would be considered an equivalent alternative in less severe 
patients.7;25
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REACTIVATION
In chronic disease conditions, patients not uncommonly express feelings of helpless-
ness, negatively colored thoughts and a diminished belief in a useful and worthwhile 
future. Anxiety and depression appear frequently, and can even occur in mildly affected 
patients.26 Illness perceptions in COPD patients have been proven to influence their 
quality of life: increased attention to symptoms, less positive beliefs about the effects 
and outcomes of illness and strong emotional reactions to the illness have found to be 
associated with lower quality of life scores.27 In the same way, patients with a current 
depression, previous history of alcohol dependency and those who perceive that their 
actions have a low influence over their disease course may have difficulty with learning 
and applying self-management plans.28
In COPD, there is a saddening lack of communication between healthcare providers 
and patients. As a striking example, up to 50% of COPD exacerbations are not reported 
to healthcare providers.29 This troublesome lack of communication could be the result 
of the negative spiral of dyspnoea, deconditioning and social deprivation that COPD 
patients find themselves in.30 Through their daily decisions about taking medication, 
applying self-measurements and performing exercise, people with chronic diseases 
play a central role in determining the course of their disease.31;32 Because suboptimal 
adherence is associated with a significant health and economic burden in patients with 
COPD33, efforts must be aimed at changing an attitude of perceived helplessness into an 
active approach, in order to break through this negative spiral. In other words, acquiring 
and applying self-management skills for an individual patient should be a crucial part of 
our treatment plan.
Ideally, patients and health care providers constitute partners in disease management, 
in order to take better control over daily symptoms and management. In these continu-
ous decision-making processes, a clearly formulated written action plan in combination 
with approachable and committed health care providers can be a helpful and reliable 
instrument. The concept of written action plans is based on their successful application 
in asthma patients, where programs that enable people to adjust their medication dos-
age using a written action plan appear to be more effective than other forms of asthma 
self-management.34 In COPD however, pharmacological treatment is considerably less 
effective than in asthma patients. Nevertheless, it has been demonstrated that action 
plans can be helpful in guiding COPD patients to recognize and react appropriately to 
an exacerbation, even in cases where limited COPD education is provided.35 In practice, 
patients must be trained in adequate symptom recognition and encouraged to state 
individual goals for the coming six months, which should then be put on record. Infor-
mation provided by general practitioners or practice nurses through different stages of 
disease must be directed to these goals and can result in an individualized treatment 
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plan, designed realistically in collaboration with the patient. When written and signed 
by the patient, patients will gain a greater feeling of self-efficacy and increase involve-
ment to achieve these targets. For example, when the personal goal is formulated as 
‘to go biking for 30 minutes every other day’ or ‘play in the park with my grandchildren 
during weekends, without acute hindrance by feelings of breathlessness’, efforts must 
be made to maximize exercise tolerance. If the target is ‘to quit smoking within two 
weeks’, different smoking cessation therapies and behavioral guidance strategies must 
be explored. When goals are chosen that are close to one’s beliefs, needs and personal 
situation, the impact will be greater. 
General practitioners and nurse practitioners have a unique position: they are often 
familiar with the patients’ habitat, are easily involved in one’s family situation and pa-
tients usually report a great trust in their general practitioner. It is essential for partners 
and relatives to be involved as they can offer support in achieving desired prospects in 
future. In keeping goals simple, realistic, relevant for daily life and patient-driven, pa-
tients’ self-efficacy will be supported and, as a result, intrinsic motivation will increase. In 
formulating these relevant and realistic goals, modern techniques such as motivational 
interviewing can be very useful, but require additional training of practice nurses and/or 
other health personnel.36 
Self-management is a ‘hot topic’  in current COPD management, and an increasing num-
ber of healthcare professionals agree that patients suffering of a chronic disease should 
receive support to help them self-manage their disease as effectively as possible.32 A well 
informed patient will be better enabled to make his or her own decisions and can assist 
in maintaining healthy behaviours during different stages and complications when dis-
ease progresses.32 Self-management education has proven to be effective as it increases 
knowledge and enhances self-confidence.37 Furthermore, proper self-management is 
associated with a reduction in COPD-related hospital admissions.38
INTEGRATED DISEASE MANAGEMENT PROGRAMMES IN PRIMARY CARE
At present, the majority of COPD patients present themselves in a primary care setting, 
of which an estimated 80% are suffering from mild to moderate disease (see Table 1). 
The World Health Organisation promotes primary care as the most viable cost-effective 
setting to combat non-communicable diseases on a global scale39, anticipating a sub-
stantial need for chronic disease-management in coming decades. Due to the resulting 
large-scale shift of COPD patients from secondary and tertiary care to primary care, gen-
eral practitioners and practice nurses find themselves at a focal point in the organisation 
of care for COPD patients.
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COPD remains a complex disease to treat. Multidisciplinary collaboration can improve 
diagnosis and management of COPD in primary care.40 To establish a program of inter-
ventions based on individual needs and strengths, sufficient cooperation within several 
disciplines in primary care and collaboration with secondary and tertiary care is neces-
sary.  As a result, a multidisciplinary team should be formed, in which different health 
care workers participate and contribute to the required care in their field of expertise, 
e.g. physiotherapists, general practitioners, pulmonary physicians, dieticians and 
practice nurses. Patients are at a central position and their role in achieving success is 
decisive. An integrated disease management (IDM) program, where the elements of PR 
are integrated into a tailor-made program consisting of self-management, regular exer-
cise and individualized targets, can effectively introduce certain elements of pulmonary 
rehabilitation into the large population that can be reached by primary care (see Figure 
1). Patients are managed in their own home-setting, making the benefits accessible for 
all COPD patients eligible. It is likely that costs will be lower while patients are helped at 
an earlier stage, possibly reducing decline and disease progression in the long term.41
In past few years, we have demonstrated favourable results in applying primary care 
integrated disease management (IDM) programs. In the Picasso Bocholtz study, 150 
primary care patients were followed up for two years during which the intervention 
group received an IDM program and the control group received usual care. The program 
consisted of exacerbation management, physical reactivation, and optimal medication. 
After one year, the results revealed a significant and clinically relevant  improvement of 
quality of life in favour of the IDM group, being strongest in patients with MRC-dyspnoea 
score >2.41 The long-term results of this study are expected soon.
Based on the experiences of this study, the Kroonluchter disease management program 
was initiated in Rotterdam, the Netherlands. In this implementation programme, over 
200 primary care COPD patients have been treated since 2005, aimed at tailored COPD 
Table 1 Current and expected rise in prevalence according to GOLD stage in the Dutch COPD population.
Gold stage Characteristics
Current prevalence and 




28% ® + 120%
II Moderate
FEV1/FVC < 0.7
50% ≤ FEV1 < 80%
54% ® + 27%
III Severe
FEV1/FVC < 0.7
30% ≤ FEV1 < 50%




3% ® + 120%
FEV1: Forced Expiratory Volume in 1 second. FVC: Forced Vital Capacity. 
Modified from:  Smeele IJ, van Weel C, van Schayck CP, van der Molen T, Thoonen B, Schermer T et al. Dutch College of 
General Practitioners Guideline for COPD Diagnosis. Huisarts Wet 2007;50(8):362-79.
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rehabilitation in primary care. Depending on their individual disease burden, patients 
may receive optimization of their medication by their primary care physician, a tailored 
6-month specific training program with a physiotherapist, or medication compliance 
monitoring and repeated inhalation instruction by a pharmacist. Drop out rates are 
very low (12%) and the majority of  participants report perceptible and measurable 
improvements in exercise tolerance after two years follow-up. Furthermore, a strong 
collaboration has developed between primary care providers, patients and secondary 
care.30 These results are consistent with another two-year randomized controlled trial, 
the INTERCOM study, in which patients were included with less advanced airflow ob-
struction but impaired exercise capacity. In this study, the intervention group received 
exercise training, education, nutritional therapy and smoking cessation counselling in a 
community-based, multidisciplinary setting. Quality of life, functional exercise capacity, 
and breathlessness remained significantly favourable in the intervention group versus 
usual care over the entire two-year intervention.42
Despite encouraging results in earlier studies as described above, more research is 
needed. We recommend large pragmatic randomized controlled trials, addressing the 
costs and long-term clinical effectiveness of an IDM program in primary care.
Secondary
care PR**






Figure 1. Estimated yield of patients with potential benefits of pulmonary rehabilitation
PR = pulmonary rehabilitation
* Proportion of potential COPD patients that could benefit from PR in primary care
** Proportion of COPD patients referred to secondary care PR for workup and guidance
*** Proportion of COPD patients referred to intensive tertiary care PR programs.
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CONCLUSION
PR has proven to be the most effective treatment for COPD patients4;5;11;12, but its use 
in daily practice is limited due to low availability and accessibility, high costs and short 
duration of administration.13-17 When a program is provided where the elements of 
PR are integrated into a tailor-made program consisting of proper self-management, 
regular exercise and based on individualized targets, people can be managed in their 
home environment, while primary care providers are more involved and in the position 
to coach this process directly.41 Training in motivational interviewing techniques is a 
prerequisite to actively include personal goals and stimulate the patients’ intrinsic moti-
vation. Our aim should be to make the benefits of PR available to the large population of 
eligible COPD patients, and possibly diminish disease progression in less severe patients 
at an earlier stage. Encouraging results have been published30;41;43, but more research is 
needed in the form of a proper cost-effectiveness analysis.  
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In people with chronic obstructive pulmonary disease (COPD) there is considerable 
variation in symptoms, limitations and well-being, which often complicates medical 
care. To improve quality of life (QoL) and exercise tolerance, while reducing the number 
of exacerbations, a multidisciplinary program including different elements of care is 
needed.
Objectives
To evaluate the effects of integrated disease management (IDM) programs or interven-
tions in people with COPD on health-related QoL, exercise tolerance and number of 
exacerbations.
Search methods
We searched the Cochrane Airways Group Register of trials, CENTRAL, MEDLINE, EMBASE 
and CINAHL for potentially eligible studies (last searched 12 April 2012).
Selection criteria
Randomized controlled trials evaluating IDM programs for COPD compared with con-
trols were included. Included interventions consisted of multidisciplinary (two or more 
health care providers) and multi-treatment (two or more components) IDM programs 
with a duration of at least three months.
Data collection and analysis
Two review authors independently assessed trial quality and extracted data; if required, 
we contacted authors for additional data. We performed meta-analyses using random-
effects modeling. We carried out sensitivity analysis for allocation concealment, blinding 
of outcome assessment, study design and intention-to-treat analysis.
Main results
A total of 26 trials involving 2997 people were included, with a follow-up ranging from 
3 to 24 months. Studies were conducted in 11 different countries. The mean age of the 
included participants was 68 years, 68% were male and the mean forced expiratory 
volume in one second (FEV1)% predicted value was 44.3% (range 28% to 66%). Partici-
pants were treated in all types of healthcare settings: primary (n = 8), secondary (n = 12), 
tertiary care (n = 1), and in both primary and secondary care (n = 5). Overall, the studies 
were of high to moderate methodological quality.
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Compared with controls, IDM showed a statistically and clinically significant improve-
ment in disease-specific QoL on all domains of the Chronic Respiratory Questionnaire 
after 12 months: dyspnea (mean difference (MD) 1.02; 95% confidence interval (CI) 0.67 
to 1.36); fatigue (MD 0.82; 95% CI 0.46 to 1.17); emotional (MD 0.61; 95% CI 0.26 to 0.95) 
and mastery (MD 0.75; 95% CI 0.38 to 1.12). The St. George’s Respiratory Questionnaire 
(SGRQ) for QoL reached the clinically relevant difference of four units only for the im-
pact domain (MD -4.04; 95% CI -5.96 to -2.11, P < 0.0001). IDM showed a significantly 
improved disease-specific QoL on the activity domain of the SGRQ: MD -2.70 (95% CI 
-4.84 to -0.55, P = 0.01). There was no significant difference on the symptom domain 
of the SGRQ: MD -2.39 (95% CI -5.31 to 0.53, P = 0.11). According to the GRADE ap-
proach, quality of evidence on the SGRQ was scored as high quality, and on the CRQ as 
moderate quality evidence. Participants treated with an IDM program had a clinically 
relevant improvement in six-minute walking distance of 43.86 meters compared with 
controls after 12 months (95% CI 21.83 to 65.89; P < 0.001, moderate quality). There 
was a reduction in the number of participants with one or more hospital admissions 
over three to 12 months from 27 per 100 participants in the control group to 20 (95% 
CI 15 to 27) per 100 participants in the IDM group (OR 0.68; 95% CI 0.47 to 0.99, P = 
0.04; number needed to treat = 15). Hospitalization days were significantly lower in the 
IDM group compared with controls after 12 months (MD -3.78 days; 95% CI -5.90 to 
-1.67, P < 0.001). Admissions and hospital days were graded as high quality evidence. No 
adverse effects were reported in the intervention group. No difference between groups 
was found on mortality (OR 0.96; 95%CI 0.52 to 1.74). There was insufficient evidence to 
refute or confirm the long term effectiveness of IDM.
Authors’ conclusions
In these COPD participants, IDM not only improved disease-specific QoL and exercise 
capacity, but also reduced hospital admissions and hospital days per person.
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BACKGROUND
Description of the condition
Chronic obstructive pulmonary disease (COPD) is a heterogeneous, systemic condition 
characterized by restricted airflow which is not fully reversible. It is a major cause of 
morbidity, due to the ageing of the world’s population and the continued use of to-
bacco and exposure to indoor biomass pollution. The prevalence of COPD is expected 
to increase substantially in the coming decades (Lopez 2006; GOLD 2009). According to 
the World Health Organization (WHO), COPD will be the third leading cause of death in 
2020 (Lopez 2006; WHO 2008). Given the rise in prevalence, COPD has important finan-
cial consequences, with high reported direct costs (healthcare resources, medication 
prescriptions) and indirect costs (absence from paid work, consequences of disability) 
(Britton 2003).
Optimal management of COPD is complex, as it is a multi-component disease. Clinical, 
functional and radiological presentation varies greatly from patient to patient, despite 
having a similar degree of airflow limitation (Wedzicha 2000; GOLD 2009; Agusti 2010). 
Evidence suggests that the previous 2007 Global Initiative for Chronic Obstructive Lung 
Disease (GOLD) classification of disease severity, solely based upon the degree of airflow 
limitation, is a poor predictor of other important negative features of COPD (Agusti 
2010; Burgel 2010).
Health-related quality of life (HRQoL) and exercise tolerance may be more important to 
people with COPD than the more traditional measure of lung function. This is because 
COPD has a profound impact on HRQoL and exercise tolerance, even in those with mod-
est airflow limitation (Engstrom 1996). Furthermore, impaired HRQoL (Domingo-Salvany 
2002; Fan 2002; Martinez 2006) and exercise tolerance (Gerardi 1996; Pinto-Plata 2004) 
have been associated with an increased risk of mortality (Cote 2009).
In addition, some people are more prone than others to episodes of acute exacerba-
tions, which are an important cause of morbidity, mortality, hospital admission and 
impaired health status (Seemungal 1998; Wedzicha 2000; Calverley 2003). Although 
exacerbations become more severe and occur more frequently with increased severity 
of COPD, this is not always the case. There is some evidence for a ‘frequent-exacerbation’ 
phenotype (or group of people) that exacerbate more often than would be expected 
given their ‘severity’ as predicted by lung function testing (Hurst 2010).
Episodes of exacerbations are often not reported by patients to health care providers 
(Seemungal 2000). An important reason for patients’ delay in reporting an increase in 
symptoms to their doctor is the fear of being sent to hospital. This passive behavior 
can eventually lead to a respiratory crisis, indeed necessitating urgent referral. In order 
to break through the self reinforcing negative spiral of dyspnoea, deconditioning and 
social deprivation doctors need to collaborate with their patients, with a focus on self 
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management skills: “if symptoms increase, you need to let us know rapidly to prevent 
further worsening” (Chavannes 2008). In viewing COPD as a disease process with a 
clinical, heterogeneous picture of progressive deterioration, an integrated system of 
care could be built on a disease management model. Ideally, it is based on active self 
management to slow down progression of the disease, including daily self care, patient-
physician collaboration and exacerbation management. Information should be tailored 
to the person’s needs, knowledge level and clinical profile and be accessible by the 
patient when they need it most (Tiep 1997; Bourbeau 2013).
Description of the intervention
In the last decade, the concept of integrated disease management (IDM) was introduced 
as a mean of improving quality and efficiency of care. IDM interventions are aimed 
at reducing symptoms and avoiding fragmentation of care, while containing costs. 
Therefore, IDM programs are generally believed to be cost-effective, but the available 
evidence is inconclusive. Several systematic reviews have shown positive results, at least 
for some outcomes of chronic IDM, in people with chronic heart failure (Gonseth 2004; 
Roccaforte 2005), diabetes (Norris 2002; Knight 2005; Pimouguet 2010) and depression 
(Badamgarav 2003; Neumeyer-Gromen 2004).
However, there is no consensus in the literature about the definition of IDM. Several 
definitions have been proposed since the introduction of the concept ‘disease manage-
ment’. In order to facilitate the communication between researchers, policy makers 
and IDM program leaders, Schrijvers proposed a definition, based on earlier reported 
definitions (Care Continuum Alliance; Dellby 1996; Epstein 1996; Ellrodt 1997; Zitter 
1997; Weingarten 2002; Faxon 2004): “Disease management consists of a group of coher-
ent interventions designed to prevent or manage one or more chronic conditions using a 
systematic, multidisciplinary approach and potentially employing multiple treatment 
modalities. The goal of chronic disease management is to identify persons at risk for one 
or more chronic conditions, to promote self-management by patients and to address the 
illness or conditions with maximum clinical outcome, effectiveness and efficiency regardless 
of treatment setting(s) or typical reimbursement patterns” (Schrijvers 2009). In addition, 
Peytremann-Bridevaux and Burnand added more elements, adapting the definition 
as follows: “Chronic disease prevention and management consists of a group of coherent 
interventions, designed to prevent or manage one or more chronic conditions using a com-
munity wide, systematic and structured multidisciplinary approach potentially employing 
multiple treatment modalities. The goal of chronic disease prevention and management is 
to identify persons with one or more chronic conditions, to promote self-management by 
patients and to address the illness or conditions according to disease severity and patient 
needs and based on the best available evidence, maximizing clinical effectiveness and effi-
ciency regardless of treatment setting(s) or typical reimbursement patterns. Routine process 
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and outcome measurements should allow feedback to all those involved, as well as to adapt 
the programme” (Peytremann-Bridevaux 2009).
How the intervention might work
There is great variation in the symptoms, functional limitations and degrees of psycho-
logical well-being of COPD patients, as well as the speed of the progression of COPD 
towards more severe stages (Agusti 2010). This calls for a multi-faceted response, 
including different elements (e.g. smoking cessation, physiotherapeutic reactivation, 
self management, optimal medication adherence) targeted at the patient, professional 
or organizational level. Therefore, IDM programs have been developed to improve ef-
fectiveness and economic efficiency of chronic care delivery (Norris 2003) by combining 
patient-related, professional-directed and organizational interventions (Wagner 2001; 
Lemmens 2009).
Why it is important to do this review
As health-related quality of life, exercise tolerance and number of exacerbations are the 
most important patient-related outcomes in COPD, the focus in this review will be on 
these primary outcomes.
Several systematic reviews have been published that evaluated the effect of IDM in 
COPD patients (Adams 2007; Niesink 2007; Peytremann-Bridevaux 2008; Lemmens 
2009; Steuten 2009). These reviews differ from our review in various ways. Adams’ review 
focused solely on interventions which could be arranged according to the chronic care 
model of Wagner (Wagner 1996; Adams 2007). Furthermore, Adams included studies 
between 1966 and 2005. Since then, several studies focusing on IDM in COPD patients 
have been published. Niesink and colleagues evaluated the quality of life in COPD pa-
tients, but did not report outcomes of exacerbations or exercise tolerance. Furthermore, 
the authors decided not to perform a meta-analysis; reasons for this were not clearly 
described (Niesink 2007). Peytremann-Bridevaux performed a meta-analysis and fo-
cused on quality of life, exacerbations and exercise tolerance. However, they did not take 
into account the differences in study design (randomised controlled trials (RCT) versus 
before/after uncontrolled studies) in their conclusions (Peytremann-Bridevaux 2008). 
Lemmens’ review examined the effectiveness of IDM in a mix of patients with COPD, 
asthma or both (Lemmens 2009). No subgroup analysis was performed for patients with 
COPD. Furthermore, conclusions were drawn irrespective of the study designs (i.e. RCTs, 
controlled clinical trials, quasi-experimental, controlled before and after time studies 
and time series designs; Lemmens 2009). Steuten et al aimed to determine the cost-
effectiveness of COPD programs and the authors did not perform a meta-analysis of 
clinical effects (Steuten 2009).
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Overall, all reviews suggested some beneficial effects on health status. However, firm 
conclusions could not be made regarding the effectiveness of IDM, due to the large 
heterogeneity in the interventions, study populations, outcome measurements and 
methodological quality. The literature searches of the aforementioned reviews for 
relevant RCTs investigating the effectiveness of IDM for patients with COPD were car-
ried out between December 2006 and May 2008. Since then, several studies have been 
published. Furthermore, none of the former published systematic reviews were carried 
out according to the latest methods for conducting a systematic review (Higgins 2011). 
Within the framework of The Cochrane Collaboration, we have systematically and com-
prehensively evaluated the effectiveness of IDM in people with COPD.
OBJECTIVES
To evaluate the effectiveness of IDM programs or interventions in people with COPD on 
health-related quality of life, exercise tolerance and the number of exacerbations.
METHODS
Criteria for considering studies for this review
Types of studies
We included only randomised controlled trials (RCTs) in which IDM programs or inter-
ventions were compared to controls in people with COPD. Cluster-randomized trials 
were also eligible. There were no restrictions regarding the language of the paper.
Types of participants
People with a clinical diagnosis of COPD according to the GOLD criteria were included: 
people having chronic respiratory symptoms (i.e. coughing, sputum or dyspnoea) and 
a limited post-bronchodilator forced expiratory volume in one second (FEV1) to forced 
vital capacity (FVC) ratio of < 0.7. Severity of airflow obstruction was classified using the 
GOLD stages of 2009 (GOLD 2009). All GOLD stages were accepted. Studies including 
participants with other diagnoses than COPD were only eligible if the results of partici-
pants with COPD were available separately. 
Types of interventions
We included studies where the IDM intervention consisted of strategies to improve the 
care for participants with COPD, including organizational, professional, patient-directed 
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and financial interventions. We classified these according to the Cochrane Effective 
Practice and Organization of Care Group (EPOC) taxonomy of interventions (EPOC 
2008), complemented with patient-directed interventions (i.e. self management and 
education). Our definitive checklist consisted of the following components of the IDM 
intervention that could be scored:
1. Education/self management: i.e. education, self-management, personal goals and/
or action plan, exacerbation management
2. Exercise: i.e. (home) exercise training and/or strength and/or endurance training
3. Psychosocial: cognitive behavioral therapy, stress management, other psychological 
assessment and/or treatment
4. Smoking cessation
5. Medication: optimal medication/prescription of medication adherence
6. Nutrition: dietary intervention
7. Follow-up and/or communication: structural follow-up and/or communication, case 
management by nurses, optimal diagnosis
8. Multidisciplinary team: active participation and formation of teams of professional 
caregivers from different disciplines, revision of professional roles, integration of 
services, local team meetings
9. Financial intervention: fees/payment/grants for providing IDM.
As IDM includes different components mentioned above, delivered by different health-
care disciplines, the RCT studies had to include:
1. at least two components of interventions as mentioned above;
2. active involvement of at least two different categories of healthcare providers; and
3. a minimum duration of the IDM intervention of three months.
In all studies, we determined the dominant component of the program.
We compared IDM versus controls (varying from usual care or no treatment to single 
interventions, mono-disciplinary interventions).
Types of outcome measures
Primary outcomes
1. Health-related quality of life (HRQoL), as reported by one of the following question-
naires: a validated disease-specific questionnaire, e.g. Clinical COPD Questionnaire 
(CCQ; van der Molen 2003; Kocks 2006), Chronic Respiratory Questionnaire (CRQ; 
Guyatt 1987), St. George’s Respiratory Questionnaire (SGRQ; Jones 1991; Jones 2005), 
COPD Assessment Test (CAT; Jones 2009) or a generic questionnaire, e.g. Short Form-
36 (SF-36; Ware 1992), Euro Qol-5D (EQ-5D; EuroQol Group 1990)).
2. Maximal or functional exercise capacity, as reported by one of the following out-
comes: the peak capacity measured in the exercise laboratory using an incremental 
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exercise test defined according to the results of timed walk tests e.g. 6- or 12-minute 
walk test (Redelmeier 1997) or shuttle run test (Singh 1992)).
3. Exacerbation-related outcomes, as reported by one of the following: time to first 
exacerbation, number of exacerbations, duration and/or severity, and measured by 
reporting of symptoms, antibiotics or prednisolone prescriptions and/or hospital 
admissions or hospital days related to exacerbations.
Secondary outcomes
Clinical outcomes
1. Dyspnea, as measured by the Medical Research Council (MRC) Dyspnea Scale (Bestall 
1999) or Borg score (Borg 1970).
2. Survival (mortality).
3. Lung function (FEV1, FVC).
4. Depression, as measured by the Hospital Anxiety and Depression Scale (HADS) 
(Zigmond 1983) or the Beck Depression Inventory (BDI) score (Beck 1961).
Process-related outcomes
1. Co-ordination of care, e.g. accessibility of care, participation rate in the disease man-
agement program, satisfaction of health care providers and participants with regard 
to the program, or the extent to which disease management was implemented, from 
the perspective of the patient (PACIC; Glasgow 2005) and the caregiver (Bonomi 
2002).
We evaluated outcomes at the following endpoints: a) short-term (12 months or less); b) 
long-term (longer than 12 months) follow-up, if possible.
Search methods for identification of studies
Electronic searches
We identified trials using the Cochrane Airways Group Register of trials, the Cochrane 
Central Register of Controlled Trials (CENTRAL) in The Cochrane Library, MEDLINE, 
EMBASE and CINAHL. The search was performed without language restrictions, using 
the highly sensitive Cochrane Collaboration search strategy, which aims to identify all 
randomised controlled trials (Lefebvre 2009). We used specific MeSH headings and ad-
ditional keywords to identify all RCTs on IDM in COPD patients. As IDM programs were 
first described in 1990, our search was restricted to publications from 1990 onwards. The 
complete search strategies for the database searches are provided in the appendices 
(MEDLINE Appendix 1; EMBASE Appendix 2; CINAHL Appendix 3; CENTRAL Appendix 
4; Airways Register Appendix 5). The search has been conducted up to April 2012. We 
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ran an update search on 12 April 2013, but the results have not been fully incorporated: 
nine studies have been added as ‘ongoing studies’ and three studies have been added 
as ‘studies awaiting classification’.
Searching other resources
In order to identify all possible studies, we carried out an additional search for system-
atic reviews in the Cochrane Database of Systematic Reviews. We screened reference 
lists of included RCTs and systematic reviews for potential studies for this review. To 
identify ongoing or new studies, we searched databases of ongoing studies, including 
ClinicalTrials.gov and other relevant registers.
Data collection and analysis
Selection of studies
Two review authors (AK and NS) independently assessed the title and abstract of all 
identified citations. We excluded all trials that were not randomised controlled trials or 
in which participants had no diagnosis of COPD. All studies excluded by the first two re-
view authors because of the nature of the intervention were double-checked by a third 
review author (NC). Furthermore, if there was any doubt, we retrieved the full-text article 
and examined it for inclusion eligibility. Disagreements were discussed in a consensus 
meeting.
Data extraction and management
We collected the following information from included studies in our review: 1) the study 
design (i.e. randomisation method, sample size, blinding); 2) participant characteristics 
(i.e. diagnosis COPD according to GOLD criteria, age, sex); 3) interventions (i.e. setting, 
number of professionals involved, elements of IDM program/intervention, frequency 
and duration of intervention); 4) outcome measures and timing of outcome assessment; 
5) results (i.e. loss to follow-up, outcomes). The outcome data were extracted by one 
author (AK) and checked by another (NC) using a standardized data extraction form. In 
case of missing data, we contacted the authors of these studies for additional informa-
tion or clarification.
Assessment of risk of bias in included studies
Two of us (AK and NC) independently assessed risk of bias for each study using the crite-
ria outlined in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 
2011), according to the following items:
1. Allocation sequence generation
2. Concealment of allocation
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3. Blinding of participants and health care providers, in relation to the intervention
4. Blinding of outcome assessment
5. Incomplete outcome data
6. Selective outcome reporting
As cluster-randomized trials were also considered for inclusion, we added the following 
design-related criteria for these types of studies:
1. Recruitment bias (i.e. individuals are recruited after the clusters have been ran-
domised)
2. Baseline imbalance between groups (i.e. the risk of baseline differences can be 
reduced by using stratified or pair-matched randomisation of clusters)
3. Loss of follow-up of clusters (i.e. missing clusters and missing outcomes for individu-
als within clusters may lead to a risk of bias in cluster-randomized trials)
4. Methods of analysis adequate for cluster-randomized controlled trials (i.e. taking 
clustering into account in the analysis) (Higgins 2011)
We judged all items as high, low or unclear risk of bias. We resolved disagreements in a 
consensus meeting. 
Measures of treatment effect
We analyzed the results of the studies using RevMan 5, using random-effects model-
ing. We used forest plots to compare results across trials. The results were related to the 
minimal clinically important difference (MCID).
We expressed the results of each RCT as risk ratios (RR) with corresponding 95% 
confidence intervals (95% CI) for dichotomous data, and mean difference (MD) or 
standardized mean difference (SMD) for continuous data, depending on the similarity 
of outcome measurement scale (i.e. MDs are used when all studies use the same out-
come measurement scale and SMDs when studies use different outcome measurement 
scales). We summarized data in a meta-analysis only if the data are clinically and statisti-
cally sufficiently homogenous. If the meta-analysis led to statistically significant overall 
estimates, we transformed these results (pooled estimate of RR, MD or SMD) back into 
measures which are clinically useful in daily practice. We planned to use the number 
needed to treat for an additional beneficial outcome (NNTB) and the absolute and/or 
relative improvement on the original units in order to report these as the final results of 
the review. 
Unit of analysis issues
In case of a unit of analysis error occurrence in cluster-randomized controlled trials, we 
adjusted for the design effect by reducing the size of the trial to its “effective sample 
size” (Rao 1992). The effective sample size of a single intervention group in a cluster-
randomized trial is its original sample size divided by a quantity called the ‘design effect’. 
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The design effect is 1+ (M-1)* ICC, where M is the average cluster size and ICC is the intra-
cluster correlation coefficient. For dichotomous data, both the number of participants 
and the number experiencing the event were divided by the design effect. For continu-
ous data, only the sample sizes were reduced; means and standard deviations remained 
unchanged (Higgins 2011).
Dealing with missing data
In case of missing data, we planned to contact the authors for additional information 
about the missing data for individuals. We sent a reminder if we did not receive a re-
sponse. Secondly, we planned to assume the missing values to have a poor outcome. 
For continuous outcomes (i.e. health-related quality of life, exercise capacity) and di-
chotomous outcomes (i.e. mortality), we planned to calculate the effect size (SMD, MD, 
RR) based on the number of participants analyzed at the time point. If the number of 
participants analyzed is not reported for each time point, we planned to use the number 
of randomised participants in each group at baseline. We planned to perform sensitivity 
analysis to investigate whether our assumptions have been reasonable (i.e. comparing 
results using number of participants analyzed with number of participants randomised).
Assessment of heterogeneity
We measured clinical and statistical heterogeneity using the I2 statistic (Higgins 2011). A 
P value of less than 0.10 or an I2 value greater than 50% indicates substantial heteroge-
neity. In case of heterogeneity, we assessed studies, if possible, with respect to:
1. control group: a) no treatment; b) treatment with one health care provider; c) treat-
ment with one component; d) other disease management programs (short duration 
of therapies);
2. intervention group, with regard to a) type of health care providers (i.e. general prac-
titioner, lung specialist, physiotherapist, practice nurse); b) different components as 
listed by the EPOC classification (EPOC 2008); c) frequency and duration of interven-
tion.
In case of substantial heterogeneity, we explored the data further, including subgroup 
analyses (see Subgroup analysis and investigation of heterogeneity) in an attempt to 
explain the heterogeneity. 
Assessment of reporting biases
In order to determine whether reporting bias was present, we evaluated whether the 
protocol for the RCT was published before recruitment of patients of the study was 
started. For studies published after 1 July 2005, we screened the Clinical Trial Register 
at the International Clinical Trials Registry Platform of the World Health Organization 
(http://apps.who.int/trialsearch) (De Angelis 2004). For each study, we evaluated wheth-
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er selective reporting of outcomes was present (outcome reporting bias). Furthermore, 
we made a funnel plot to assess the possibility of reporting bias. 
Data synthesis
We pooled results of the studies using the random-effects model. For continuous data, 
we recorded the mean change from baseline to endpoint and standard deviation (SD) 
for each group. For dichotomous data we recorded the number of participants with each 
outcome event and calculated the odds ratio (OR). We used results reported at three 
months, as our predetermined inclusion criteria postulated a program of at least three 
months duration (to ensure sufficient impact). If data at three months were unavailable, 
we analyzed the data measured most closely to this time point. We evaluated outcomes 
at short- (3 to 12 months) and long-term (> 12 months) follow-up.
We presented the main results of the review in a ‘Summary of findings’ table, which 
includes an overall grading of the evidence using the GRADE approach in accordance 
with the recommendations laid out in the Cochrane Handbook for Systematic Reviews 
of Interventions (Higgins 2011). This involves making separate ratings for quality of 
evidence for each patient-important outcome and identifies five factors that can lower 
the quality of evidence, including: study limitations; indirectness of evidence (also called 
clinical heterogeneity with regard to study population, intervention, control group and 
outcomes); unexplained heterogeneity or inconsistency of results (i.e. statistical het-
erogeneity); imprecision of results (i.e. due to small sample sizes and few events); and 
high probability of publication bias. However, other factors can increase the quality of 
evidence, such as large magnitude of effect; plausible confounding, which could reduce 
the demonstrated effect; and dose-response gradient (GRADE Working Group 2004). We 
presented the short- and long-term outcomes for our primary outcomes in the ‘Sum-
mary of findings’ table if possible.
Subgroup analysis and investigation of heterogeneity
In order to explain heterogeneity between the results of the included studies, we 
planned the following subgroup analyses a priori (where data were available) to deter-
mine if outcomes differed among:
1. patients with different severity of disease, according to GOLD stage (GOLD 2009) 
or MRC Dyspnea Scale (Bestall 1999) (e.g. patients with GOLD 1/2 versus GOLD 3/4, 
and/or patients with a MRC score 0 to 2 versus MRC 3 to 5);
2. the setting of the IDM intervention (e.g. primary, secondary or tertiary care);
3. design of the studies (individually randomised patients versus cluster-randomized 
patients (with and without adjusting for design effect));
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4. control group: a) no treatment; b) treatment with one health care provider; c) treat-
ment with one component; d) other disease management interventions (short dura-
tion of therapies);
5. intervention group, with regard to a) type of health care provider (i.e. general prac-
titioner, lung specialist, physiotherapist, practice nurse); b) different components as 
listed by the EPOC classification (EPOC 2008); c) frequency and duration of interven-
tion.
Sensitivity analysis
We carried out sensitivity analyses for the primary outcome measurements, in order to 
explore effect size differences and the robustness of conclusions. We planned sensitivity 
analysis determined a priori based on:
1. studies without study limitations with regard to a) allocation concealment; b) blind-
ing of participants and investigators; c) recruitment bias; d) baseline imbalance 
between groups; e) loss of follow-up of clusters; f ) adequate analysis;
2. method of analysis: a) results of studies using number of patients analyzed; b) stud-
ies using number of patients randomised.
We presented the main results of the review in a ‘Summary of findings’ table, which 
includes an overall grading of the evidence using the GRADE approach (GRADEpro; 
GRADE Working Group 2004) and a summary of the available data on the main out-




See Characteristics of included studies.
Results of the search
Our literature search identified 6700 titles and abstracts, resulting in 4776 references 
after de-duplication. Two review authors (AK, NS) screened the title/abstracts of these 
studies based on the predetermined inclusion criteria. Studies that were excluded be-
cause of the IDM intervention were double-checked by a third review author (NC). We 
retrieved the full-text articles of these studies and they were discussed in a consensus 
meeting. Finally, we identified 49 potentially relevant articles about IDM in COPD pa-
tients. We obtained full-text versions of these papers and data were extracted by one 
review author (AK) and double-checked by a second review author (NC). Finally, a total 
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Figure 1. Study flow diagram
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of 26 (cluster) randomised controlled trials were included in the review. The PRISMA flow 
diagram is presented in Figure 1.
Included studies
Characteristics of the included studies are described in Table 1, Table 2 and Characteris-
tics of included studies.
Twenty-six RCTs met the eligibility criteria for the review, of which two were cluster-
randomized trials (Rea 2004; Wood-Baker 2006). One trial was a cross-over trial (Cam-
bach 1997). The studies were published between 1994 and 2011. Five studies originated 
from the Netherlands (Wijkstra 1994; Strijbos 1996; Cambach 1997; van Wetering 2010; 
Trappenburg 2011), four studies from Spain (Güell 2000; Farrero 2001; Güell 2006; Fer-
nandez 2009), three studies from Australia (Smith 1999; Boxall 2005; Wood-Baker 2006), 
three from the United Kingdom (Littlejohns 1991; Dheda 2004; Sridhar 2008) and three 
from the United States (Aiken 2006; Koff 2009; Rice 2010). Two studies were conducted 
in Denmark (Bendstrup 1997; Gottlieb 2011), two originated from Sweden (Engstrom 
1999; Theander 2009) and one each from Brazil (Mendes 2010), Canada (Bourbeau 2003), 
Japan (Wakabayashi 2011) and New Zealand (Rea 2004).
Participants
A total of 2997 COPD patients were randomised in the 26 studies, with a range of 30 to 
713 patients per study. Of these, 2523 (84%) patients completed the studies (range 18 to 
725). The mean age of the study population was 68 years (SD 3.7), with 68% being male. 
Patients had a mean FEV1 % predicted of 44.3% (range 28 to 66).
Interventions
Patients were treated in all types of healthcare settings: primary care (eight studies), 
secondary care (12 studies), tertiary care (one study) and a combination of primary and 
secondary health care (five studies). The number of health care providers involved in the 
IDM program ranged from two to seven, with a mean number of three. Furthermore, we 
calculated the number of components per program, which ranged from two to eight, 
with a mean number of four.
A priori, we planned to arrange the interventions in order to perform subgroup analysis 
based on type of intervention, according to type of health care providers, different com-
ponents, and frequency and duration of intervention. However, it was not possible to 
determine the mean intensity, frequency or duration of all programs, due to lack of data. 
Furthermore, as the studies were too heterogeneous, it was not possible to arrange pro-
grams according to different combinations of components or combinations of health 
care providers. Therefore, we determined the dominant component of the IDM program 
in all studies. The main component of the intervention could directly be determined in 
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nine studies (Littlejohns 1991; Smith 1999; Farrero 2001; Bourbeau 2003; Dheda 2004; 
Aiken 2006; Wood-Baker 2006; Koff 2009; Trappenburg 2011) from the objective or title 
of the study. For example, in Aiken 2006: “The objective is to document outcomes of a ran-
domised trial of the PhoenixCare demonstration program of palliative care and coordinated 
care/case management for seriously chronically ill individuals who simultaneously received 
active treatment from managed care organizations. Intensive home-based case manage-
ment provided by registered nurse case managers, in coordination with patients’ existing 
source of medical care, comprised the intervention”.
In the remaining 17 studies, the main component was not directly clear from the 
objective. In 15 studies (Wijkstra 1994; Strijbos 1996; Bendstrup 1997; Cambach 1997; 
Engstrom 1999; Güell 2000; Boxall 2005; Güell 2006; Fernandez 2009; Theander 2009; 
Mendes 2010; Rice 2010; van Wetering 2010; Gottlieb 2011; Wakabayashi 2011), we 
chose the main component of the intervention as the component on which most of the 
time of the intervention was spent. For example: Bendstrup 1997: “The intervention pro-
gramme lasted 12 weeks. The programme consisted of the following components. Exercise 
training: the patients trained together at the hospital for 1h, three times a week for 12 weeks. 
Occupational therapy: two lessons each group. Education: 12 sessions. Smoking cessation: 
only for patients wishing to stop smoking.”
In one study (Sridhar 2008) there were two components on which most of the time 
of the intervention was spent (exercise and self management action plan). In another 
study (Rea 2004) there were two main components: self management action plan and 
structured follow-up. Therefore we arranged these two studies as separate categories.
We made the following categories:
1. IDM dominant component exercise (13 studies: Wijkstra 1994; Strijbos 1996; Bend-
strup 1997; Cambach 1997; Engstrom 1999; Güell 2000; Boxall 2005; Güell 2006; 
Fernandez 2009; Theander 2009; Mendes 2010; van Wetering 2010; Gottlieb 2011).
2. IDM dominant component self management with an exacerbation action plan (five 
studies: Bourbeau 2003; Wood-Baker 2006; Koff 2009; Rice 2010; Trappenburg 2011).
3. IDM structured follow-up with nurses/GP (five studies: Littlejohns 1991; Smith 1999; 
Farrero 2001; Dheda 2004; Aiken 2006).
4. IDM exercise and self management action plan (one study: Sridhar 2008).
5. IDM self management action plan and structured follow-up (one study: Rea 2004)
6. IDM program of educational sessions, follow by a phase of individually tailored edu-
cation according to scores on the Lung Information Needs Questionnaire score (one 
study: Wakabayashi 2011).
In two studies, IDM was compared to another IDM intervention and a control group 
(Strijbos 1996; Mendes 2010). Both studies involved two intervention groups including 
an IDM program with a focus on exercise training and one control group. In both stud-
ies, we combined and pooled data from the two intervention arms as one group. One 
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study had a cross-over design with drug treatment after three months (Cambach 1997). 
Therefore, we used solely the data for the intervention and control group at baseline and 
at three months.
Control groups consisted of usual care in 20 studies, in two studies control patients 
received a mono-disciplinary treatment including optimization of drug treatment 
(Cambach 1997; Güell 2006) and in four studies control patients received a treatment 
solely with education (Wood-Baker 2006; Fernandez 2009; Rice 2010; Wakabayashi 
2011). Usual care consisted in all studies of regular follow-up visits to health care provid-
ers, which depended on the type of setting. There was access to health care providers on 
a ‘need to’ basis, without additional treatment or management programs. In all studies, 
no attempts were made to influence this usual care.
Outcomes
We recorded the number of studies reporting a specific outcome as follows:
•	 Quality of life (22 studies)
•	 Exercise capacity (18 studies)
•	 Exacerbation-related outcomes: measured by number of exacerbations; hospital 
admissions; hospitalisation days; emergency department (ED) visits; number of 
prednisolone or antibiotics courses (15 studies)
•	 Lung function (14 studies)
•	 Survival, mortality (five studies)
•	 Depression (four studies)
•	 Dyspnea, measured by MRC Dyspnea score (three studies) or Borg score (three 
studies)
•	 Co-ordination of care (three studies)
Details of the included studies are provided in Characteristics of included studies.
We requested additional data from the authors of 14 studies. Of these, 11 authors re-
sponded (79%) and six (43%) could provide us with additional data. Therefore, it was 
not necessary to impute missing data as described in our research protocol (see Dealing 
with missing data). 
Excluded studies
After the first selection based on abstract and title, 49 potentially eligible studies were 
identified. Finally, after reading the full-text papers, we excluded 23 studies for one of 
the following reasons:
1. not a RCT (n = 1);
2. no diagnosis of COPD or no obtainable results reported for COPD as a subgroup (n = 
2);
3. intervention includes one component of care (n = 3);
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4. intervention includes one health care provider of different disciplines (n = 4);
5. duration of intervention is less than three months (n = 4);
6. active treatment as a control group (n = 9).
Figure 2. ‘Risk of bias’ summary: review authors’ judgments about each risk of bias item for each included 
study.
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The reasons for exclusion are further specified in Characteristics of excluded studies. For 
ongoing studies, refer to Characteristics of ongoing studies.
Risk of bias in included studies
For full details of ‘Risk of bias’ judgments see Characteristics of included studies and for an 
overview see Figure 2.
Allocation
Nineteen studies reported full details of adequate sequence generation and we judged 
them to be of low risk of bias. We judged the remaining seven studies as having un-
clear risk of bias as they were reported as randomised, but gave no description of the 
methods used to conceal the sequence. Fourteen studies reported adequate allocation 
concealment, while we judged four studies as high risk of bias. There were insufficient 
details for the remaining six studies for us to reach a firm conclusion so we judged them 
to be at unclear risk of bias. There were 13 studies in which both the sequence genera-
tion and concealment of allocation were adequately described, thus selection bias was 
minimized in these studies.
Blinding
The nature of the intervention precludes the possibility of blinding patients or health 
care providers. Therefore, we judged all the studies, except Trappenburg 2011, to be at 
high risk of performance bias. Trappenburg 2011 made a good attempt in using a modi-
fied informed consent procedure (postponed information), which meant that patients 
were unaware of the major aim of the study (education and an action plan), thereby en-
abling a single-blind study design (Trappenburg 2011). Therefore, we scored this study 
as low risk of bias. While blinding of health care providers and patients is impossible with 
this type of intervention, outcome assessors could be blinded to participants’ allocation. 
This was reported in nine trials indicating a low risk of bias. Outcome assessors were 
unblinded in seven studies (high risk) and 10 studies provided insufficient information 
(unclear risk).
Incomplete outcome data
We judged 19 out of the 26 studies as low risk of bias, as they had low drop-out rates, 
drop-out rates were balanced across groups or trial authors performed an intention-
to-treat analysis. We rated seven studies as high risk of bias and they were likely to be 
subject to attrition bias. Three out of these seven studies (Dheda 2004; Mendes 2010; 
Gottlieb 2011) had unbalanced drop-out rates, with higher rates in the intervention 
group compared to the control group. One study had a high drop-out rate balanced in 
both groups (31%) and the authors performed no intention-to treat-analysis (Bendstrup 
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1997). Cambach 1997 excluded all patients who did not return for one or more of the as-
sessments from the final analyses. In Farrero 2001, quality of life was only investigated in 
the first 40 consecutive patients, therefore inducing risk of bias. In Smith 1999, all control 
participants refused to fill in the quality of life questionnaire and expressed that the 
burden of participating in a study, including questionnaires, was greater than expected.
Selective reporting
We rated 21 studies as low risk of bias and five studies as high risk of bias. Three stud-
ies (Rice 2010; van Wetering 2010; Trappenburg 2011) published a study protocol, with 
which we could compare the results sections. In the other studies, we checked whether 
the outcomes reported in the methods section of the article were reported in the results 
section. Five studies (Littlejohns 1991; Smith 1999; Bourbeau 2003; Dheda 2004; Got-
tlieb 2011) selectively reported outcomes. In two studies (Bourbeau 2003; Dheda 2004) 
the authors reported no statistically significant difference in the outcome and therefore 
did not present data, indicating selection bias. In the other three studies (Littlejohns 
1991; Smith 1999; Gottlieb 2011), it remained unclear why it was planned to measure an 
outcome but it was not ultimately published.
Other potential sources of bias
We included two cluster-randomized trials (Rea 2004; Wood-Baker 2006). Unfortunately, 
both studies introduced noteworthy biases related to cluster-randomization in differ-
ent ways. In one study (Wood-Baker 2006) recruitment bias remained unclear, as the 
authors provided insufficient information regarding the cluster-randomization process. 
In contrast, we judged Rea 2004 to have low risk of bias, as clusters were randomised 
before patients were recruited. Furthermore, we rated both studies as high risk of bias 
for baseline imbalance between groups, which could have been reduced when stratified 
or if pair-matched randomisation of the clusters had been used instead (Higgins 2011). 
In the Rea 2004 study, there was loss to follow-up of five clusters (four control and one 
intervention cluster), therefore this study was subject to bias. There was no follow-up of 
clusters in Wood-Baker 2006 (low risk of bias). Finally, both studies introduced bias as 
they analyzed data by incorrect statistical methods, not taking the clustering into ac-
count. This may account for the over-precise results and can result in much more weight 
in a meta-analysis (Higgins 2011). Therefore, in our meta-analyses we adjusted for the 
design effect by reducing the size of the trial to its “effective sample size” (Rao 1992). 
Based on similar primary care cluster-randomized trials, we used an intra-class correla-
tion coefficient (ICC) of 0.01 (Kerry 1998; Campbell 2001). For dichotomous data, we 
divided both the number of participants and the number experiencing the event by the 
design effect. For continuous data, we reduced the sample sizes; means and standard 
deviations remained unchanged (Higgins 2011).
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Effects of interventions
See: Summary of findings for the main comparison: Integrated disease management com-
pared to control for patients with chronic obstructive pulmonary disease
In the majority of the outcomes, heterogeneity was not encountered. However, there 
was substantial heterogeneity present in SGRQ total score, six-minute walk distance 
(6MWD), CRQ dyspnoea (long-term), hospital admissions for all causes, hospital days 
and ED visits. If possible, we performed sensitivity and subgroup analysis on these 
outcomes to see if the heterogeneity could be explained. Our a priori determined sub-
group analysis based on type of health care provider and the frequency and duration 
of intervention was impossible, as there was large heterogeneity among combinations 
of health care providers and the exact composition in terms of duration, frequency and 
intensity of programs was often not clearly reported. In addition, we were not able to 
perform subgroup analysis on GOLD stage or MRC Dyspnea score, as most studies did 
not report GOLD stages or MRC Dyspnea score. Furthermore, the definitions and clas-
sifications of GOLD stages have been changed over the years, resulting in large variation 
in severity within subgroups.
Instead, we performed subgroup analysis based on type of setting of the intervention 
(primary, secondary, tertiary care) and type of control group. Furthermore, we performed 
subgroup analysis with regard to the dominant component of the IDM program.
We used unadjusted data for meta-analyses, as only unadjusted data were reported, 
with the exception of two studies (van Wetering 2010; Trappenburg 2011). 
Primary outcomes
1. Quality of life
Of the 26 included studies, 23 measured HRQoL using six different instruments (see 
Characteristics of included studies):
1. St. George’s Respiratory Questionnaire (SGRQ) (13 studies);
2. Chronic Respiratory Questionnaire (CRQ) (eight studies);
3. Short Form-36 (SF-36) (three studies);
4. Sickness Impact Profile (SIP) (two studies);
5. Dartmouth Primary Care Co-operative Quality of Life questionnaire (COOP) (one 
study).
The SGRQ and CRQ are both disease-specific quality of life questionnaires. However, 
a meta-analysis combining CRQ and SGRQ score should not be used as Puhan 2006 
has shown that the CRQ is more responsive than the SGRQ. Furthermore, the included 
generic quality of life questionnaires (SF-36, SIP and COOP) measure other dimensions 
of generic health quality of life, and therefore combining data in a meta-analysis across 
tools was not possible. 
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1.1 Respiratory-specific QoL
1.1.1.1 SGRQ total score - short-term
The SGRQ is a disease-specific, validated questionnaire with a scale from 0 (good health) 
to 100 (worse health status). A negative sign on this questionnaire indicates improve-
ment, and the minimal clinically important difference (MCID) is -4 points (Jones 1991). 
Thirteen studies with a total population of 1425 patients provided data on the SGRQ total 
score with a follow-up of 3 to 12 months (Engstrom 1999; Bourbeau 2003; Dheda 2004; 
Boxall 2005; Wood-Baker 2006; Koff 2009; Fernandez 2009; Theander 2009; Rice 2010; 
van Wetering 2010; Gottlieb 2011; Trappenburg 2011; Wakabayashi 2011). The pooled 
mean difference (MD) on the SGRQ total score was -3.71 in favor of IDM (95% confidence 
interval (CI) of -5.83 to -1.59;  Analysis 1.1; Figure 3;  Summary of findings for the main 
comparison) which reached statistical significance (P < 0.001) and was close to, but did 
not reach, the MCID of -4 points. In other words, those treated with IDM had 3.71 out of 
100 points better quality of life on this questionnaire. Pooling indicated a high degree 
of heterogeneity (I² = 56%, P = 0.01). Heterogeneity was due to differences in the quality 
of studies. We were able to reduce heterogeneity if we performed multiple sensitivity 
analyses based on studies with adequate allocation concealment, adequate blinding 
of outcome assessment, cluster-randomization bias, or studies analyzing outcomes by 
intention-to-treat. Sensitivity analysis on studies with adequate allocation concealment 
(Bourbeau 2003; Boxall 2005; Koff 2009; Theander 2009; van Wetering 2010; Gottlieb 
2011; Trappenburg 2011; Wakabayashi 2011) demonstrated that there was still a statisti-
cally significant effect in favor of the intervention group (MD -3.16; 95% CI -4.75 to -1.57, 
P < 0.001). In the same way, in trials (Engstrom 1999; Bourbeau 2003; van Wetering 2010; 
Rice 2010; Trappenburg 2011; Wakabayashi 2011) with adequate blinding of outcome 
assessment the effect did not change (MD -3.16; 95% CI -4.81 to -1.51, P < 0.001). A 
sensitivity analysis excluding the cluster-randomized study of Wood-Baker 2006, in 
which there was an unclear risk of recruitment bias and a high risk of bias on baseline 
imbalance, the effect changed to a clinically and statistically significant MD in favor of 
IDM (-4.22; 95% CI -6.14 to -2.30, P < 0.001). Lastly, a sensitivity analysis on the studies 
that analyzed the data using the intention-to-treat principle (Bourbeau 2003; Rice 2010) 
showed a statistically significant and clinically relevant difference in favor of IDM (MD 
-4.65; 95% CI -6.69 to -2.62, P < 0.0001) compared to controls.
Subgroup analysis based on type of setting
There were six studies conducted in primary care on 456 participants (Boxall 2005; 
Wood-Baker 2006; Koff 2009; Fernandez 2009; van Wetering 2010; Gottlieb 2011) and 
seven studies in secondary care on 969 participants (Engstrom 1999; Bourbeau 2003; 
Dheda 2004; Theander 2009; Rice 2010; Trappenburg 2011; Wakabayashi 2011). No stud-
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Figure 3. Forest plot of comparison: 1 Integrated disease management versus control, outcome: 1.1 
SGRQ: short-term (3 to 12 months).
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ies were performed in tertiary care. Subgroup analysis based on primary care studies 
showed a clinically relevant mean difference of -4.68 (95% CI -8.80 to -0.56) in favor of 
IDM. This result was statistically significant and clinically relevant. Subgroup analysis on 
secondary care studies showed a statistically significant difference of -3.41 (95% CI -5.97 
to -0.85)( Analysis 1.3). This difference was not clinically relevant. The test for subgroup 
difference did not show a statistically significant difference in treatment effects in pa-
tients treated in different types of health care setting (Chi² = 0.27, df = 1 (P = 0.61)).
Subgroup analysis based on study design
We performed subgroup analysis based on study design and compared RCTs (n = 1304) 
versus cluster-RCTs (n = 121). There was no difference in SGRQ total score between 
intervention and control in the cluster-RCT of Wood-Baker 2006 (MD 2.30; 95% CI -1.62 
to 6.22;  Analysis 1.4). Pooled meta-analysis of RCTs showed a clinically relevant effect in 
favor of the IDM group of -4.22 (95% CI -6.14 to -2.30, P < 0.0001). The test for subgroup 
differences showed a statistically significant difference between the pooled analysis of 
the RCTs and the effect in the cluster-RCT (Chi² = 8.57, df = 1 (P = 0.003)). 
Subgroup analysis based on type of control group
In nine studies including 744 participants, control patients received usual care, and in 
four studies (n = 681) the control group received a mono-disciplinary treatment of edu-
cation. Meta-analysis of the usual care studies showed a significant difference between 
groups of -4.09 (95% CI -6.35 to -1.84, P < 0.001) ( Analysis 1.5). Subgroup analysis of 
studies in which the control group received education showed no significant difference 
in effect between groups (MD -2.98; 95% CI -7.69 to 1.74, P = 0.022), which was neither 
statistically nor clinically relevant. There was no statistically significant difference in the 
test for subgroup difference (Chi² = 0.17, df = 1 (P = 0.68)).
Subgroup analysis based on dominant component of the program
There were four studies including 942 patients (Bourbeau 2003; Wood-Baker 2006; 
Koff 2009; Rice 2010) in which self management was the dominant component, and 
six studies including 373 patients in which exercise training was the dominant com-
ponent (Engstrom 1999; Boxall 2005; Theander 2009; Fernandez 2009; van Wetering 
2010; Gottlieb 2011). One study (Wakabayashi 2011) evaluated an individual tailored 
education program and one study (Dheda 2004) focused mainly on structured follow-
up with nurses and GPs. Subgroup analysis of the self management studies revealed 
neither a statistically nor a clinically relevant mean difference: MD -2.76 (95% CI -5.88 to 
0.36, P = 0.08). Subgroup analysis of exercise studies showed a statistically and clinically 
relevant difference of -4.74 in favor of IDM (95% CI -7.05 to -2.43, P < 0.0001). There was 
86 Chapter 4
no statistically significant difference between subgroups (Chi² = 1.00, df = 1 (P = 0.32)) 
(Analysis 1.6).
1.1.1.2. SGRQ - long-term
Two studies including 189 participants measured the long-term effect on the SGRQ total 
score: at 18 (Gottlieb 2011) and 24 (van Wetering 2010) months follow-up. There was no 
statistically significant difference between groups (MD -0.22; 95% CI -7.43 to 6.99, P = 
0.95; I² = 54%, P = 0.14)(Analysis 1.2).
1.1.2.1 SGRQ domain scores - short-term
Eleven studies with a total population of 1377 patients reported scores on the SGRQ 
domains of symptoms, activity and impact. For all domains, there was no significant 
heterogeneity (I² between 35% and 28%) ( Analysis 1.1). We found the following results:
Symptom domain: MD -2.39 (95% CI -5.31 to 0.53, P = 0.11)
Activity domain: MD -2.70 (95% CI -4.84 to -0.55, P = 0.01)
Impact domain: MD -4.04 (95% CI -5.96 to -2.11, P < 0.0001)
1.1.2.2. SGRQ domain scores - long-term
Two studies measured the long-term effect on the SGRQ at 18 months (van Wetering 
2010; Gottlieb 2011). Mean differences on all domains had wide confidence intervals 
and included zero (Analysis 1.2).
1.1.3.1. CRQ domain scores - short-term
The Chronic Respiratory Disease Questionnaire (CRQ), with a scale from 0 to 7 and a 
MCID of 0.5, was reported in eight trials (Wijkstra 1994; Bendstrup 1997; Cambach 1997; 
Güell 2000; Farrero 2001; Rea 2004; Güell 2006; Sridhar 2008). Three of these (Bendstrup 
1997; Farrero 2001; Rea 2004) could not be used in a meta-analysis. Bendstrup 1997 and 
Rea 2004 reported insufficient data and the authors could not provide us with additional 
data. In addition, Farrero 2001 administered the CRQ in the first 40 consecutive patients 
and therefore outcomes were not published.
The pooled results of four studies including 160 participants (Wijkstra 1994; Cambach 
1997; Güell 2000; Güell 2006) measuring the CRQ until 12 months follow-up are shown 
in Figure 4 and  Analysis 1.7. For each of the CRQ domains, the MD was well above the 
MCID of 0.5 units and differences in scores were statistically significant: dyspnoea (MD 
1.02; 95% CI 0.67 to 1.36, P < 0.0001), fatigue (MD 0.82; 95% CI 0.46 to 1.17, P < 0.0001), 
emotion (MD 0.61; 95% CI 0.26 to 0.95, P < 0.0005) and mastery (MD 0.75; 95% CI 0.38 to 
1.12, P < 0.0001). The results showed homogeneity across studies.
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1.1.3.2. CRQ domain scores - long-term
Two studies (n = 151) (Güell 2000; Sridhar 2008) measured the long-term effectiveness 
on CRQ domain scores at 24 months follow-up( Analysis 1.8). There was no difference 
between groups on the CRQ dyspnoea domain: MD 0.47 (95% CI -0.31 to 1.25, P = 0.24). 
Pooled data showed substantial heterogeneity (I² = 70%, P = 0.07), which was related to 
differences in the type of intervention (exercise in the Güell 2000 study versus structured 
follow-up with a respiratory nurse and exacerbation plan in Sridhar 2008). Güell 2000 
demonstrated a significant difference in favor of IDM (MD 0.92; 95% CI 0.19 to 1.65, P = 
0.01). In contrast, there was no statistically significant difference between groups on the 
CRQ dyspnoea domain in Sridhar 2008 (MD 0.12; 95% CI -0.32 to 0.58, P = 0.61).
Pooled mean differences on the domains fatigue, emotion and mastery showed homo-
geneity across studies. On the CRQ fatigue domain, there was a statistically significant 
but not clinically relevant difference of 0.45 in favor of IDM (95% CI 0.05 to 0.85, P = 0.03). 
On the CRQ emotion and mastery domain, the statistically and clinically relevant effect 
Figure 4. Forest plot of comparison: 1 Integrated disease management versus control, outcome: 1.7 CRQ: 
short-term (3 to 12 months).
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was in favor of IDM: emotion MD 0.53 (95% CI 0.10 to 0.95, P = 0.02) and mastery MD 0.80 
(95% CI 0.37 to 1.23, P < 0.01).
1.2 General health-related QoL
General HRQoL was measured with the SF-36 in three studies (Dheda 2004; Rea 2004; 
Aiken 2006). The authors of these studies could not provide us with sufficient data for 
pooling in a meta-analysis. Neither study found a significant effect between groups. 
Two of these studies (Dheda 2004; Aiken 2006) suffer from small sample sizes varying 
from 15 to 10 patients per group per study, which makes it difficult to detect an effect 
(underpowered studies).
We pooled the data from two studies (Littlejohns 1991; Engstrom 1999) reporting data 
on the SIP ( Analysis 1.9). No between-group differences in any domain of the SIP were 
found. One other study used the York Quality of Life Questionnaire (Bendstrup 1997) and 
reported no significant difference. Smith 1999 used a modified version of the Dartmouth 
Primary COOP. In this study, the authors analyzed only the data from the intervention 
group (n = 30) due to lack of data in the control group. The authors concluded that the 
total COOP scores in the intervention group significantly improved HRQoL at 12 months.
2. Exercise capacity
Seventeen studies measured exercise capacity using either the 6MWD or the cycle 
ergometer test. The MCID on the 6MWD is estimated at 35 meters (Puhan 2008). There 
is no MCID reported in the current literature for the cycle ergometer test. Results are 
shown in Figure 5.
2.1.1 Functional exercise capacity - short-term
We pooled data from 14 studies using the 6MWD including 871 participants. One study 
could not be pooled, as the authors reported no data because there was no significant 
difference between groups at 12 months follow-up (Bourbeau 2003).
Patients treated with IDM improved their 6MWD by a statistically and clinically relevant 
43.86 meters (95% CI 21.83 to 65.89)(Figure 5;  Analysis 1.10). There was heterogeneity 
between the results of the studies (I² = 83%). This heterogeneity is explained by dif-
ferences in the quality of studies. We performed sensitivity analysis on studies with 
adequate allocation concealment, which reduced heterogeneity (I² = 0%) and reduced 
the effect to a MD of 15.15 meters, which was still statistically significant (95% CI 6.37 
to 23.93, P < 0.001), however no longer clinically relevant. Furthermore, we performed 
subgroup analysis based on type of setting, type of control group and dominant com-
ponent of the intervention.
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Subgroup analysis based on type of setting
There were seven studies with 427 participants (Wijkstra 1994; Cambach 1997; Boxall 
2005; Fernandez 2009; van Wetering 2010; Mendes 2010; Gottlieb 2011) conducted in 
primary care, seven studies with 438 participants (Littlejohns 1991; Bendstrup 1997; 
Engstrom 1999; Güell 2000; Theander 2009; Mendes 2010; Wakabayashi 2011) in 
secondary care and one study in tertiary care with 35 participants (Güell 2006). Both 
subgroup analyses showed similar statistically and clinically relevant improvements: 
exercise training in primary care revealed a MD of 45.16 meters (95% CI 8.65 to 81.67, P 
= 0.02), whereas in the secondary care setting the MD was 49.18 meters (95% CI 14.28 to 
84.08, P = 0.006). The tertiary care study showed a significant effect in favor of IDM of 85 
meters (95% CI 30.43 to 139.57). Results are shown in  Analysis 1.11 and Figure 6.
Subgroup analysis based on control group
We pooled four studies with 180 participants in which control patients received a treat-
ment with optimal medication (Cambach 1997; Güell 2006) or an education session 
(Fernandez 2009; Wakabayashi 2011) in a subgroup analysis. In the same way, we pooled 
10 studies (Littlejohns 1991; Wijkstra 1994; Bendstrup 1997; Engstrom 1999; Güell 2000; 
Boxall 2005; Theander 2009; Mendes 2010; van Wetering 2010; Gottlieb 2011) including 
691 participants in which the control group consisted of usual care.
Subgroup analysis in which one component of treatment was used showed no difference 
between groups (MD 35.99; 95% CI -5.34 to 77.31, P = 0.09)( Analysis 1.12). In studies in 
Figure 5. Forest plot of comparison: 1 Integrated disease management versus control, outcome: 1.10 
Functional exercise capacity: 6MWD mean difference.
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which the control group consisted of usual care, the 6MWD improved clinically and sta-
tistically significantly by 46.59 meters in favor of IDM (95% CI 19.68 to 73.51, P = 0.0007). 
However, the test for subgroup differences did not show any difference between control 
groups (Chi² = 0.18, df = 1 (P = 0.67)).
Subgroup analysis based on dominant component of intervention
Twelve out of the 14 studies (n = 653) measuring exercise capacity incorporated some 
kind of exercise training in their IDM programs. We performed subgroup analysis, which 
showed that the 6MWD improved by 51.47 meters (95% CI 26.53 to 76.40). This effect 
was statistically and clinically relevant. In the remaining two studies (n = 218), exercise 
was not part of the IDM programs. In one study (Wakabayashi 2011), which consisted of 
individually tailored education sessions, there was no difference between groups (MD 
0.40; 95% CI -39.64 to 40.44, P = 0.98). The other study (Littlejohns 1991), in which there 
was a focus on structured follow-up with GP and nurses, revealed no effect (MD 3.50; 
95% CI -28.31 to 35.31, P = 0.83). In conclusion, studies incorporating exercise training 
in their IDM programs demonstrated larger effect sizes; this was statistically significant 
using the test for subgroup difference (Chi² = 7.49, df = 2 (P = 0.02))(Analysis 1.13).
Figure 6. Forest plot of comparison: 1 Integrated disease management versus control, outcome: 1.11 
Subgroup analysis 6MWD based on type of setting.
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2.1.2 Functional exercise capacity - long-term
Two studies on 184 participants published long-term results on the 6MWD (van Wetering 
2010; Gottlieb 2011). Both studies showed that IDM statistically significantly improved 
exercise capacity measured on the 6MWD by 16.8 meters (MD 16.84; 95% CI 3.01 to 
30.67) compared to the control group. However, this effect did not exceed the MCID. 
There was no heterogeneity present. Results are shown in Figure 5 and  Analysis 1.10.
2.2. Maximal exercise capacity
Four studies on 298 participants assessed the maximal exercise capacity (in Watts) us-
ing the cycle ergometer test. Both studies showed that IDM statistically significantly 
improved the maximal exercise capacity by 7 Watts (MD 6.99; 95% CI 2.96 to 11.02, P < 
0.0001)(Analysis 1.14).
3. Exacerbations
3.1.1 Number of patients experiencing at least one exacerbation - short-term
Two studies (Bourbeau 2003; Trappenburg 2011) including 407 patients reported on the 
number of patients experiencing at least one exacerbation during 12 months of follow-
up. Both studies used the same definition and defined an exacerbation as an increase 
in symptoms, with deterioration of dyspnoea or purulent sputum. Pooled meta-analysis 
showed homogeneity and a pooled OR of 1.21 (95% CI 0.77 to 1.91) (Analysis 1.15), 
which showed no statistically or clinically relevant difference between groups. The trial 
authors of the Bourbeau 2003 study reported that although there were more patients 
experiencing at least one exacerbation in the intervention group (85 versus 81), the total 
number of exacerbations was higher in the control group (362) compared to the inter-
vention group (299). This was of borderline significance (P = 0.06). Similarly, the number 
of patients experiencing three or more exacerbations during 12-month follow-up was 
higher in the control group (67.9%), compared to the action plan group (62.3%). Exac-
erbations in the intervention group were treated successfully at an early stage, which 
probably resulted in fewer patients with a hospital admission (17.2% versus 36.3%, P 
< 0.01). Trappenburg 2011 reported similar findings: although exacerbation rates did 
not differ between groups, exacerbations in the action plan group were perceived as 
substantially milder by patients, and they reported on average three days faster than 
those in the control group.
3.1.2. Number of patients experiencing at least one exacerbation - long-term
Two studies (Sridhar 2008; van Wetering 2010) including 301 patients assessed the 
number of patients experiencing at least one exacerbation at 24 months follow-up. Both 
studies related the definition of an exacerbation to health care. Sridhar 2008 stated they 
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defined an exacerbation as the “unscheduled need for healthcare, or need for steroid 
tablets, or antibiotics for worsening of their COPD”. Similarly, van Wetering 2010 defined 
a moderate exacerbation as “a visit to the general practitioner or respiratory physician 
in combination with a prescription of antibiotics and/or prednisolone or a visit to the 
emergency department or day care of a hospital, which according to the patient, was 
related to a COPD exacerbation. A severe exacerbation was defined as a hospitalisation 
for a COPD exacerbation”. Pooled meta-analysis demonstrated no difference between 
groups (OR 1.53; 95% CI 0.90 to 2.60, P = 0.12) (Analysis 1.16). There was homogeneity 
between studies. Sridhar 2008 stated that patients in the intervention group were more 
likely to have exacerbations treated with oral steroids alone or oral steroids and antibiot-
ics than the control group. The initiator of treatment was statistically more likely to be 
the patient themselves compared to the GP in the control group.
3.1.3 Mean exacerbation rate - long-term
Two studies (Güell 2000; van Wetering 2010) including 226 participants reported on the 
exacerbation rate in both groups at 24 months follow-up. Data on exacerbations were 
skewed in the van Wetering study, therefore we decided not to pool both studies in a 
meta-analysis. In Güell 2006, control group patients (n = 23) experienced 207 exacerba-
tions, with an average of 6.9 (3.9) exacerbations per patients, ranging from 0 to 16 ex-
acerbations during the 24 months. The IDM group experienced 111 exacerbations, with 
an average of 3.7 (2.2) exacerbations per patients, ranging from 0 to 9 exacerbations 
during the 24 months. This difference was statistically significant (P < 0.0001) favoring 
IDM. In van Wetering 2010, the exacerbation rate was 2.78 in the IDM group and 2.16 in 
the control group, resulting in a rate ratio of 1.29 (95% CI 0.89 to 1.87), which was not 
statistically significant (P = 0.113).
3.2.1 Hospital admissions, all causes - short-term
Two studies on 266 participants (Littlejohns 1991; Rea 2004) reported data on the num-
ber of patients who were admitted for all causes until 12 months follow-up. There was 
no heterogeneity and there was no difference between groups (OR 0.62; 95% CI 0.36 to 
1.07, P = 0.49) (Analysis 1.17).
3.2.2. Hospital admissions, all causes - long-term
Two studies including a total of 283 patients (Sridhar 2008; van Wetering 2010) assessed 
the number of patients admitted until 24 months follow-up. Pooled results showed 
heterogeneity (I² = 53%), which could be explained as van Wetering 2010 showed a 
positive effect in favor of IDM and Sridhar 2008 showed no significant difference in ef-
fect between groups. Therefore, a pooled meta-analysis showed no difference between 
groups (OR 0.78; 95% CI 0.38 to 1.57)(Analysis 1.18).
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3.3.1. Respiratory-related admissions - short-term
We pooled data from seven studies (Smith 1999; Bourbeau 2003; Rea 2004; Boxall 2005; 
Koff 2009; Rice 2010; Trappenburg 2011) measuring respiratory-related admissions until 
12 months follow-up in a meta-analysis. Studies were homogeneous. Pooled estimates 
showed a statistically significant difference in favor of IDM (OR 0.68; 95% CI 0.47 to 0.99, 
P = 0.04)(Analysis 1.19). In the control group 27 people out of 100 had a respiratory-
related hospital admission over 3 to 12 months, compared to 20 (95% CI 15 to 27) out 
of 100 in the integrated disease management group, as presented in Figure 7. Over the 
course of a year, the number needed to treat with IDM to prevent one hospital admis-
sion was NNT(B) 15 (95% CI 9 to 506).
3.3.2. Respiratory-related admissions - long-term
Data from one trial (van Wetering 2010) presented data on the number of patients ad-
mitted until 24 months follow-up. There was no difference between the control and IDM 
group on the number of respiratory-related admissions (OR 0.59; 95% CI 0.28 to 1.22, P 
= 0.16)(Analysis 1.20).
Figure 7. Number needed to treat
In the control group 27 people out of 100 had a respiratory-related hospital admission over 3 to 12 months, compared to 
20 (95% CI 15 to 27) out of 100 for integrated disease management group.
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3.4.1 Hospital days per patient - short-term
Six studies on 741 patients (Engstrom 1999; Farrero 2001; Bourbeau 2003; Rea 2004; 
Boxall 2005; Trappenburg 2011) reported the difference in mean hospitalisation days 
per patient per group (intervention versus control). Patients treated with IDM were 
on average discharged from the hospital nearly four days earlier compared to control 
patients, with a confidence interval from six to two days (MD -3.78; 95% CI -5.90 to -1.67, 
P < 0.001) (Analysis 1.21). There was heterogeneity in the results (I² = 55%). Inspection 
of the forest plot shows that this was the result of one outlying study (Engstrom 1999), 
which reported more days for intervention patients. The authors stated that the data 
on admission days in his study were skewed, as one patient accounted for 50% of the 
increase in the IDM group. Reanalysis with exclusion of this trial did not change the 
significance, direction or effect of the mean difference. 
3.4.2. Hospital days per patient - long-term
One trial with 175 patients (van Wetering 2010) reported the difference in mean number 
of total hospital days per patient per group at 24 months follow-up. There was no differ-
ence between groups (MD 0.60; 95% CI -3.01 to 4.21, P = 0.74) (Analysis 1.22).
3.5 Emergency Department (ED) visits
Six trials (Smith 1999; Farrero 2001; Bourbeau 2003; Rea 2004; Rice 2010; Wakabayashi 
2011) assessed in various ways the number of ED visits. We were able to pool the data 
from four studies with 1161 patients (Smith 1999; Bourbeau 2003; Rea 2004; Rice 2010), 
which revealed no difference between groups with high heterogeneity (OR 0.64; 95% CI 
0.33 to 1.25; I² = 71%)(Analysis 1.23). Sensitivity analysis on two studies which analyzed 
by intention-to-treat and which blinded outcome assessors revealed a mean difference 
of 0.49 in favor of the control group (MD 0.49; 95% CI 0.36 to 0.67, P < 0.0001, I² = 0%). 
Three studies could not be pooled, due to lack of required data. Of these excluded stud-
ies, Trappenburg 2011 and Wakabayashi 2011 reported the mean ED visits per patient 
at baseline and follow-up. Both studies concluded no statistically significant difference 
between groups compared to baseline. On the other hand, Farrero 2001 reported 
a significant decrease in ED visits per patient in favor of the IDM group (0.45 ± 0.83 
for intervention group, 1.58 ± 1.96 for control group; P = 0.0001). There were no data 
presented on the number of ED visits at long-term follow-up.
3.6 Patients using at least one course of oral steroids
We pooled data from three studies including 348 patients (Littlejohns 1991; Farrero 
2001; Rea 2004) on the number of patients using at least one course of oral steroids until 
12 months follow-up. Results were homogeneous and there was no difference between 
groups (OR 1.13; 95% CI 0.64 to 2.01, P = 0.66) (Analysis 1.24).
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3.7. Patients using at least one course of antibiotics
There were two studies with 236 participants (Littlejohns 1991; Rea 2004) reporting on 
the number of patients using at least one course of antibiotics. The studies presented 
conflicting results and heterogeneity was large, as Rea 2004 was a primary care, cluster-
randomized trial and Littlejohns 1991 was a RCT in the secondary care setting. The 
number of patients using at least one course of antibiotics was not different between 




Four studies reported the MRC Dyspnea Scale as an outcome (Mendes 2010; van 
Wetering 2010; Gottlieb 2011; Wakabayashi 2011), however Gottlieb failed to publish 
any results. We pooled data from the remaining three studies, including 345 patients. 
Dyspnea was improved in the IDM group by -0.30 points (MD -0.30; 95% CI -0.48 to -0.11, 
I² = 0%, P < 0.001)(Analysis 1.26).
Furthermore, three studies on 145 patients used the Borg score to detect changes in 
perceived dyspnoea (Güell 2000; Boxall 2005; Gottlieb 2011). These data were pooled 
and revealed no change in dyspnoea (MD 0.14; 95% CI -0.70 to 0.98, P = 0.74, I² = 39%)
(Analysis 1.27).
5. Mortality
Five trials assessing 1207 patients explicitly recorded mortality as an outcome. Of these, 
four trials assessed mortality at 12 months (Littlejohns 1991; Smith 1999; Farrero 2001; 
Rice 2010) and one study at 24 months (Sridhar 2008). There was no statistically sig-
nificant difference between groups at short- (OR 0.96; 95% CI 0.52 to 1.74, P = 0.33; I² 
= 59%) and long-term follow-up (OR 0.45; 95% CI 0.16 to 1.28, P = 0.13) (Analysis 1.28). 
Heterogeneity in the short-term studies is due to different dominant components of the 
interventions.
6. Lung function
Lung function was measured in three different ways in 10 trials (Littlejohns 1991; Wi-
jkstra 1994; Güell 2000; Farrero 2001;Bourbeau 2003; Wood-Baker 2006; Sridhar 2008; 
Fernandez 2009; van Wetering 2010; Wakabayashi 2011). Therefore, we created three 
different subgroups, which we pooled in two different meta-analyses: forced expiratory 
volume in one second (FEV1) in liters and FEV1 as per cent predicted for age, gender and 
height (FEV1% predicted), as well as the mean difference in FEV1% predicted from base-
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line. All pooled data on short- as well as on long-term outcome revealed no significant 
difference in lung function between groups(Analysis 1.29;  Analysis 1.30).
7. Anxiety and depression
Four studies assessed depression as an outcome (Engstrom 1999; Littlejohns 1991; Güell 
2006; Trappenburg 2011). Two studies (Littlejohns 1991; Trappenburg 2011) used the 
HADS, one study (Engstrom 1999) used the Mood Adjective Check List (MACL) and one 
study (Güell 2006) used a Revised Symptom Checklist. We pooled results on the HADS in 
a meta-analysis including 316 patients, which revealed no statistically significant differ-
ence between groups for anxiety (MD 0.22; 95% CI -0.41 to 0.85, I² = 0%) or depression 
(MD 0.21, 95% CI -0.39 to 0.81, I² = 0%)(Analysis 1.31). Engstrom 1999 used the MACL, 
a shortened 38-item version covering three basic dimensions of mood: pleasantness/
unpleasantness, activation/deactivation and calmness/tension. No significant differ-
ences were found between groups. The aim of Güell 2006 was specifically to evaluate 
the effect of a pulmonary rehabilitation program on psychosocial morbidity (without 
including any specific psychological intervention), as well as effort capacity and HRQoL. 
Therefore, the authors used a Revised Symptom Checklist, containing 90 items, which 
included depression and anxiety. Following a per protocol analysis, the intervention 
group showed a significant improvement in depression (P ≤ 0.01) and anxiety (P ≤ 0.05).
8. Co-ordination of care
Three studies (Littlejohns 1991; Bendstrup 1997; Koff 2009) reported in some way on 
the co-ordination of care. However, these studies had different intervention programs 
and reported on co-ordination of care in different ways. Therefore, interpretation of 
outcomes is difficult. Bendstrup 1997 reported an attendance rate of 78% of patients 
following a 12-week IDM program (consisting of education, exercise training, smoking 
cessation and occupational therapy).
Patient satisfaction with regard to the provided health care was measured in two stud-
ies. In Koff 2009, satisfaction with a self management/action plan program was assessed 
on a scale from 1 to 10 in the intervention group, with 1 being strongly dissatisfied and 
10 completely satisfied. Patients expressed high satisfaction with all of the equipment 
used, except for the pedometer. Littlejohns 1991 designed a satisfaction questionnaire 
for his study, which included questions on satisfaction with level of care, the information 
given to patients and their knowledge of medication. The questionnaire was used in 
both study groups. At 12 months follow-up, there was little difference in the level of 
satisfaction with the service provided between groups.
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DISCUSSION
Summary of main results
We reviewed the results of 26 randomised controlled trials evaluating the effect of an in-
tegrated disease management (IDM) program in patients with COPD. All included stud-
ies contained a program provided by caregivers from at least two different disciplines, 
with two different components (for example exercise, education, self management etc) 
and with a duration of at least three months. Firstly, pooled data showed statistically 
and clinically relevant improvements in disease-specific quality of life on the CRQ in 
the IDM group: dyspnoea (MD 1.02; 95% CI 0.67 to 1.36); fatigue (0.82; 95% CI 0.46 to 
1.17); emotional (0.61; 95% CI 0.26 to 0.95) and mastery (0.75; 95% CI 0.38 to 1.12). All 
domains (dyspnoea, fatigue, emotional and mastery) exceeded the minimum clinically 
relevant difference until 12 months follow-up. Only two studies measured long-term re-
sults on the CRQ, which showed that the positive effect was maintained for the fatigue, 
emotion and mastery domains at 24 months follow-up. Furthermore, disease-specific 
quality of life was also measured with the SGRQ. There was considerable heterogeneity 
in the score on the SGRQ. After multiple sensitivity analyses, we concluded that there 
was a difference in the SGRQ total score in favor of patients treated with IDM, which lies 
around the minimal clinically relevant difference of four units. The effect was greatest for 
the impact domain. We could not find a difference in the SGRQ total score at long-term 
follow-up. Remarkably, only two studies could provide data.
Second, the pooled data showed statistically significant improvements in maximal and 
functional exercise capacity, with an improvement of 7 Watts and 44 meters in favor of 
the IDM group, respectively. Sensitivity analysis of the 6MWD lowered the effect to 15 
meters, indicating the likelihood of an overestimated effect in the lower quality studies.
Thirdly, the total number of patients with at least one respiratory-related hospital admis-
sion decreased from 27 per 100 to 20 per 100 patients in favor of the intervention group, 
with a number needed to treat of 15 patients to prevent one being admitted to hospital 
over three to 12 months. Mean hospitalisation days decreased on average by three days 
in the IDM group. The effects on the aforementioned primary outcomes are summarized 
in the  Summary of findings for the main comparison. There was no evidence of an effect 
on generic quality of life, the number of patients with at least one exacerbation, the 
number of hospital admissions for all causes, emergency department visits, courses of 
antibiotics/prednisolone, dyspnoea, lung function parameters or depression scores. 
Overall completeness and applicability of evidence
We found sufficient studies to address the objective of this review. All studies reported at 
least one primary outcome, and all studies were included in at least one pooled analysis. 
The COPD population in the included studies ranged from mild to very severe COPD 
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and trials were conducted across all types of healthcare settings in a range of different 
countries. Although the results of this review appear therefore to be applicable to all 
COPD patients worldwide, one should bear in mind that applicability may depend on 
the context of available healthcare resources. The IDM programs included in this review 
differed in the type of health care providers involved, type of components and duration 
of intervention, reflecting the diversity of daily practice. Overall, programs containing 
at least two health care providers and two different elements, showed improvements 
in quality of life and exercise capacity, and reduced the number of hospital admissions 
and days spent in the hospital. We found no differences in quality of life and exercise 
tolerance between patients treated in primary or secondary care. Although the mean 
differences between groups were lower in studies using a mono-disciplinary treatment 
as a control group compared to usual care, the subgroup difference did not reach 
statistical significance. Furthermore, subgroup analysis on studies focusing mainly on 
exercise programs showed a statistically significant greater improvement in exercise 
capacity. Further research is required to define the optimal combination, intensity and 
duration of components in IDM programs.
Quality of the evidence
We included RCTs only and found 26 trials assessing almost 3000 participants. A priori, 
we intended to perform meta-analyses on some outcomes when feasible. However, with 
this amount of data we were able to perform pooled data analysis for all outcomes. As a 
result of the complex intervention, there was a certain amount of clinical and statistical 
heterogeneity among studies. We have incorporated heterogeneity into the estimated 
effects by using random-effects analyses, where possible. Using the GRADE approach, 
we specified the levels of quality of the evidence (high, moderate, low and very low) in 
our ‘Summary of findings’ table. According to this approach, we checked if the included 
trials had limitations in terms of design, indirectness of the evidence, unexplained het-
erogeneity or inconsistency of the results, imprecision of the results or high probability 
of publication bias. If one of these factors was present, we downgraded the evidence. 
On the SGRQ, there was considerable variation in risk of bias between studies. Risk of 
bias tended to be lower in the more recently published trials compared to older trials. 
Sensitivity analyses based on studies with low quality did not change the direction, 
significance or magnitude of the effect. Therefore we concluded that the quality of the 
evidence was ‘high’. For the CRQ, there were four studies which were all of moderate 
quality and presented with some form of bias, therefore we did downgrade the evidence 
to ‘moderate’ quality. We downgraded the evidence on functional exercise capacity for 
inconsistency, as substantial heterogeneity (I² = 84%) was present. After performing 
sensitivity analysis, the mean difference substantially decreased to 15 meters. We did 
not downgrade for respiratory-related admissions or hospitalisation days, as we feel the 
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studies presented consistent, homogeneous results. We expect that additional trials 
with proper description of their methods and data collection could upgrade the quality 
of evidence and further our findings.
Potential biases in the review process
Several methodological strengths minimized the risk of bias in this review. As definitions 
of IDM are still under debate, we a priori strictly determined the inclusion criteria for an 
IDM program, which was published in our protocol. Our definition was derived from 
the definitions published in the literature (Peytremann-Bridevaux 2009; Schrijvers 2009). 
Overall, they reported on “multiple interventions, designed to manage chronic condi-
tions, with a focus on a multidisciplinary approach”. Furthermore, these definitions sug-
gest that IDM interventions should “focus on maximum clinical outcome, regardless of 
treatment setting(s) or typical reimbursement patterns”. As a result, we chose to include 
all interventions, independent of treatment setting, and to keep our definition as simple 
as possible, in order to be easily understandable for readers and easy to use for us as 
authors when checking on all relevant literature. Therefore, we restricted the inclusion 
of trials to multi-component, multidisciplinary programs of at least three months dura-
tion. Furthermore, we performed comprehensive searches to identify possible studies, 
leading to almost 4800 potentially relevant abstracts being identified. Subsequently, 
three different assessors assessed the abstracts. All studies that were excluded by two 
authors because of the type of intervention were triple-checked by a third review author 
to make sure all studies describing an IDM program were included. We reached consen-
sus on all included studies. Although we followed the inclusion criteria for IDM as stated 
in our protocol, final decisions on the inclusion of studies are open to interpretation or 
criticism.
Limitations of this review include possible bias from inconsistent reporting of data from 
included studies. We requested additional data from 14 authors and received an answer 
from 11. Six of them could provide us with additional data, which could potentially have 
biased the results. Furthermore, only three out of 26 studies published a study protocol 
with which we could compare the results sections. In the other studies, we examined 
whether the outcomes reported in the methods section of the paper were reported 
in the results section. It is possible that this could have introduced bias if the authors 
blanked out outcomes from their methods section.
Lastly, there was heterogeneity present in the control group as we used a broad a priori 
definition of controls, varying from no treatment to treatment including one component 
of COPD care. We acknowledge the fact that controls and usual care differ between coun-
tries and between healthcare settings. Therefore, we performed subgroup analysis to 
investigate to what extent a difference between the control groups possibly influenced 
the results. From these analyses we concluded that the effect between intervention and 
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control groups is less strong if patients in control groups receive one component of IDM 
compared to patients receiving no treatment or usual care.
Agreements and disagreements with other studies or reviews
This review adds to the results of four earlier systematic reviews analyzing IDM for COPD 
patients (Adams 2007; Niesink 2007; Peytremann-Bridevaux 2008; Lemmens 2009). The 
current review brings together new trials that were not included in any of these reviews. 
Some of these earlier reviews analyzed some of our primary outcomes. Adams 2007 
examined the effectiveness of programs for COPD patients including chronic care model 
components and pooled six trials including at least two components. Pooled results did 
not demonstrate statistically significant differences on the SGRQ. Patients with COPD 
who received interventions with two or more chronic care model components had 
lower rates of hospitalisation and a shorter length of stay compared with control groups, 
comparable to our results. Lemmens 2009 examined the effectiveness of multiple inter-
ventions in asthma and COPD patients. The authors pooled data on the SGRQ from three 
studies in which two components of IDM were compared to usual care and three studies 
in which three components of IDM were compared to usual care. The effect on the SGRQ 
was larger if three components of IDM were used (MD -4.69; 95% CI -8.34 to -0.83 versus 
MD -0.95; 95% CI -4.23 to 2.34). Pooled data from five studies showed a decrease in 
the number of respiratory-related hospitalizations, with a pooled OR of 0.58, which is 
comparable to the OR of 0.67 found in this review. Niesink 2007 evaluated quality of life 
in COPD patients, but did not perform a meta-analysis; reasons for this were not clearly 
described. Five out of 10 studies showed a clinically relevant improvement in quality of 
life. Peytremann-Bridevaux 2008 examined the effectiveness of IDM in COPD patients 
on exercise tolerance, quality of life, hospital admissions and mortality. Only data on 
hospital admissions and exercise tolerance were pooled. Positive effects on exercise ca-
pacity are in line with this review. The authors demonstrated a mean improvement of 32 
meters on the 6MWD in five studies, which is comparable to our results. Furthermore, a 
pooled odds ratio of 0.85 (95% CI 0.54 to 1.36) for mortality is comparable to our review. 
Differences between this review and these other reviews are related to differences in 
the inclusion criteria for patients and the focus of programs. All reviews used different 
definitions of IDM; however there was some overlap with this review. Lemmens 2009 et 
al also based their definition on the EPOC list (EPOC 2008), whereas Adams 2007 and 
Steuten 2009 based their definition of IDM on the chronic care model as reported by 
Wagner 1996. The definition used by Peytremann-Bridevaux 2008 was similar to our 
definition, with the only difference being a duration of the intervention of at least 12 
months instead of three months. Finally, all the aforementioned systematic reviews 
included study designs other than RCTs.
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Our findings from the St. George’s Respiratory Questionnaire (SGRQ) showed improve-
ments of a similar magnitude to those reported in two recent Cochrane reviews evaluat-
ing two other supposedly important pharmaceutical cornerstones of COPD treatment, 
tiotropium (Karner 2012a) and inhaled corticosteroids (Yang 2012). IDM resulted in a 
higher MD on the SGRQ of -3.71 compared to the MD of tiotropium (-2.89); however, the 
confidence interval for IDM is wider (95% CI -5.83 to -1.59) compared to the confidence 
interval (95% CI -3.35 to -2.44) for tiotropium.
Eight studies in this review are also evaluated in a Cochrane review assessing the ef-
fectiveness of pulmonary rehabilitation (Lacasse 2006) and four studies included in this 
review are also evaluated in a Cochrane review assessing the effect of self management 
programs (Effing 2007). In line with the review of Effing 2007 (OR 0.64; 95% CI 0.47 to 
0.89) we found a decrease in respiratory-related hospital admissions (OR 0.64; 95% 
CI 0.47 to 0.89). Furthermore, both reviews demonstrated improvements in disease-
specific quality of life, although the effects tended to be higher and clinically relevant 
in the pulmonary rehabilitation review (Lacasse 2006), whereas in the self management 
review the improvement was too small to be of clinical relevance (Effing 2007). A priori 
we determined subgroup analyses on the type of dominant intervention in the program. 
Subgroup analysis of studies containing some form of exercise training showed greater 
improvement in quality of life, which exceeded the clinically relevant threshold on al-
most all domains. These results are in line with the Lacasse review. However, a subgroup 
analysis performed on studies that mainly focused on self management did not exceed 
the minimum clinically important difference, in line with the Effing review.
Furthermore, Effing 2007 and Lacasse 2006 reported pooled estimates for functional 
exercise capacity. Not surprisingly, as the focus in most included pulmonary rehabilita-
tion studies lies on exercise training, the 6MWD improved significantly by 48 meters in 
the Lacasse review. This effect size is comparable to our overall estimate of 44 meters 
and our subgroup analyses on studies including an exercise program in which we found 
a mean difference of 50 meters. In contrast to these results, Effing did not find any sig-
nificant differences in exercise capacity at all (weighted mean difference -6.25; 95% CI 
-24.05 to 11.05).
We did not find a difference between groups in the number of patients with at least 
one exacerbation. However, we concluded that there was a reduction in the number of 
patients admitted and the mean number of hospital days related to exacerbations. Self 
management education including the use of action plans might lead to more and better 
self treatment of exacerbations. As a result, hospital admissions will decrease (Effing 
2007). In our included studies, a self management program caused patients to respond 
three days sooner on complaints (Trappenburg 2011). Furthermore, patients more often 
initiated treatment by themselves, which could then be successfully treated with oral 
steroids at an early stage (Sridhar 2008). As a result, perceived exacerbations were rated 
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as substantially milder (Trappenburg 2011) and were less likely to result in an admission 
(Bourbeau 2003).
In the past few years, several systematic reviews evaluating IDM for various other 
chronic conditions have been published (Norris 2002; Badamgarav 2003; Gonseth 2004; 
Neumeyer-Gromen 2004; Knight 2005; Roccaforte 2005; Pimouguet 2010). Overall, qual-
ity of care improved with these programs, however some of the differences were in fact 
clinically modest (Peytremann-Bridevaux 2008). We found that the results of this review 
were most comparable to a systematic review evaluating patients with heart failure, 
which demonstrated that all-cause and heart failure-related hospitalisation rates were 
significantly reduced: OR 0.76 (CI 0.69 to 0.94, P < 0.0001) and OR 0.58 (CI 0.50 to 0.67, P 
< 0.0001), respectively (Roccaforte 2005). In studies evaluating depression and diabetes, 




This meta-analysis provides evidence for the efficacy of integrated disease management 
(IDM) programs of at least three months duration for chronic obstructive pulmonary 
disease (COPD) patients, for up to 12 months follow-up. We found positive effects on 
disease-specific quality of life and exercise capacity in studies containing an exercise 
program, suggesting that exercise training is an important element in an IDM program. 
Long-term effects are still unclear, as only a few studies evaluated these. The magnitude 
of improvement in disease-specific quality of life was clinically relevant, especially using 
the Chronic Respiratory Questionnaire (CRQ).
We calculated that seven hospital admissions related to respiratory problems can be 
prevented for every 100 patients treated with IDM for three to 12 months, giving to a 
number needed to treat of 15 patients to prevent one being admitted. Furthermore, 
hospitalisation decreased by three days in patients treated with IDM compared to con-
trols. This is of utmost importance, as hospitalizations contribute to the highest burden 
and costs in patients with COPD. The effects of IDM on the total number of patients 
suffering at least one exacerbation still remain unclear. It is possible that patients who 
have learned from education and have an action plan may recognize exacerbations at 
an early stage and can start medical treatment directly. It is therefore likely that further 
worsening of health status and hospital admissions can be prevented in these patients.
Cochrane review 103
Implications for research
The following issues could be assessed if authors are planning future trials regarding the 
effectiveness of IDM:  
1. Study quality: Overall, studies included in this systematic review were of moderate 
quality, as not all aspects of risk of bias were appropriately addressed. Therefore, 
there is a need for future trials to report a proper description of the processes of ran-
domisation and data collection. Preferentially, a study protocol including measured 
outcomes should be published in advance to minimize selection and reporting bias.
2. More detailed description of intervention: A detailed description of the precise 
nature of the intervention is important, in order to be able to determine in the future 
which components, duration and intensity of a program are most effective. Ideally, 
we wish to determine which combination of health care providers and which com-
ponents are most effective in IDM programs.
3. Consensus on reporting common outcomes: Given the huge variation in outcome 
measures and follow-up time points, we strongly recommend consensus on the 
reporting of common outcomes, such as change from baseline in health-related 
quality of life, in order to be able to combine more results in future meta-analyses. 
We advise future trial authors to measure at least one of the following outcomes: 
quality of life, exercise tolerance or exacerbation-related outcomes.
4. Adequate power calculation and methods of analysis: two cluster-randomized con-
trolled trials introduced noteworthy bias due to inadequate methods of analysis, not 
taking the clustering into account (Rea 2004; Wood-Baker 2006) and loss to follow-
up of clusters (Rea 2004). Therefore, we recommend performing a proper power 
calculation beforehand and, if needed, adjusting this calculation for intra-cluster 
effects (Guyatt 2011; Higgins 2011).
Finally, given the heterogeneity of interventions, there is a need to reach consensus on 
which interventions are likely to yield the best results when applying integrated care 
programs for COPD.
104 Chapter 4
REFERENCES TO STUDIES  
Included studies  
Aiken 2006  
Aiken LS, Butner J, Lockhart CA, Volk-Craft BE, Hamilton G, Williams FG. Outcome evaluation of a 
randomized trial of the PhoenixCare intervention: program of case management and coordinated 
care for the seriously chronically ill. Journal of Palliative Medicine 2006;9(1):111-26.
Bendstrup 1997  
Bendstrup KE, Ingemann Jensen J, Holm S, Bengtsson B. Out-patient rehabilitation improves activi-
ties of daily living, quality of life and exercise tolerance in chronic obstructive pulmonary disease. 
European Journal of Respiratory Diseases 1997;10(12):2801-6.
Bourbeau 2003  
Bourbeau J, Collet JP, Schwartzman K, Ducruet T, Nault D, Bradley C. Economic benefits of self-
management education in COPD. Chest 2006;130(6):1704-11. 
* Bourbeau J, Julien M, Maltais F, Rouleau M, Beaupre A, Begin R, et al. Reduction of hospital utiliza-
tion in patients with chronic obstructive pulmonary disease: a disease-specific self-management 
intervention. Archives of Internal Medicine 2003;163(5):585-91.
Sedeno MF, Nault D, Hamd DH, Bourbeau J. A self-management education program including an ac-
tion plan for acute COPD exacerbations. COPD 2009;6(5):352-8. 
Boxall 2005  
Boxall AM, Barclay L, Sayers A, Caplan GA. Managing chronic obstructive pulmonary disease in the 
community. A randomized controlled trial of home-based pulmonary rehabilitation for elderly 
housebound patients. Journal of Cardiopulmonary Rehabilitation 2005;25(6):378-85.
Cambach 1997  
Cambach W, Chadwick-Straver RV, Wagenaar RC, van Keimpema AR, Kemper HC. The effects of a 
community-based pulmonary rehabilitation programme on exercise tolerance and quality of life: a 
randomized controlled trial. European Respiratory Journal 1997;10(1):104-13.
Dheda 2004  
Dheda K, Crawford A, Hagan G, Roberts CM. Implementation of British Thoracic Society guidelines for 
acute exacerbation of chronic obstructive pulmonary disease: impact on quality of life. Postgradu-
ate Medical Journal 2004;80(941):169-71. 
Engstrom 1999  
Engstrom CP, Persson LO, Larsson S, Sullivan M. Long-term effects of a pulmonary rehabilitation pro-
gramme in outpatients with chronic obstructive pulmonary disease: a randomized controlled study. 
Scandinavian Journal of Rehabilitation Medicine 1999;31(4):207-13.
Farrero 2001  
Farrero E, Escarrabill J, Prats E, Maderal M, Manresa F. Impact of a hospital-based home-care program 
on the management of COPD patients receiving long-term oxygen therapy. Chest 2001;119(2):364-
9. 
Fernandez 2009  
Fernandez AM, Pascual J, Ferrando C, Arnal A, Vergara I, Sevila V. Home-based pulmonary rehabilitation 




Gottlieb V, Lyngso AM, Nybo B, Frolich A, Backer V. Pulmonary rehabilitation for moderate COPD (GOLD 
2)--does it have an effect? COPD 2011;8(5):380-6. 
Güell 2000  
Güell R, Casan P, Belda J, Sangenis M, Morante F, Guyatt GH, et al. Long-term effects of outpatient 
rehabilitation of COPD: A randomized trial. Chest 2000;117(4):976-83. 
Güell 2006  
Güell R, Resqueti V, Sangenis M, Morante F, Martorell B, Casan P, et al. Impact of pulmonary rehabilita-
tion on psychosocial morbidity in patients with severe COPD. Chest 2006;129(4):899-904. 
Koff 2009  
Koff PB, Jones RH, Cashman JM, Voelkel NF, Vandivier RW. Proactive integrated care improves quality of 
life in patients with COPD. European Respiratory Journal 2009;33(5):1031-8. 
Littlejohns 1991  
Littlejohns P, Baveystock CM, Parnell H, Jones PW. Randomised controlled trial of the effectiveness of 
a respiratory health worker in reducing impairment, disability, and handicap due to chronic airflow 
limitation. Thorax 1991;46(8):559-64. 
Mendes 2010  
Mendes de Oliveira JC, Studart Leitao Filho FS, Malosa Sampaio LM, Negrinho de Oliveira AC, Hirata 
RP, Costa D, et al. Outpatient vs. home-based pulmonary rehabilitation in COPD: a randomized 
controlled trial. Multidisciplinary Respiratory Medicine 2010;5(6):401-8. 
Rea 2004  
Rea H, McAuley S, Stewart A, Lamont C, Roseman P, Didsbury P. A chronic disease management 
programme can reduce days in hospital for patients with chronic obstructive pulmonary disease. 
Internal Medicine Journal 2004;34(11):608-14. 
Rice 2010  
Rice KL, Dewan N, Bloomfield HE, Grill J, Schult TM, Nelson DB, et al. Disease management program for 
chronic obstructive pulmonary disease: a randomized controlled trial. American Journal of Respira-
tory and Critical Care Medicine 2010;182(7):890-6. 
Smith 1999  
Smith BJ, Appleton SL, Bennett PW, Roberts GC, Del Fante P, Adams R, et al. The effect of a respiratory 
home nurse intervention in patients with chronic obstructive pulmonary disease (COPD). Australian 
and New Zealand Journal of Medicine 1999;29(5):718-25. 
Sridhar 2008  
Sridhar M, Taylor R, Dawson S, Roberts NJ, Partridge MR. A nurse led intermediate care package in 
patients who have been hospitalised with an acute exacerbation of chronic obstructive pulmonary 
disease. Thorax 2008;63(3):194-200. 
Strijbos 1996  
Strijbos JH, Postma DS, van Altena R, Gimeno F, Koeter GH. A comparison between an outpatient 
hospital-based pulmonary rehabilitation program and a home-care pulmonary rehabilitation 
program in patients with COPD. A follow-up of 18 months. Chest 1996;109(2):366-72. 
Theander 2009  
Theander K, Jakobsson P, Jorgensen N, Unosson M. Effects of pulmonary rehabilitation on fatigue, 
functional status and health perceptions in patients with chronic obstructive pulmonary disease: a 
randomized controlled trial. Clinical Rehabilitation 2009;23(2):125-36. 
106 Chapter 4
Trappenburg 2011  
Trappenburg JC, Koevoets L, de Weert-van Oene GH, Monninkhof EM, Bourbeau J, Troosters T, et al. 
Action Plan to enhance self-management and early detection of exacerbations in COPD patients; a 
multicenter RCT. BMC Pulmonary Medicine 2009;9:52. 
* Trappenburg JC, Monninkhof EM, Bourbeau J, Troosters T, Schrijvers AJ, Verheij TJ, et al. Effect of an 
action plan with ongoing support by a case manager on exacerbation-related outcome in patients 
with COPD: a multicentre randomised controlled trial. Thorax 2011;66(11):977-84. 
van Wetering 2010  
Hoogendoorn M, van Wetering CR, Schols AM, Rutten-van Molken MP. Is INTERdisciplinary COMmunity-
based COPD management (INTERCOM) cost-effective? European Respiratory Journal 2010;35(1):79-
87. 
* van Wetering CR, Hoogendoorn M, Mol SJ, Rutten-van Molken MP, Schols AM. Short- and long-term 
efficacy of a community-based COPD management programme in less advanced COPD: a ran-
domised controlled trial. Thorax 2010;65(1):7-13. 
Wakabayashi 2011  
Wakabayashi R, Motegi T, Yamada K, Ishii T, Jones RC, Hyland ME, et al. Efficient integrated education 
for older patients with chronic obstructive pulmonary disease using the Lung Information Needs 
Questionnaire. Geriatrics & Gerontology International 2011;11(4):422-30. 
Wijkstra 1994  
Wijkstra PJ, Ten Vergert EM, van Altena R, Otten V, Kraan J, Postma DS, et al. Long term benefits of 
rehabilitation at home on quality of life and exercise tolerance in patients with chronic obstructive 
pulmonary disease. Thorax 1995;50(8):824-8. 
Wijkstra PJ, Van Altena R, Kraan J, Otten V, Postma DS, Koeter GH. Quality of life in patients with chronic 
obstructive pulmonary disease improves after rehabilitation at home. European Respiratory Journal 
1994;7(2):269-73.
Wijkstra PJ, van der Mark TW, Kraan J, van Altena R, Koeter GH, Postma DS. Effects of home rehabilitation 
on physical performance in patients with chronic obstructive pulmonary disease (COPD). European 
Respiratory Journal 1996;9(1):104-10. 
Wijkstra PJ, van der Mark TW, Kraan J, van Altena R, Koeter GH, Postma DS. Long-term effects of home 
rehabilitation on physical performance in chronic obstructive pulmonary disease. American Journal 
of Respiratory and Critical Care Medicine 1996;153(4 Pt 1):1234-41. 
Wood-Baker 2006  
Wood-Baker R, McGlone S, Venn A, Walters EH. Written action plans in chronic obstructive pulmo-




Adams SG, Smith PK, Allan PF, Anzueto A, Pugh JA, Cornell JE. Systematic review of the chronic care 
model in chronic obstructive pulmonary disease prevention and management. Archives of Internal 
Medicine 2007;167(6):551-61. 
Agusti 2010  
Agusti A, Calverley PM, Celli B, Coxson HO, Edwards LD, Lomas DA, et al. Characterisation of COPD 
heterogeneity in the ECLIPSE cohort. Respiratory Research 2010;11:122. 
Badamgarav 2003  
Cochrane review 107
Badamgarav E, Weingarten SR, Henning JM, Knight K, Hasselblad V, Gano A Jr, et al. Effectiveness of 
disease management programs in depression: a systematic review. American Journal of Psychiatry 
2003;160(12):2080-90. 
Beck 1961  
Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Archives 
of General Psychiatry 1961;4:561-71. 
Bestall 1999  
Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research 
Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmo-
nary disease. Thorax 1999;54(7):581-6. 
Bonomi 2002  
Bonomi AE, Wagner EH, Glasgow RE, VonKorff M. Assessment of chronic illness care (ACIC): a practical 
tool to measure quality improvement. Health Services Research 2002;37(3):791-820. 
Borg 1970  
Borg G. Perceived exertion as an indicator of somatic stress. Scandinavian Journal of Rehabilitation 
Medicine 1970;2(2):92-8. 
Bourbeau 2013  
Bourbeau J, Saad N. Integrated care model with self-management in chronic obstructive pulmonary 
disease: From family physicians to specialists. Chronic Respiratory Disease 2013;10:93-4. 
Britton 2003  
Britton M. The burden of COPD in the U.K.: results from the Confronting COPD survey. Respiratory 
Medicine 2003;97(Suppl C):S71-9. 
Burgel 2010  
Burgel PR, Paillasseur JL, Caillaud D, Tillie-Leblond I, Chanez P, Escamilla R, et al. Clinical COPD phe-
notypes: a novel approach using principal component and cluster analyses. European Respiratory 
Journal 2010;36(3):531-9. 
Calverley 2003  
Calverley PM, Walker P. Chronic obstructive pulmonary disease. Lancet 2003;362(9389):1053-61. 
Campbell 2001  
Campbell MK, Mollison J, Grimshaw JM. Cluster trials in implementation research: estimation of intra-
cluster correlation coefficients and sample size. Statistics in Medicine 2001;20(3):391-9. 
Care Continuum Alliance  
Care Continuum Alliance (CCA) Definition of Disease Management. www.carecontinuum.org/ (ac-
cessed 19 May 2011).
Chavannes 2008  
Chavannes NH. Integrated chronic obstructive pulmonary disease management in primary care. 
Disease Management & Health Outcomes 2008;16(5):1.
Cote 2009  
Cote CG, Celli BR. BODE index: a new tool to stage and monitor progression of chronic obstructive 
pulmonary disease. Pneumonologia i Alergologia Polska: organ Polskiego Towarzystwa Ftyzjo-
pneumonologicznego, Polskiego Towarzystwa Alergologicznego, i Instytutu Gruzlicy i Chorob Pluc 
2009;77(3):305-13. 
De Angelis 2004  
De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al. Clinical trial registration: a state-




Dellby U. Drastically improving health care with focus on managing the patient with a disease: the 
macro and micro perspective. International Journal of Health Care Quality Assurance 1996;9(2):4-8. 
Domingo-Salvany 2002  
Domingo-Salvany A, Lamarca R, Ferrer M, Garcia-Aymerich J, Alonso J, Felez M, et al. Health-related 
quality of life and mortality in male patients with chronic obstructive pulmonary disease. American 
Journal of Respiratory and Critical Care Medicine 2002;166(5):680-5. 
Effing 2007  
Effing T, Monninkhof EEM, van der Valk PP, Zielhuis GGA, Walters EH, van der Palen JJ, et al. Self-man-
agement education for patients with chronic obstructive pulmonary disease. Cochrane Database 
of Systematic Reviews 2007, Issue 4. Art. No.: CD002990. DOI: 10.1002/14651858.CD002990.pub2.
Ellrodt 1997  
Ellrodt G, Cook DJ, Lee J, Cho M, Hunt D, Weingarten S. Evidence-based disease management. JAMA 
1997;278(20):1687-92. 
Engstrom 1996  
Engstrom CP, Persson LO, Larsson S, Ryden A, Sullivan M. Functional status and well being in chronic 
obstructive pulmonary disease with regard to clinical parameters and smoking: a descriptive and 
comparative study. Thorax 1996;51(8):825-30.
EPOC 2008  
Cochrane Effective Practice and Organization of Care Review Group. Data collection checklist. 
Epstein 1996  
Epstein RS, Sherwood LM. From outcomes research to disease management: a guide for the perplexed. 
Annals of Internal Medicine 1996;124(9):832-7. 
EuroQol Group 1990  
The EuroQol Group. EuroQol--a new facility for the measurement of health-related quality of life. 
Health Policy 1990;16(3):199-208. 
Fan 2002  
Fan VS, Curtis JR, Tu SP, McDonell MB, Fihn SD. Using quality of life to predict hospitalization and 
mortality in patients with obstructive lung diseases. Chest 2002;122(2):429-36. 
Faxon 2004  
Faxon DP, Schwamm LH, Pasternak RC, Peterson ED, McNeil BJ, Bufalino V, et al. Improving quality 
of care through disease management: principles and recommendations from the American Heart 
Association’s Expert Panel on Disease Management. Circulation 2004;109(21):2651-4. 
Gerardi 1996  
Gerardi DA, Lovett L, Benoit-Connors ML, Reardon JZ, ZuWallack RL. Variables related to increased mor-
tality following out-patient pulmonary rehabilitation. European Respiratory Journal 1996;9(3):431-5. 
Glasgow 2005  
Glasgow RE, Wagner EH, Schaefer J, Mahoney LD, Reid RJ, Greene SM. Development and validation of 
the Patient Assessment of Chronic Illness Care (PACIC). Medical Care 2005;43(5):436-44. 
GOLD 2009  
GOLD. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmo-
nary disease 2009. http://www.goldcopd.com/ (accessed 4/10/13).
Gonseth 2004  
Gonseth J, Guallar-Castillon P, Banegas JR, Rodriguez-Artalejo F. The effectiveness of disease manage-
ment programmes in reducing hospital re-admission in older patients with heart failure: a system-
atic review and meta-analysis of published reports. European Heart Journal 2004;25(18):1570-95. 
Cochrane review 109
GRADE Working Group 2004  
GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ 
2004;328:1490-4.
Guyatt 1987  
Guyatt GH, Berman LB, Townsend M, Pugsley SO, Chambers LW. A measure of quality of life for clinical 
trials in chronic lung disease. Thorax 1987;42(10):773-8. 
Guyatt 2011  
Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al. GRADE guidelines: 4. Rating the 
quality of evidence--study limitations (risk of bias). Journal of Clinical Epidemiology 2011;64(4):407-
15.
Higgins 2011  
Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 
5.1 (updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-
handbook.org.
Hurst 2010  
Hurst JR, Vestbo J, Anzueto A, Locantore N, Mullerova H, Tal-Singer R, et al. Susceptibility to exacerbation 
in chronic obstructive pulmonary disease. New England Journal of Medicine 2010;363(12):1128-38. 
Jones 1991  
Jones PW, Quirk FH, Baveystock CM. The St George’s Respiratory Questionnaire. Respiratory Medicine 
1991;85 Suppl B:25-31; discussion 33-7. 
Jones 2005  
Jones PW. St. George’s Respiratory Questionnaire: MCID. COPD 2005;2(1):75-9. 
Jones 2009  
Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of 
the COPD Assessment Test. European Respiratory Journal 2009;34(3):648-54. 
Karner 2012a  
Karner C, Chong J, Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Co-
chrane Database of Systematic Reviews 2012, Issue 7. Art. No.: CD009285. DOI: 10.1002/14651858.
CD009285.pub2.
Kerry 1998  
Kerry SM, Bland JM. The intracluster correlation coefficient in cluster randomisation. BMJ (Clinical 
research ed.) 1998;316(7142):1455. 
Knight 2005  
Knight K, Badamgarav E, Henning JM, Hasselblad V, Gano AD Jr, Ofman JJ, et al. A systematic review 
of diabetes disease management programs. American Journal of Managed Care 2005;11(4):242-50. 
Kocks 2006  
Kocks JW, Tuinenga MG, Uil SM, van den Berg JW, Stahl E, van der Molen T. Health status measurement 
in COPD: the minimal clinically important difference of the clinical COPD questionnaire. Respiratory 
Research 2006;7:62. 
Lacasse 2006  
Lacasse Y, Goldstein R, Lasserson TJ, Martin S. Pulmonary rehabilitation for chronic obstructive pul-




Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In Higgins JPT, Green S (edi-
tors). Cochrane Handbook for Systematic Reviews of Interventions 5.1 (updated March 2011]. The 
Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Lemmens 2009  
Lemmens KM, Nieboer AP, Huijsman R. A systematic review of integrated use of disease-management 
interventions in asthma and COPD. Respiratory Medicine 2009;103(5):670-91. 
Lopez 2006  
Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, Held LS, et al. Chronic obstructive pulmonary 
disease: current burden and future projections. European Respiratory Journal 2006;27(2):397-412. 
Martinez 2006  
Martinez FJ, Foster G, Curtis JL, Criner G, Weinmann G, Fishman A, et al. Predictors of mortality in pa-
tients with emphysema and severe airflow obstruction. American Journal of Respiratory and Critical 
Care Medicine 2006;173(12):1326-34. 
Neumeyer-Gromen 2004  
Neumeyer-Gromen A, Lampert T, Stark K, Kallischnigg G. Disease management programs for 
depression: a systematic review and meta-analysis of randomized controlled trials. Medical Care 
2004;42(12):1211-21. 
Niesink 2007  
Niesink A, Trappenburg JC, de Weert-van Oene GH, Lammers JW, Verheij TJ, Schrijvers AJ. Systematic 
review of the effects of chronic disease management on quality-of-life in people with chronic ob-
structive pulmonary disease. Respiratory Medicine 2007;101(11):2233-9. 
Norris 2002  
Norris SL, Nichols PJ, Caspersen CJ, Glasgow RE, Engelgau MM, Jack L, et al. The effectiveness of disease 
and case management for people with diabetes. A systematic review. American Journal of Preven-
tive Medicine 2002;22(Suppl 4):15-38. 
Norris 2003  
Norris SL, Glasgow RE, Engelgau MM, O’Connor PJ, McCulloch D. Chronic disease management: a 
definition and systematic approach to component interventions. Disease Management and Health 
Outcomes 2003;11(8):477-88.
Peytremann-Bridevaux 2008  
Peytremann-Bridevaux I, Staeger P, Bridevaux PO, Ghali WA, Burnand B. Effectiveness of chronic 
obstructive pulmonary disease-management programs: systematic review and meta-analysis. 
American Journal of Medicine 2008;121(5):433-43.e4. 
Peytremann-Bridevaux 2009  
Peytremann-Bridevaux I, Burnand B. Letter to the editor. Disease management: a proposal for a new 
definition. International Journal of Integrated Care 2009;9:1.
Pimouguet 2010  
Pimouguet C, Le Goff M, Thiebaut R, Dartigues JF, Helmer C. Effectiveness of disease-management 
programs for improving diabetes care: a meta-analysis. Canadian Medical Association Journal 
2010;183(2):E115-27. 
Pinto-Plata 2004  
Pinto-Plata VM, Cote C, Cabral H, Taylor J, Celli BR. The 6-min walk distance: change over time and value 
as a predictor of survival in severe COPD. European Respiratory Journal 2004;23(1):28-33. 
Cochrane review 111
Puhan 2006  
Puhan MA, Soesilo I, Guyatt GH, Schunemann HJ. Combining scores from different patient reported 
outcome measures in meta-analyses: when is it justified? Health and Quality of Life Outcomes 
2006;4:94. 
Puhan 2008  
Puhan MA, Mador MJ, Held U, Goldstein R, Guyatt GH, Schunemann HJ. Interpretation of treat-
ment changes in 6-minute walk distance in patients with COPD. European Respiratory Journal 
2008;32(3):637-43. 
Rao 1992  
Rao JNK, Scott AJ. A simple method for the analysis of clustered binary data. Biometrics 1992;48:577-
85.
Redelmeier 1997  
Redelmeier DA, Bayoumi AM, Goldstein RS, Guyatt GH. Interpreting small differences in functional 
status: the Six Minute Walk test in chronic lung disease patients. American Journal of Respiratory 
and Critical Care Medicine 1997;155(4):1278-82. 
RevMan 5  
Review Manager (RevMan) (Computer program]. Version 5.1. Copenhagen: The Nordic Cochrane 
Centre, The Cochrane Collaboration, 2008.
Roccaforte 2005  
Roccaforte R, Demers C, Baldassarre F, Teo KK, Yusuf S. Effectiveness of comprehensive disease man-
agement programmes in improving clinical outcomes in heart failure patients. A meta-analysis. 
European Journal of Heart Failure 2005;7(7):1133-44. 
Schrijvers 2009  
Schrijvers G. Disease management: a proposal for a new definition. International Journal of Integrated 
Care 2009;9:e06. 
Seemungal 1998  
Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on 
quality of life in patients with chronic obstructive pulmonary disease. American Journal of Respira-
tory and Critical Care Medicine 1998;157(5 Pt 1):1418-22. 
Seemungal 2000  
Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exac-
erbations in patients with chronic obstructive pulmonary disease. American Journal of Respiratory 
and Critical Care Medicine 2000;161(5):1608-13. 
Singh 1992  
Singh S. The use of field walking tests for assessment of functional capacity in patients with chronic 
airways obstruction. Physiotherapy 1992;78:102-4.
Steuten 2009  
Steuten LM, Lemmens KM, Nieboer AP, Vrijhoef HJ. Identifying potentially cost effective chronic care 
programs for people with COPD. International Journal of Chronic Obstructive Pulmonary Disease 
2009;4:87-100. 
Tiep 1997  
Tiep BL. Disease management of COPD with pulmonary rehabilitation. Chest 1997;112(6):1630-56. 
van der Molen 2003  
van der Molen T, Willemse BW, Schokker S, ten Hacken NH, Postma DS, Juniper EF. Development, valid-




Wagner EH, Austin BT, Von Korff M. Improving outcomes in chronic illness. Managed Care Quarterly 
1996;4(2):12-25. 
Wagner 2001  
Wagner EH, Austin BT, Davis C, Hindmarsh M, Schaefer J, Bonomi A. Improving chronic illness care: 
translating evidence into action. Health Affairs (Project Hope) 2001;20(6):64-78. 
Ware 1992  
Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework 
and item selection. Medical Care 1992;30(6):473-83. 
Wedzicha 2000  
Wedzicha JA. The heterogeneity of chronic obstructive pulmonary disease. Thorax 2000;55(8):631-2. 
Weingarten 2002  
Weingarten SR, Henning JM, Badamgarav E, Knight K, Hasselblad V, Gano A Jr, et al. Interventions used 
in disease management programmes for patients with chronic illness - which ones work? Meta-
analysis of published reports. BMJ (Clinical Research Ed.) 2002;325(7370):925. 
WHO 2008  
World Health Organization. World Health Statistics 2008. Available from: http://www.who.int/whosis/
whostat/2008/en/index.html.
Yang 2012  
Yang IA, Clarke MS, Sim EHA, Fong KM. Inhaled corticosteroids for stable chronic obstructive pulmo-
nary disease. Cochrane Database of Systematic Reviews 2012, Issue 7. Art. No.: CD002991. DOI: 
10.1002/14651858.CD002991.pub3.
Zigmond 1983  
Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatrica Scandinavica 
1983;67(6):361-70. 
Zitter 1997  
Zitter M. A new paradigm in health care delivery: disease management. In: Todd WE, Nash D, editor(s). 
Disease Management: a Systems Approach to Improving Patient Outcomes. Chicago: American 
Hospital Association, 1997:1-25.
Cochrane review 113
Characteristics of included studies
Aiken 2006  
Methods RCT; follow-up: unknown; control group: usual care, which means patients receiving care 
from managed care organizations (MCO)
Participants Eligible: 192 (COPD and congestive heart failure); Randomized COPD: 61 
Mean age/sex: not reported for COPD patients Inclusion criteria: COPD or congestive 
heart failure patients, palliative treatment residing at home, receiving care by MCO, mean 
life expectancy of 2 years, saturation < 88%, oxygen usage, marked limitation of physical 
functioning, recent exacerbation
Interventions Phoenix Care palliative intervention services were added to treatment services of local 
MCOs. Registered nurse case managers (serving 30 to 35 patients) provided the intervention 
service. These nurses worked with protocols and held contact with the attending physicians. 
Furthermore, they developed care plans, provided education to patients and tailored self 
management of the disease. They supported services including assessing psychological 
and spiritual needs. During exacerbation episodes, the nurses assessed medical status, 
implemented a symptom control intervention and contacted the physician 
Included health care providers (HCP): GP, nurse case manager
Outcomes SF-36, medical utilization
Notes Main component of program: structured follow-up with nurses/GP
Bendstrup 1997  
Methods RCT; follow-up: 24 weeks; control group: no treatment
Participants Eligible: 47 Completed: 32 Mean age I: 64 yrs, C: 65 yrs Sex (% male) both groups: 56% 
Inclusion criteria: diagnosis of COPD according to GOLD, FEV1 of 25% to 55% of predicted 
value, Tiffeneau index less than 70%, stable condition for 4 weeks (no change in exercise 
status, sputum color/quantity, no change in medication) Major exclusions: heart disease, 
musculoskeletal disease limiting exercise, intermittent claudication limiting exercise
Interventions 12 week program including: 
- Exercise training (strength training, backwards/sideways walking, endurance training): 3 
times per week for 1 hour during 12 weeks. Patients were encouraged to train at home 
- Occupational therapy: 2 group sessions 
- Education: 12 sessions, including proper administration, inhalation techniques, 
psychological education, socioeconomic problems and nutrition 
- Smoking cessation: free nicotine patches, education 
Included HCP: practice nurse, physiotherapist, dietician, psychologist, occupational therapist, 
social worker, physician
Outcomes Chronic Respiratory Disease Questionnaire (CRDQ), York Quality of Life Questionnaire (YQLQ), 
6MWD, lung function, patient attendance, staff working hours
Notes Main component of program: exercise
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Bourbeau 2003  
Methods RCT; follow-up: 12 months; control group: usual care
Participants Eligible: 469 Randomized: 191 Completed: 165 Mean age: I: 69 yrs; C: 70 yrs; Sex (% male): 
I: 52%; C: 59%; Inclusion criteria: stable COPD with at least one hospitalisation for an 
exacerbation in preceding year, age ≥ 50 yrs, pack yrs ≥ 10 yrs, FEV1% predicted (post-
bronchodilator): 25% to 70%, FEV1/VC < 70%; Major exclusions: no previous diagnosis of 
asthma or left congestive heart failure, terminal disease, dementia, uncontrolled psychiatric 
disease, no pulmonary rehab < 1 yrs ago, no long-term facility stays
Interventions A disease-specific self management program (Living Well with COPD) of 7 to 8 weeks of 
follow-up including: 
- Individual sessions of education by an experienced health professional at the patient’s home 
- Content of education: COPD knowledge, breathing and coughing techniques, energy 
conservation during day-by-day activities, relaxation exercises; preventing and controlling 
symptoms through inhalation techniques, understanding and using a plan of action for acute 
exacerbation, adopting a healthy lifestyle, leisure activities and travelling, a simple home 
exercise program and long-term home oxygen therapy 
- An action plan for acute exacerbations was customized for each patient 
Intensity: education 1 hour per week during 7 to 8 weeks, follow-up first 2 months weekly 
telephone calls, then once a month a telephone call. Exercise evaluation (not mandatory): 3 
times per week, 30 to 45-min/session + exercise teaching 
Included HCP: nurse, physiotherapist, physician, pulmonologist
Outcomes SGRQ, exacerbations, spirometry, FEV1 (L), forced vital capacity, hospital admissions, 
symptoms, emergency room visits, outpatients visits, 6MWT, walking distance
Notes Main component of program: self management (including action plan)
Boxall 2005  
Methods RCT; follow-up 12 weeks; control group: usual care
Participants Eligible: not clear; Randomized: 60; Completed: 46; Mean age I: 78 yrs; C: 76 yrs; Sex (% male): 
I: 48%; C: 65%; Inclusion criteria: diagnosis of COPD by a respiratory specialist, age > 60 yrs, 
dyspnoea on exertion, live locally, motivated to exercise daily unsupervised, stable for 2 
weeks, functionally housebound; Major exclusions: attending outpatient based PR, restricted 
shoulder movement, living in nursing home, previous lung volume surgery, pain limiting 
mobility
Interventions 12 week program including: 
- Exercise consisting of walking (level 1 to 10) and arm exercises (1 to 18) + education 
sessions. Patients were required to carry out exercise daily. Weekly physiotherapy visits were 
scheduled for the first 6 weeks, and then visits were made until week 12 of the program. 
Visits were used to monitor exercise performance, progress exercises, retest 6MWT at regular 
intervals (weeks 1, 4, 6, 8 and 12 of the program) and provide encouragement to patients 
- Educational sessions for patients and carers were conducted by physiotherapists, nurses 
and occupational therapy staff in their homes. Those sessions covered: anatomy and 
physiology of the lungs, use of respiratory devices, medications, breathing techniques, 
secretion removal techniques, energy conservation, use of adaptive aids and stress 
management. Patients received on average 11 home visits during the program 
Included HCP: physiotherapists, nurses, occupational therapist
Outcomes Health status: SGRQ, 6MWD, hospital admissions, average length of stay, dyspnoea Borg Scale
Notes Main component of program: exercise
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Cambach 1997  
Methods RCT with cross-over design; follow-up 6 months; control group: drug treatment only
Participants Eligible: 89 (asthma and COPD) Analyzed: 23 (COPD); Mean age I : 62 yrs, C: 62 yrs; Sex (% 
male): I: 47%, C: 75%; Diagnosis of asthma or COPD according to guidelines, evidence of 
dyspnoea and decreased exercise tolerance as a result of obstructive lung disease, 18 to 75 
yrs, ability to travel independently to the physiotherapy practice, medication prescribed by a 
pulmonary physician, motivation to improve self care, informed consent. Major exclusions: 1) 
manifest cardiac complaints, 2) hypercapnia and/or hypoxia
Interventions 12 weeks intervention including: 
Exercise group sessions of 3 to 4 participants including techniques of breathing retraining 
and evacuation of mucus, exercise training, patient education, relaxation techniques and 
recreational activities. Training was 3 days a week for 90 minutes. Exercise training was 
performed twice a week on a cycle ergometer and by stair-walking. Recreational activities 
were once a week for 45 min. Education sessions were every week for 45 min 
Included HCP: nurse, physiotherapist
Outcomes 6MWT, incremental cycle ergometer test, CRQ
Notes Main component of program: exercise
Dheda 2004  
Methods RCT; follow-up 6 months; control group: primary care follow-up
Participants Eligible: 33; Completed: 25; Mean age I: 68 yrs, C: 71 yrs; Sex (% male) both groups: unknown. 
Diagnosis COPD according to British Thoracic Society guidelines, patients with a first 
admission to hospital, with progressive symptoms, a smoking history of > 20 pack-years. 
Major exclusions: another dominant medical condition, a mandatory reason for hospital 
follow-up
Interventions Intervention program of 6 months 
A respiratory nurse and/or chest physician reviewed the intervention group at least 4 times 
in the 6 month period (at 6, 8, 12 or 16 weeks). The following interventions were made at 
some or all of these visits: spirometry with reversibility, review of inhaler technique and peak 
flow diary, ambulatory oxygen assessment, smoking cessation advice, steroid trial, nebuliser 
assessments, review of medication, advice about nutrition and exercise, and introduction to a 
patient support group 
Included HCP: nurse, chest physician
Outcomes SGRQ, SF-36
Notes Main component of program: structured follow-up with nurse/GP
116 Chapter 4
Engstrom 1999  
Methods RCT; follow-up 12 months; control group: usual outpatient care
Participants Eligible: 58; Randomized: 55; Completed: 50; Mean age I: 66 yrs, C: 67 yrs; Sex (% male) I: 54%, 
C: 50%. Clinical diagnosis of COPD, developing after at least 10 yrs of smoking, FEV1 < 50%, 
debut of symptoms after 40 yrs of age, dyspnoea mainly elicited by exercise or infections, 
no allergy. Major exclusions: disabling or severe diseases, co-existence of other causes of 
impaired pulmonary function
Interventions 12 months rehabilitation program including: 
- Exercise training sessions (bicycle, arm and breathing techniques), 2/week for 6 weeks, 
once weekly for 6 weeks, once every second week for 6 weeks and then once a month for 
remaining period. Every session: 45 min. Furthermore, instructions for daily walks and an 
individualized daily 30-min home-training program 
- Individualized educational program with outpatient team (nurse and physician) on visit 
every 3 months 
- Occupational therapist gave 2 group sessions about energy saving techniques and 2 global 
education sessions 
- Dietician gave information about nutrition in COPD patients and intervened in malnutrition 
Included HCP: physiotherapist, nurse, physician, dietician, occupational therapist
Outcomes SGRQ, 6-MWD, W-max, days in hospital, SIP, Mood Adjective Check List (MACL)
Notes Main component of program: exercise
Farrero 2001  
Methods RCT; follow-up 12 months; control group: usual care
Participants Randomized: 122; Completed: 94; Mean age I: 69 yrs, C: 69 yrs 
Clinical diagnosis of COPD, requiring oxygen for at least 6 months, with willingness to 
participate in a hospital based home-care program, and with residence within easy reach of 
the hospital
Interventions Hospital based home-care program of 12 months with the aim of combining home-care 
management and easy access to hospital resources. Program included: 
- Monthly telephone calls and 3-monthly home visits from a nurse, working closely with a 
physician. Patients could also request with an immediate response, which varied according 
to a home visit, a hospital visit, telephone advice or a control visit. Included HCP: nurse and 
physician
Outcomes CRQ, spirometry, mortality, hospital admissions, hospital days, ED visits
Notes Main component of program: structured follow-up with nurses
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Fernandez 2009  
Methods RCT; follow-up 12 months; control group: education (mono-disciplinary intervention)
Participants Eligible: 50; Randomized: 50 (I: 30; C: 20); Mean age: 66 yrs, C: 70 yrs; Sex: 100% male (both 
groups) 
Inclusion criteria: GOLD 4 patients, younger than 80 yrs of age, stable COPD, defined as a 
period of 2 months without any exacerbations, defined as signs of acute dyspnoea requiring 
medical attention, changes in the quantity and characteristics of sputum, an increase in 
pulmonary noise or an increase in the necessity for medication, the correct administration of 
pharmacological treatment according to GOLD, home treatment with oxygen for at least 6 
months prior to the commencement of the study 
Major exclusions: severe cardiovascular pathology, unstable angina, acute myocardial 
infarction, cerebral vascular accident, or physical or psychological disorder that impede the 
practice of physical exercise
Interventions Rehab program of 11 months 
At the start: 2 one-hour sessions of respiratory re-education in the hospital, where exercises 
at home were taught.  
Home-rehab program : 
- 1 hour of exercise per day (respiratory reeducation, muscular inspiratory training, muscular 
training of upper and lower limbs) 
- First 2 months: attendance of physiotherapist at home (who visited twice monthly for 1 
hour) 
- Month 2 to 9: single monthly visits physiotherapist, included resistance training, respiratory 
reeducation, isotonic training, training of respiratory muscles 
- 3 respiratory education sessions by nursing staff (handling of inhalers, knowledge of the 
illness, what to do in the event of attack) 
Included HCP: nurse, physiotherapist
Outcomes Pulmonary function, SGRQ, 6MWD
Notes Main component of program: exercise
Gottlieb 2011  
Methods RCT; follow-up: 18 months; control group: usual care
Participants Eligible: 133; Randomized: 61; Completed: 26; Mean age I: 74 yrs, C: 73 yrs; Sex (% male): I: 
32%, C: 35%. Inclusion criteria: a diagnosis of moderate COPD, FEV1/FVC < 0.7 and 50% ≤ 
FEV1 < 80% with motivation for pulmonary rehabilitation. Exclusion criteria:1. Co-morbidity 
contraindicating rehabilitation, 2. Participation in PR within the last year, 3. Cognitive 
disorders limiting the ability to participate in physical training and educational sessions
Interventions Program of intensive training for 7 weeks, with maintenance program for 6 months, including: 
- Intensive 7-week physical training and educational phase led by a multidisciplinary team. 
Furthermore, smoking cessation counseling given on an individual basis and a dietary 
intervention consisted of group cookery classes and individual sessions 
- Final interview following completion of the program, in which participants’ achievements 
were compared to the original goals 
- Maintenance program for 6 months, including a 90-min monthly session focusing on 
ways of incorporating exercise in daily life, and 2 sessions on exercise activities in the local 
community, and another 2 sessions on exercise as well as on repetition of relevant topics 
Included HCP: multidisciplinary team, not further specified. Authors were unreachable for 
further information.
Outcomes SGRQ, 6MWD, MRC, Borg dyspnoea scale, Sit-to-Stand test
Notes Main component of program: exercise
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Güell 2000  
Methods RCT; follow-up: 24 months; control group: usual care
Participants Eligible: 65; Randomized: 60; I: 30, C: 30; Completed (24 months): 47 (I: 23; C: 24); Mean age I: 
66 yrs, C: 64 yrs; Sex (% male) both groups: 100% 
Inclusion criteria: age ≤ 75 years, FEV1 < 70%, FEV1/FVC < 65%, PaO2 > 55 mm Hg at rest 
with no indication for prescribing home oxygen therapy. Major exclusion criteria: clinically 
apparent heart disease, bone or joint disease. Exacerbation or hospitalisation in previous 
month
Interventions 6 months intensive rehabilitation program, followed by a 6-month maintenance program 
- First 3 months: 2 30-min sessions each week: breathing retraining, combined with a low-
level home exercise program. If indicated, patients also received chest physiotherapy, which 
involved teaching effective cough and postural drainage. Patients attended educational 
sessions on the anatomy and basic physiology of the respiratory system as well as on the 
nature of their disease and of PR 
- Month 3 to 6: exercise training program of 5 30-min sessions weekly on a stationary cycle 
ergometer. During this period, patients also began a program of home exercise with either 30 
min of pedaling on a stationary cycle or 1 h of walking 
- Month 6 to 12: single weekly session in groups during which they performed exercises for 
breathing and leg-arm co-ordination 
- Month 12 to 24: instructed to do home exercises without supervision 
Included HCP: nurse, physiotherapist, pulmonologist
Outcomes Lung function, 6MWD, cycle ergometer, VAS, MRC, CRQ, exacerbations, hospital admissions
Notes Main component of program: exercise
Güell 2006  
Methods RCT; follow-up: 4 months; control group: usual care
Participants Randomized: 40; I: 20; C: 29; Completed: 35; I: 18, C: 17; Mean age: I: 68 yrs, C: 66 yrs; Male: 
I: 88%, C: 100%. Inclusion criteria: age ≤ 75 years, FEV1 < 70%, FEV1/FVC < 65%, PaO2 > 55 
mm Hg at rest with no indication for prescribing home oxygen therapy. Exclusion criteria: 
psychiatric disturbances, no heart, bone or joint disease. Exacerbation or hospitalisation in 
previous 2 months
Interventions PR program of 4 months, including: 
- First 2 months: 2 30-min sessions each week, including relaxation techniques, breathing 
retraining, and chest wall and abdominal muscle wall work. Patients attended 4 45 to 60-min 
educational sessions 
- Month 2 to 4: 5 30-min sessions weekly exercise training on cycle ergometer 
Included HCP: nurse, physiotherapist, pulmonologist
Outcomes Millon Behavior Health Inventory (MBHI), Revised Symptom Checklist (SCL-90-R), 6MWD, CRQ
Notes Main component of program: exercise
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Koff 2009  
Methods RCT; follow-up 3 months; control group: usual care
Participants Eligible: 40; randomised: 40; completed 38; Mean age I: 67 yrs, C: 65 yrs; Sex (% male): I: 45%, 
C: 50% 
Inclusion criteria: clinical diagnosis of COPD, GOLD 3+4, with a telephone land line 
Exclusion criteria: active treatment for lung cancer, illiteracy, non-English speaking, inability 
to complete a 6MWD
Interventions 3-month intervention program, including: 
- Disease-specific education, by respiratory therapist at enrolment and daily by Health Buddy 
System (tele healthcare) Education included disease description, medications and their use, 
nutrition, breathing techniques 
- Teaching of self management skills (use of an oximeter and increased awareness of clinical 
changes/problems). Patients could contact the co-ordinator in case of deterioration 
- Patients were remotely monitored 5 days per week with the Health Buddy system for 
change in symptoms, saturation, 6MWD and lung function. The study co-ordinator reviewed 
these results and patients were contacted if they were at high risk for exacerbation. They 
started exacerbation management or had contact with respiratory physician/GP 
Included HCP: physician, pulmonologist
Outcomes SGRQ, 6MWD, exacerbations, hospitalizations, ED visits, equipment satisfaction, number of 
calls
Notes Main component of program: self management
Littlejohns 1991  
Methods RCT; follow-up 12 months; control group: usual care
Participants Eligible: 166; Randomized: 152; I:73, C: 79; Completed (12 months): 133; I: 68, C: 65; Mean age 
I: 63 yrs, C: 63 yrs; Sex (% male): I: 67, C: 63. Inclusion criteria: COPD diagnosed by spirometry, 
according to guidelines. Inclusion criteria: age 30 to 75 yrs, prebronchial FEV1 % < 60%, 
stable state, no change in medication for at least 6 weeks before recruitment, no other major 
disease
Interventions Intervention group received the care of the respiratory health worker while continuing with 
their routine outpatient appointments during 12 months. The health worker provided: 
- Health education directed at the patient and the primary care team 
- Monitoring of treatment compliance and optimizing treatment by ensuring correct 
inhalation techniques and supervision of domiciliary oxygen 
- Monitoring of the results of spirometry and the patients’s symptoms to enable acute 
exacerbations and worsening heart failure to be detected and treated early 
- Liaison between GP and hospital-based services (including domiciliary physiotherapy 
services and social services) Included HCP: GP, respiratory health worker
Outcomes Mortality, spirometry, 6MWD, step test, MRC chronic bronchitis questionnaire, HADS, SIP, 
hospital admissions, drug prescriptions, visits to GP or clinic, satisfaction
Notes Main component of program: structured follow-up with respiratory health worker
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Mendes 2010  
Methods RCT; follow-up 12 weeks; 2 intervention groups (at home PR versus outpatient PR), 1 control 
group: usual care
Participants Eligible: 117; Randomized: 117 (Intervention I: 42; Intervention II: 46; Control: 29); Analyzed: 
85 (Intervention group I: 33; Intervention II: 23; Control: 29) Mean age: Intervention I: 66 yrs, 
Intervention II: 71, Control: 71; Sex (% male): Intervention I: 82%, Intervention II: 83, Control: 
66%; Inclusion criteria: diagnosis of COPD according to GOLD, stable at inclusion. Major 
exclusions: hospitalisation or COPD instability, presence of neuromuscular disease, associated 
respiratory disease, orthopedic or neurological disease that affected gait, recent impairment 
due to co-morbidities, such as myocardial infarction, heart failure, stroke or neoplasm; prior 
pneumonectomy or other thoracic surgery
Interventions Intervention program of 3 months performed either at home or at the outpatient clinic: 
- Both intervention groups received 1 session of education about COPD, treatment and 
relevance of PR 
- Both intervention groups trained 3 mornings a week for 3 months, with aerobic and 
strengthening exercises. Patients in the outpatient clinic trained under supervision; patients 
who trained at home were instructed in the clinic and received support by telephone calls. 
Included HCP: physiotherapist, pulmonologist
Outcomes 6-MWD, MRC, FEV1, BMI, all included in BODE index (body mass, obstruction, dyspnoea, 
exercise tolerance- index)
Notes Main component of program: exercise
Rea 2004  
Methods Cluster RCT; follow-up: 12 months; control: conventional care
Participants Eligible: 158; Randomized: 135; I: 83, C: 52; Completed: 117; Mean age of both groups: 68 yrs; 
Sex (% male) of both groups: 41.5%. Inclusion criteria: COPD diagnosed by ICD-9-CM codes 
and GP records for a clinical diagnosis of moderate to severe COPD. Major exclusion criteria 
for patients: chronic asthma, bronchiectasis, comorbidity more significant than COPD, unable 
to give informed consent, prognosis < 12 months, long-term oxygen therapy or too unwell, 
deceased. Major exclusion criteria GP: no longer enrolled with participating GP practice or 
moved out of area, unable to contact patient, insufficient practice nurse resource
Interventions A chronic disease management program was implemented including: 
- An action plan, which was implemented by patient’s own GP and practice nurse, with 
advice from the respiratory nurse and specialist physician. The plan comprised a timetable for 
regular maintenance checks and set achievable goals for lifestyle changes 
- Patients visited the nurse monthly, the GP 3 monthly and at other times if worsening 
symptoms demanded more visits 
- Patients received education about smoking cessation, medication. Annual influenza 
vaccination and pulmonary rehabilitation were recommended 
Included HCP: GP, nurse, pulmonologist
Outcomes Health status, SF-36, CRQ, shuttle walk test, spirometry, hospital admissions, medication, 
courses of oral steroids, courses of antibiotics, smoking cessation 
Randomization at cluster level, analysis at patient level




Methods RCT; follow-up 12 months; control: single intervention (one page of information and 
telephone number)
Participants Eligible: 743; Randomized: 743; I: 372, C: 371; Completed: 743. Mean age I: 69 yrs, C: 71 yrs; 
Sex (% male) I: 98%, C: 98%. Inclusion criteria: COPD diagnosed by spirometry. Inclusion 
criteria: at high risk for hospitalisation as predicted by one or more of the following during 
the previous year: hospital admission or ED visit for COPD, chronic home oxygen use, or 
a course of systemic corticosteroids for COPD. Major exclusion criteria: any condition that 
might preclude effective participation in the study or that would reduce life expectancy to 
less than a year, or no access to a telephone
Interventions Chronic disease management program of 12 months, including: 
- Group session (1-1, 5-hour): general information about COPD, medication, smoking 
cessation, vaccinations and exercise 
- All patients received an individualized written action plan including prescriptions for 
prednisone and antibiotics with contact information with a case manager. Participants 
were in possession of action plan medications at all times and were to refill prescriptions 
immediately upon initiating the action plan 
- The case manager made monthly telephone calls 
Included HCP: case manager, pharmacist
Outcomes ED and hospital admissions related to COPD, SGRQ, mortality, number of telephone contacts
Notes Main component of program: self management/action plan
Smith 1999  
Methods RCT; follow-up 12 months; control: usual care
Participants Eligible: 105; Randomized: 96; I: 48, I: 48; Completed: 36 (data only completed in Intervention 
group); Mean age I: 70 yrs, C: 70 yrs. Major inclusion criteria: COPD diagnosis according to 
guidelines, age > 40 years, FEV1/FVC less than 60%, in a stable state, have a carer involved 
in their management, be able to speak and read English and give written consent. Major 
exclusion criteria: no other active illness
Interventions An intervention of 12 months including: 
- Follow-up planning of in- and outpatients with a nurse in shared care approach with GP and 
medical staff. Goals for discharge and nurses discussed with the GP the needs and facilitated 
involvement of domiciliary service. Goals were inserted into patients’ notes 
- During 12 months every 2 to 4 weeks there was a home visit including education, 
spirometry, optimal medication, exacerbation management, smoking cessation and fitness 
advice 
Included HCP: nurse, GP, social worker, hospital medical officer
Outcomes COOP (HRQoL), mortality, hospital admissions, lung function
Notes Main component of program: structured follow-up with nurses/GP
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Sridhar 2008  
Methods RCT; 104 weeks; control group: usual care
Participants Eligible: 297; Randomized: 122 (I: 61; C: 61); Mean age both groups: 70 yrs; Sex (% male): both 
groups: 49%; Inclusion criteria: diagnosis of COPD and admitted between 2000 and 2004 
with an acute exacerbation of COPD. Exclusion criteria: significant comorbidity (severe heart 
disease or cancer, or any condition that would preclude participation in the physical therapy 
component of a PR program)
Interventions Intervention program of 24 months: 
- Patients started with a PR program for 4 weeks, including general education about disease 
and treatment, and physical training program 
- After 4 weeks, patients received a home visit, including a written COPD action plan for 
exacerbations. The GPs provided medication 
- Patients received monthly telephone calls and a home visit every 3 months until 24 months 
follow-up. They reinforced advice regarding treatments, smoking cessation, the need to 
continue their exercise therapy and reinforced the self management education 
Included HCP: GP, nurse, physiotherapist
Outcomes CRQ, mortality, exacerbations, hospital admissions, lung function  
Notes Main component of program: exercise + action plan
Strijbos 1996  
Methods RCT; 18 months; intervention group 1: hospital based PR, intervention group 2: home based 
PR, control group: usual care
Participants Eligible: 50; Randomized: 50; I group 1: 18, I group 2: 17, C: 15; Completed: 41; Mean age I 1: 
61 yrs, I 2: 60 yrs, C: 63. Sex (% male): I 1: 93%, I2: 80%, C: 80%. Inclusion criteria: diagnosis 
COPD as evidenced by history, physical examination, chest radiograph and pulmonary 
function test results, PaCO2 at rest of less than 6.5 kPa, and PaO2 at rest of more than 7.5 kPa; 
FEV1 < 65% predicted. Major exclusion: ischaemic heart disease, musculoskeletal disorders or 
other disabling diseases that could restrict the rehab therapy
Interventions 12-week rehabilitation program: 
- Both groups: exercise twice a week during 12 weeks, 1 hour each session 
- In the hospital group exercise was administered by a physiotherapist (1 hour twice a week) 
and patients were instructed to practice daily exercise for at least 15 min. Patient education 3 
times/1 hour by a respiratory nurse 
- In the home-care group, exercise was carried out at home by the local physiotherapist and 
home-care nurse, under supervision of the GP. Patients received an individualized exercise 
program from physiotherapist of 30 minutes (24 sessions), and were instructed to exercise 
at least 15 to 30 min. They received 3 times education by a nurse and 3 times a visit by the 
physician or GP 
- Both groups were intended to continue exercise daily at home, after completion of the 
program 
Included HCP: nurse, physiotherapist and GP or pulmonologist
Outcomes 4minute walking test (4MWT), cycle test (measured as maximum watts, W-max) and 
interviews
Notes Main component of program: exercise
Cochrane review 123
Theander 2009  
Methods RCT; 3 months; control group: usual care
Participants Eligible: 30; Randomized: 30; I:15, C:15; Completed: 26. Mean age I: 66; C: 64 yrs; Sex (% male): 
I: 25%; C: 71%. Inclusion criteria: diagnosis of COPD: according to British guidelines, with FEV1 
between 60% to 25% post bronchodilation, and age ≤ 75 yrs. Major exclusions: disabling or 
severe disease other than COPD, impaired pulmonary function due to other disease, long-
term oxygen therapy, alpha1-antitrypsine deficiency, cancer disease, untreated obstructive 
sleep apnea syndrome and no COPD-related symptoms affecting their activities of daily life
Interventions Multidisciplinary program: 
- Physiotherapy 2 days per week (1 hour) for 12 weeks, with additional home training after q 
month 
- Dietician support (3 sessions of 1 hour): education and, if needed, additional nutritional 
supplementation 
- Occupational therapist: education and teaching 
- Nurse (two sessions of 1 hour): education and self care advice 
Included HCP: physiotherapist, dietician, occupational therapist, nurse
Outcomes BMI, FEV1, fatigue impact scale, 6MWD, grip strength, SGRQ, SF-36
Notes Main component of program: exercise
Trappenburg 2011  
Methods RCT; follow-up 6 months; control group: usual care
Participants Eligible: 391; Randomized: 233, I: 111, C: 122; Completed (6 months): 193; I: 91, C: 102. Mean 
age: I 66 years, C: 65 years. Sex (% male): I: 65% C: 69% 
Inclusion criteria: COPD diagnosed by spirometry, age > 40 years, smoking history of > 20 
years or 15 pack-years, diagnosis of COPD as a major functionally limiting disease, current use 
of bronchodilator therapy. Major exclusions: primary diagnosis of asthma, primary diagnosis 
of cardiac disease, presence of disease that could either affect mortality or participation in 
the study
Interventions 6-month self management/action plan program: 
- Individualized action plan with treatment prescriptions related to a color-coded symptom 
status to enhance an adequate response to periods of symptom deterioration 
- The action plan included ongoing support of a case manager, in concordance with a GP/
respiratory physician. There were 2 reinforcement sessions by telephone at 1 and 4 months 
Included HCP: GP, nurse, pulmonologist
Outcomes Exacerbation rates and recovery time, SGRQ, HADS, courses of antibiotics, corticosteroids, ED 
visits for exacerbation, CCQ score during exacerbation
Notes Main component of program: self management/action plan
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van Wetering 2010  
Methods RCT; follow-up: 24 months, control group: usual care (pharmacotherapy according to 
guidelines, short smoking cessation advice by chest physician and recommendation to eat 
more in case of nutritional depletion)
Participants Eligible: 199; Randomized: 199; I: 102, C: 97; Completed 4 months: I: 87; C: 88; Completed 24 
months: I: 77; C: 81. Mean age I: 66 yrs, C: 67 yrs. Sex: I: 71%; C: 71% 
Inclusion criteria: diagnosis of COPD according to guidelines, other inclusion criteria: 
impaired exercise capacity, W-max < 70%, GOLD 2+3 and clinical stable at inclusion. Major 
exclusion criteria: prior rehabilitation and patients with serious co-morbidity that precluded 
exercise therapy were excluded
Interventions 24-month program including: 
- Intensive 4-month standardized, supervised physiotherapy 2/week (30 min), with home-
based exercises 
- Patients participated in an individualized education program 
- All smokers were offered smoking cessation counselling 
- Nutritionally depleted patients received counseling from a dietician 
- During the 20-month active maintenance phase, patients were instructed to train at home 
and visited the physiotherapist once a month. Dietician support was continued 
Included HCP: nurse, physiotherapist, dietician 
Outcomes SGRQ, total score and number of exacerbations, MRC dyspnoea scale, exercise performance 
(measured as maximum Watts: W-max), 6MWD, muscle strength, isometric quadriceps peak 
torque, maximal inspiratory mouth pressure, fat-free mass and lung function
Notes Main component of program: exercise
Wakabayashi 2011  
Methods RCT; follow-up 12 months; control group: single intervention (education)
Participants Eligible: 102; Randomized: 102; I: 52, C: 50; Completed: 85; I: 42, C: 43. Clinical diagnosis of 
COPD, > 65 years, exclusively visit the clinic with monthly scheduled appointments, have a 
history of cigarette smoking. Exclusion criteria: history of atopy or any apparent asthmatic 
features, were illiterate or had cognitive impairment score of less than 26 on MMSE, lived in 
a residential care facility or a nursing home, had exacerbations during preceding 3 months, 
or had other respiratory diseases such as bronchiectasis, any type of pulmonary fibrosis or 
congestive heart failure
Interventions Patients underwent a program of educational sessions for 6 months, individually tailored 
according to their domain scores on the LINQ questionnaire, which was designed to assess 
the need for information from a patients’ perspective. The program was given by respiratory 
nurses and pulmonary physicians. There were six domains: 1) understanding of COPD, 2) 
pharmacological treatments, 3) exercise, 4) avoidance of exacerbations, including action 
plan with instructions in the event of exacerbations, 5) smoking cessation, 6) nutrition. All 
patients were provided with a booklet that was used during each session. After the intensive 
education period, each patient was followed up for 6 months in the same way as the patients 
in the usual care group 
Included HCP: nurse, pulmonologist
Outcomes FEV1, MRC, SGRQ, 6MWD, Lung Information Needs Questionnaire (LINQ), BMI, BODE index 
(body mass index, dyspnoea, airflow obstruction, exercise capacity), Activities of Daily Living 
(ADL), co-morbidities, hospitalizations
Notes Main component of program: self management/action plan
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Wijkstra 1994 
Methods RCT; follow-up 12 weeks; control group: no treatment
Participants Randomized: 45; Completed: 43 (I: 28; C: 15); Mean age I: 64 yrs, C: 62 yrs; Sex (% male): I: 82%, 
C: 93%. Inclusion criteria: diagnosis of COPD with FEV1 % < 60%, FEV1/IVC < 50%. Exclusion 
criteria: evidence of ischaemic heart disease, intermittent claudication, musculoskeletal 
disorders or other disabling diseases that could restrict the rehab program
Interventions Intervention program of 12 weeks: 
- Patients were supervised by a multidisciplinary team: pulmonologist, physiotherapist, 
nurse, GP 
- Patients visited physiotherapist twice a week for 12 weeks and the program consisted 
of conventional physiotherapy, upper limb training, inspiratory muscle training, exercise 
training. They had to practice twice a day for half an hour at home 
- Furthermore, they received education at home from a nurse (once a month) 
- They visited the GP once a month and he supervised clinical status and maintenance 
treatment 
Included HCP: GP, physiotherapist, nurse
Outcomes Lung function, CRQ, cycle ergometer test
Notes Main component of program: exercise
Wood-Baker 2006  
Methods Cluster-RCT; follow-up 12 months, control group: education + usual care
Participants Eligible: 218; Randomized: 138; I: 67, C: 72; Completed (12 months): 112; I: 54, C: 58; Mean age 
I: 69 yrs, C: 71 yrs. Sex (% male): I: 49%, C: 71% 
Inclusion criteria: COPD diagnosed by spirometry, age > 50 yrs, tobacco smoking history 
of greater than 10 pack-years and FEV1 < 65% predicted. Exclusion criteria: nursing home 
residents
Interventions Control + intervention group: COPD information booklet, individual education session 
with nurse. Intervention group: written self management plan, which was developed in 
consultation with their treating GP. Patients were encouraged to make early contact with 
their GP during an exacerbation 
Included HCP: GP, nurse
Outcomes SGRQ, exacerbations (courses of antibiotics/prednisone), ED and hospital admissions, GP 
consultations, spirometry, mortality, physical exercise (pedometer)
Notes Prior to commencement of the randomisation process, only 50% of the included GPs 
attended one of a series of educational workshops on the management of COPD. Main 


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































COPD multidisciplinary team meetings in the UK: health 
care professionals perceptions of aims and structure




Over the last ten years, community and hospital-based multidisciplinary teams (MDTs) 
have been set up for the management of patients with chronic obstructive pulmonary 
disease (COPD) in the UK. Meetings of the MDTs have become a regular occurrence, 
mostly on healthcare professionals’ own initiatives. There are no standardized methods 
to conduct an MDT meeting and although cancer MDT meetings are widely imple-
mented, the value and purpose of COPD MDT meetings are less clear. Therefore, the 
aim of this study was to conduct a cross-sectional descriptive online survey to explore 
COPD MDT members’ perceptions of the purpose and usefulness of MDT meetings, and 
to identify suggestions or requirements to improve the meetings.
In total, we received 68 responses from 10 MDTs; six teams (n=36 members) were located 
in London and four (n=32 members) outside. Analysis of the replies by two independent 
researchers found that MDT meetings aim to optimise management and improve path-
ways for respiratory patients by improving communication between providers across 
settings and disciplines. Education of the MDT members also occurs with the aim of 
safer practice. Discussed patients are characterised by (multiple) comorbidities, frequent 
exacerbations and admissions, social and mental health problems, unclear diagnosis 
and suboptimal responses to interventions. Members reported participating in a COPD 
MDT as very useful (74%) or useful (20%). Meetings could be improved by ensuring 
attendance through requirement in job plans, by clear documentation and sharing of 
derived plans with a wider audience including general practitioners and patients.
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INTRODUCTION
There is increasing interest in implementing integrated multidisciplinary teams (MDTs) 
in the care of patients with chronic diseases including chronic obstructive pulmonary 
disease (COPD).1 In chronic disease care, MDTs have the potential to improve coordi-
nation, communication, and decision making between healthcare professionals and 
patients2, and lead to fewer hospital admissions whilst improving quality of life.3 Over 
the last ten years, community and hospital-based COPD MDT meetings have evolved 
within the UK, mostly on the initiative of healthcare professionals. Doctors, nurses, phys-
iotherapists, occupational therapists, pharmacists, dieticians, social workers and mental 
health specialists can be involved and contribute within their field of expertise.1 
While the quality of cancer MDT meetings is well studied4, little is known about COPD 
MDT members’ attitudes, perceptions and satisfaction. The aim of this study was to 
explore COPD MDT members’ perceptions of the purpose and usefulness of MDT meet-
ings, and to identify suggestions or requirements to improve the meetings. Through 
this process we wished to explore which patients should be discussed, how value and 
outcomes can be measured, and if other healthcare providers or patients themselves 
should be included in the meetings.
METHODS
We conducted a cross-sectional descriptive online survey to assess the attitudes, per-
ceptions and experiences of UK healthcare professionals participating in a COPD MDT 
meeting. The survey was developed by the first and last author and comprised 15 ques-
tions: six closed and nine open-ended. Questions were intended to determine members’ 
perceptions on the purpose of the meeting, its usefulness, examples of discussed pa-
tients, suggestions for improvement, the need to involve patients and other healthcare 
providers in the meeting and ideas on how to measure the success of the meeting. The 
survey was developed and distributed using Qualtrics survey tool (www.qualtrics.com). 
The first author visited six COPD MDTs in London and collected 48 team members’ 
email-addresses. Four chairpersons of known MDTs outside London were requested 
to disseminate the survey to all their team members on our behalf. All MDT members 
participated voluntarily and remained anonymous, so that they are not individually 
identifiable in the results. To optimise response rates, non-respondents were followed 
up with three additional mailings over a four-week period. Surveys and reminders were 
sent out between 23rd of January and the 21st of February 2014. The first and last author 
individually performed thematic analysis of the survey through an inductive process.5 
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Chi squared tests were used to compare findings between different healthcare providers 
and between MDT members in and outside London.
RESULTS
In total, 68 MDT members participated in the survey, of which 36 (53%) were nurses, 
14 (21%) physiotherapists, 10 (15%) respiratory physicians, three general practitioners 
(GPs) and five other healthcare providers. Fifty-three percent (n=36) were working in 
London and 47% (n=32) outside London. 
Purpose of the MDT
The first question was about the purpose of the MDT. 
The main themes that emerged were:
1. Communication: around 49% reported the MDT meetings improved communication 
and team working, and established more consistent and efficient care across set-
tings.
2. Education and improvement of knowledge: 40% of the respondents considered the 
MDT as a platform for information exchange and believed participation in an MDT 
improved their knowledge about the disease.
3. Devising management plans: 81% percent of respondents reported the aim of the 
meeting was to obtain a proper diagnosis and assessment, to create a management 
plan or to obtain quick and efficient referral to other disciplines. Other aims men-
tioned were to reduce hospital admissions or to discuss end of life issues.
4. Co-ordination of care: 44% felt the meetings helped align pathways and processes 
between professions and organisations so that care became more coordinated for 
patients. 
The perceived purpose appeared to be ‘to optimise management and improve pathways 
for respiratory patients by improving communication between providers across settings 
and disciplines.’ There were no differences in answers between disciplines and between 
professionals working in or outside London. 
Examples of patients that should be discussed
When asked about which patients were usually discussed in the MDT, the themes that 
emerged were: 
1. Complex needs: the majority of the respondents stated that those with complex 
needs, including anxiety and depression, social care, and comorbidities should be 
discussed.
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2. Palliative care: there appears to be a need for support in the management of patients 
nearing the end of life. Both researchers rated this as the second most cited group of 
patients requiring discussion.
3. Admission to, and discharge from hospital: as part of coordinated care pathways.
4. Managing severe disease; including those on oxygen and non-invasive ventilation.
5. Exacerbation management and disease optimisation.
Patients that the MDT members felt should be discussed were sub-optimally managed 
patients with complex needs and comorbidities, an unclear diagnosis, psychological/so-
cial problems, frequent exacerbations or hospital admissions, or those requiring oxygen 
or palliative care. There were no differences in answers between disciplines or between 
members working in or outside London.
Usefulness of the MDT meetings and suggestions for improvement
Ninety four percent of the members rated their MDT meetings as either very useful 
(74%) or useful (20%). The professionals outside London rated the MDT meetings more 
often as very useful compared to the professionals working in London (p=0.03).  Six 
percent gave no answer; nobody rated the MDT meetings as not useful. Nurses and 
physiotherapists reported the meetings were an opportunity to discuss management 
plans and to receive support and advice on their decisions from the consultants and 
senior colleagues. Furthermore, they mentioned the meetings were an opportunity to 
learn more about the disease and share knowledge. Finally, the meetings improved com-
munication between healthcare providers and were a unique way to further improve 
integrated working. Thirty-one percent of the members suggested meetings could be 
improved by formalising the structure to include clear objectives, adequate prepara-
tion of cases and accountability of outcomes. Other suggestions included a (rotating) 
chairperson (7%) and to end every meeting with a proper documentation of the derived 
agreements (17%) in the form of a care plan to be shared with the patient. They also 
suggested reporting outcomes to primary care (5%).
Involving the GP
In our sample, there were only three GPs included from two MDTs, one in London and 
one outside London. Almost all (99%) members reported they wanted the GP to some-
how be included in the meeting. They mentioned GPs to be an essential part of the team 
as they have knowledge of their patients including comorbidities and social background 
and are responsible for the care in the community. Others felt involving the GP could 
assure better care delivery and could make the treatment more successful. Finally, they 
mentioned GPs could increase their own disease-specific knowledge when participating 
in the MDT. Concerns for feasibility included GPs’ time and cost.
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Involving other healthcare professionals
Eighty-three percent of the members reported it would be useful to extend the member-
ship of the MDT. There was a need for social service expertise (33%), community matrons 
or district nurses (28%), palliative care (15%), mental health workers (15%), nutritionists 
(13%) and oxygen specialist therapists (13%). Sixteen percent indicated that they had no 
need to include other healthcare professionals.  
Involving patients
Although 43% of the respondents reported they would like to invite the discussed pa-
tients to the meeting, most of them expressed practical reasons not to do so. There were, 
however, differences between healthcare providers: 75% of the respiratory physicians 
wished to include the patient, while in nurses it was 50% and in physiotherapists 21%. 
Lack of time during the meetings and logistical problems were the main reasons given 
(84%) for not inviting patients. Others expressed problems with confidentially or health-
care providers including too much medical details in professional discussions, which 
might not necessarily benefit the patient. However, members appeared to agree that 
sharing the care plan with the patient was important, especially to gain more insight 
into the patients or family’s perspective of the plan, and to assure patients would com-
ply with the plans (‘no decision about me, without me’). However, they suggested this 
could be discussed and fed back in a separate consultation with the patient and carers. 
Outcomes for success
When asked how the success of a meeting could be measured the following outcomes 
were suggested:
1) Number of management plans devised per meeting;
2) Number of interventions/care plans implemented;
3) Team satisfaction or team surveys;
4) Patient satisfaction or related outcomes, such as health-related quality of life; 
5) Decrease in emergency hospital admissions or attendances.
DISCUSSION
This cross-sectional survey of members of COPD multidisciplinary teams (MDT) in the UK 
shows that the majority rate participation in MDT meeting as (very) useful. The meetings 
aim to optimise management and improve pathways for COPD patients by improving 
communication between providers across settings and disciplines. Education of the MDT 
members is an important aim to ensure safer practice and maintain up to date knowl-
edge. Discussed patients are often characterized by (multiple) comorbidities, frequent 
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exacerbations or admission to hospital, social or mental health problems, an unclear 
diagnosis or suboptimal responses to interventions. Meetings could be improved by 
ensuring attendance through requirement in job plans, by clear documentation, sharing 
of derived plans and by inclusion of the GP and patient in the meeting outcomes.
Our findings are subject to certain limitations. The sample size was relatively small, 
and with the sampling method outside London we were not able to estimate the rep-
resentativeness of respondents. However, the sample adequately represented types of 
respondents across core hospital and community based MDTs in and outside London, 
in which a variety of patients are discussed. Furthermore, our survey was not developed 
using an iterative process of consultations with experts, but was developed by clini-
cians with expertise in MDTs, in order to provide illustrative findings rather than to be 
conclusive. As a result of the high response rate and extensive responses, this is the first 
study to date which gained insight into members’ perceptions on the value of COPD 
MDT meetings. 
Despite recommendations in the recent NICE guidelines1, there is currently no standard-
ized method of conducting a COPD MDT meeting. Our survey indicated a need for a 
more structured approach, with an agenda and chairperson, more pre-planned discus-
sions linked to specific questions and evidence based learning and outcomes. There 
should be clear documentation of the derived plan and actions that are shared with 
the extended MDT including GPs and possibly patients. In addition, the measurement 
of the effectiveness of COPD MDT meetings remains debatable. It may not be possible 
to attribute changes in usage of healthcare to the success of MDTs only, as there are 
more recent developments influencing these outcomes.5 In our survey, patient and 
team satisfaction were also suggested as a way to measure success of team working. In 
cancer MDTs, there is evidence that the ability of an MDT to reach a decision on first-case 
presentation and ability of decisions to be implemented appear to be a useful marker 
of the performance of the MDT meetings.3 This study demonstrates a need for further 
evaluation of MDT meetings to define how the effectiveness can be measured, and 
if standardisation of team meetings can lead to better outcomes for the patient and 
higher satisfaction within the whole team. 
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In the past decade, self-management of chronic obstructive pulmonary disease (COPD) 
has often been regarded as the way forward to reduce the sharply increasing costs of 
treatment and limit future demands on health-care capacity. In 2003, Bourbeau and 
colleagues1 were the first to show substantial reductions of up to 40% in exacerbation-
related hospital admissions and emergency department visits from a self-management 
programme in Canada. Numerous attempts were made to replicate these promising 
results, of which two trials2;3 showed similar beneficial effects on hospital admissions 
and emergency department visits. By contrast, an increasing number of trials with 
mixed or negative results have also been reported, revealing a striking absence of these 
positive effects in Scotland and the Netherlands4-7, or even showing unsettling excess 
mortality in the self-management group in a well-designed trial in the USA.8 So what 
can we learn from this growing, but rather contradictory, evidence? Should we now be 
cautious with the rolling out of self-management, or even refrain from it? Or might we 
be able to identify factors that affect the effectiveness of self-management for COPD, 
and thus identify patients for whom it does actually work?
An important characteristic of the positive trials1-3 is the presence of substantial room for 
improvement all patients had advanced, symptomatic COPD, and were at high risk for 
hospital admission. Furthermore, patients were in regular, sometimes intensive contact 
with a case manager, a key individual who worked closely with the treating physician. 
In other words, these patients were not being left alone with their self-management 
materials, but acted to some extent under proactive guidance.
When looking closely at the trials with mixed or negative results, several observations 
can be made. In two of these studies, no effect was seen in COPD-related hospital admis-
sions5;7 or deaths7  in the intervention groups overall. However, both studies reported 
relevant effects in a subgroup of apparently successful self-managers, representing 
about 40% of patients with COPD. This subgroup was characterised by being of rela-
tively younger age5;7, living with others7, having severe airflow obstruction5, and having 
cardiac comorbidity.5  Another study6  into the effects of an individualised action plan 
showed a clinically relevant effect on health status and suggested some positive effects 
on exacerbation length, but this finding was not significant, suggesting that the study 
was probably underpowered. However, exacerbations in the intervention group were 
perceived by the patients as having become substantially milder, and patients also 
showed enhanced recovery of health status and reduced average length of exacerba-
tions. Therefore, inclusion of an action plan with sufficient education and support can be 
a key component of self-management programmes in patients with COPD.
Despite assessing a population with disease severity comparable to the two trials with 
positive results1;2, the study by Fan and colleagues8  was stopped early because of an 
increase in mortality in the intervention group. One crucial difference in this negative 
study might have been the number of telephone calls from case managers; these calls 
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were scheduled every month for 1 year in the two positive studies1;2,  whereas in the 
negative study8  they were made on a monthly basis for the first 3 months, and only 
every 3 months thereafter. Patients might have underreported symptoms and delayed 
referral by misplaced overconfidence in the self-management system, possibly leading 
to a self-management delay that has now been shown to be potentially lethal. These 
findings suggest that we should probably not try to apply self-management in patients 
with severe COPD without proper case management in place.
Self-management is not a goal in itself, but a means of treatment and one element of 
integrated care. It does not replace the proactive involvement of health-care workers. 
In a Dutch study9into adherence to an online self-management application for patients 
with COPD or asthma, patients tended to use the online application on a regular basis 
when the health-care provider was involved, whereas patients on their own used the 
application only sporadically. No other parameter (sex, age, lung function, or clinical 
severity) seemed to be correlated with adherence to the programme. This finding is 
in line with the results of a study in Scotland7, which showed that a dedicated health-
care provider, spouse, or family member makes all the difference in the successful 
management of complex diseases such as COPD. The importance of this point is further 
emphasised by Koff and colleagues3  and Vandivier and colleagues10,  who report that 
a staggering 47~78% of self-managed patients did not make the crucial telephone 
call to the case manager despite being warned by an online application that they had 
symptoms of an exacerbation. In another study by Koff and colleagues11, as a result of 
proactive coordinators who contacted patients nonetheless, the investigators noted a 
non-significant decrease in mortality, which contrasts with the increased mortality seen 
in Fan and colleagues’ study.8 
Health-care providers should be aware that reducing the total number of exacerbations 
might be difficult to achieve when a programme is targeted at early recognition of 
exacerbations. It might be the case that well-implemented self-management strategies 
actually detect increased numbers of exacerbations overall, but of lesser severity and 
with fewer days spent in hospital, as a result of vigilant early treatment. Additionally, im-
provement in symptom awareness does not necessarily result in adequate detection of 
exacerbations, since non-pulmonary symptoms are often misinterpreted as pulmonary 
alarm symptoms, and vice versa.12 
In summary, interventions to enhance self-management in patients with COPD are very 
diverse and lead to conflicting outcomes. Self-management seems not to be suitable for 
everyone, but when hands-on guidance is provided (by a case manager, or a dedicated 
spouse, friend, or family member), it can be successful in a subgroup of up to 40% of 
patients. This finding should be further investigated in large, carefully designed stud-
ies. Furthermore, reports of future studies should describe precisely the nature of the 
intervention, including the intensity and frequency of contact with a case manager, to 
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allow valid comparisons across different programmes. In this way, guidelines could be 
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COPD constitutes a worldwide growing health care problem. Integrated Disease Man-
agement (IDM) of mild to moderate COPD-patients has been demonstrated to improve 
exercise capacity and health status after one year, but long-term results are currently 
lacking in primary care.
Methods
Long-term data from the Bocholtz Study, a controlled clinical trial comparing the effects 
of IDM versus usual care on health status in 106 primary care COPD patients during 
24 months follow-up, were analyzed using the Clinical COPD Questionnaire (CCQ). In 
addition, the Kroonluchter IDM-implementation program has treated 216 primary care 
patients with mild to moderate COPD since 2006. Longitudinal six-minute walking dis-
tance (6MWD) results of patients reaching 24 months of follow-up were analyzed using 
paired-samples T-tests.  In pre-specified subgroup analyses, the differential effects of 
baseline CCQ score, MRC Dyspnoea scale and 6MWD were investigated.
Results
In the Bocholtz Study, subjects were aged 64 years, with an average post-bronchodilator 
FEV1 of 63% predicted and FEV1/FVC ratio of 0.56. No significant differences existed 
between groups at baseline. CCQ improved significantly and clinically relevant with 
0.4 points during 24 months; effect sizes were doubled in patients with CCQ>1 at 
baseline and tripled in patients with MRC>2. In the Kroonluchter Cohort, 56 subjects 
had completed follow-up, were aged 69 with an FEV1/FVC ratio of 0.59, while their post-
bronchodilator FEV1 of 65% predicted was somewhat lower than the total group. 6MWD 
improved significantly and clinically relevant up to 93m at 12 months and was sustained 
at 83m during 24 months; the effect occurred faster in patients with MRC>2. In patients 
with baseline 6-MWD<400m the improvement remained >100 meters at 24 months.
Conclusion
In this study, integrated disease management (IDM) improves and sustains health status 
and exercise capacity in primary care COPD-patients during two years follow-up. Im-
provements in health status are consistently higher in patients with CCQ >1 at baseline, 
being strongest in patients with baseline MRC Dyspnoea score >2. Improvements in 
exercise capacity remain highest in patients with 6MWD < 400m at baseline and seem 
to occur earlier in patients with MRC Dyspnoea score >2.
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BACKGROUND
COPD constitutes a major and progressive health care problem worldwide and is 
expected to be the third cause of global death over the next twenty years.1  Besides 
smoking cessation, pulmonary rehabilitation (PR) is the recommended treatment and 
has been proven to be effective across the whole spectrum of COPD patients.2-5 A recent 
meta-analysis shows that PR relieves dyspnoea and fatigue, improves mental status and 
enhances patients’ control over their disease.6 However, despite proven efficacy, PR is 
still only available for a small proportion of the worst patients, due to capacity problems 
and high costs.7 It is expected that the rise in prevalence of COPD will progressively 
cause an even higher burden on rehabilitation programmes in the future. 
At present, the majority of COPD patients are treated in primary care, of which ap-
proximately 80% suffer from mild to moderate disease.8 As a result, general practitioners 
often find themselves at a crossroads in the organisation of care for COPD patients. Nev-
ertheless, interdisciplinary cooperation between primary health care providers as well 
as primary and secondary care is often needed. In earlier reports9;10, we hypothesized 
that when components of PR would be tailored into an integrated disease management 
program available for primary care and carried out by a multidisciplinary, integrated 
care team, the benefits of PR could be extended to a larger population of COPD patients 
in need. This would explicitly include those with milder stages of disease, given that they 
have sufficient symptom burden to justify an integrated intervention. Elements that 
often can be integrated are: smoking cessation, exacerbation management, optimal 
medication, self-management, patient education, dietary intervention and physiothera-
peutic reactivation. 
In an earlier paper, we demonstrated that our IDM program in primary care improved 
health status clinically relevant in mild to moderate COPD patients at 12 months follow-
up. Greatest room for improvement was shown in COPD patients with a Medical Re-
search Council Dyspnoea score >2.9 As we had thus demonstrated 12 months’ efficacy of 
the IDM program in a controlled setting, a real-life implementation cohort was set up in 
the city of Rotterdam. In this pragmatic IDM program, we focused on improving exercise 
capacity, as we believed this would be an important driver to sustain effectiveness. Cur-
rently, long-term results of PR programs are mixed and some authors report that most 
benefits of PR dissolve over time.11-13 Similarly, the longer-term effect of IDM in primary 
care is still unclear. The aim of the present study is thus to determine the long-term 
effects of IDM on health status and exercise capacity in primary care COPD patients. 
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METHODS
In this study we analyzed 24 months follow up data of both the controlled clinical Bocholtz 
trial and the Kroonluchter implementation cohort of primary care IDM programs. In both 
studies, the study population consisted of primary care patients with chronic respiratory 
symptoms and a post-bronchodilator FEV1/FVC<0.7, in accordance with national and 
international guidelines.3,8 Exclusion criteria consisted of terminal or immobile patients, 
substance abuse or inability to fill in questionnaires. In the Bocholtz clinical trial, the 
regional Medical Ethics Committee of the Atrium Medical Centre Heerlen approved of 
the study protocol. All participating patients gave their written informed consent. In the 
Kroonluchter cohort, all  patients gave their written informed consent for participating 
in the implementation program. 
Below follows a short description of both study settings and design. We refer to our 
previous publications for an extensive description of the clinical one-year results and 
methods of the Bocholtz study9, as well as background and design of the Kroonluchter 
IDM program.10  
Picasso Bocholtz study
The Picasso Bocholtz study is a pragmatic controlled clinical trial, comparing the effects 
of integrated disease management (IDM) on health status. COPD patients of two com-
parable primary health care centres in the south of the Netherlands were followed up 
for two years, during which the intervention group received an IDM program and the 
control group received usual care. Patients were included based on chronic respiratory 
complaints, post-bronchodilator lung function testing and adequate work-up in case of 
more complex disease by the local pulmonologist, on indication by the patients’ primary 
care physician. In the intervention setting, an integrated COPD management team was 
formed including two physiotherapists, a respiratory nurse, a physician assistant, a dieti-
cian, a pharmacist, a supervising primary care physician and a logistical manager. All 
team members contributed in their area of expertise to a written standardised treatment 
protocol, which included different elements of IDM, based on the joint ATS/ERS COPD 
Standards.14 Examples included personalised physical activity training programmes, 
optimal medication prescribing and adherence monitoring, rapid action plans for exac-
erbations, and continuous self-management education.9 
Kroonluchter cohort
Based on the favourable experiences of the Bocholtz study, the Kroonluchter integrated 
disease management program was implemented in a low-SES borough in Rotterdam, the 
Netherlands. Since 2006, a total of 216 primary care patients with chronic respiratory com-
plaints have been included, after clinical assessment including post-bronchodilator lung 
Integrated COPD management in primary care 153
function testing confirmed eligibility according to GOLD-criteria. A multidisciplinary, dedi-
cated team of primary care physicians, nurse specialists and physiotherapists was formed 
and trained to establish a locally agreed collaborative protocol. Diagnostic work-up in case 
of complex disease was provided by collaborating pulmonologists, after referral by the 
primary care physician. In cooperation with the patient, an individualized, tailor-made 
plan of action was designed, based on an explicitly formulated personal target, varying 
from “quitting smoking with guidance within 6 months” to “climbing a short flight of stairs 
without hindrance by feelings of dyspnoea within 6 months”. Based on disease burden and 
patient needs, an individual program was assembled, that could include self-management 
training and exacerbation management, an exercise training program, smoking cessation 
strategies, better medication use and personalized disease education. 
In case of obesity or muscular depletion, referral to a dietician for a dietary interven-
tion was possible. Because of good local collaboration and arrangements for additional 
workup, patients could be referred to pulmonary physicians on a short notice. In addition, 
extra attention was given to follow up of patients after an exacerbation. Patients with 
a Medical Research Council (MRC) Dyspnoea score>2 or notoriously inactive patients 
(according to their primary care physician) were assigned to a 6-month COPD-specific 
training program by specialized physiotherapists. Physical exercise training consisted 
of one month of individual training, followed by five months of group training. Training 
was focused on strength as well as endurance exercises, and was tailored to individual 
abilities and deficiencies of the patient. Patients trained 2 times for one hour per week 
under supervision and were instructed to train 1 hour per week at home. After 6 months, 
there was a follow-up of 1 hour per week in order to sustain any effects over time.10  
Outcomes and measurements
Baseline measurements in both studies included age, gender, smoking habits, body 
mass index (BMI), lung function and score on the MRC Dyspnoea scale: a short and valid 
questionnaire to quantify dyspnoea.15  
In the Bocholtz study, the Clinical COPD Questionnaire (CCQ) was used to assess health 
status, since it is well validated and easy to administer in primary care.15 Primary outcome 
at 24 months in the Bocholtz study was the difference in CCQ at 24 months compared to 
baseline CCQ score in both the intervention and control groups. 
In the Kroonluchter cohort, the 6 minute walking distance (6MWD), a measure of 
functional capacity, was conducted according to international recommendations.16 The 
6MWD is a practical, self-paced test, measuring the maximum distance subjects can 
walk in 6 minutes. Primary outcome of this program was the difference in 6MWD at 24 
months compared to baseline 6MWD score. 
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Power calculation
In the Bocholtz study, we calculated that a sample size of 2x45 patients was needed 
(with a power of 80% with α = 0.05) to detect a minimum clinically important difference 
(MCID) of -0,4 unit change in quality of life on the CCQ.15 
As the Kroonluchter project was designed as an ongoing implementation program, 
no formal group comparison and hence no power calculation was conducted. On the 
basis of earlier studies and an MCID of 54m which represents the threshold value for a 
clinically significant change on the 6MWD16, a minimum group size of 50 patients was 
deemed necessary to analyze 24 month results. In this study the first batch of consecu-
tive COPD patients completing 6MWD measurements at baseline, 3, 6, 12 and 24 months 
were analyzed.
Statistical analysis
Data were analyzed with SPSS version 13, using independent T-tests and chi-square 
tests for baseline characteristics comparison. Baseline and annual differences in CCQ 
(Bocholtz) and 6-MWD (Kroonluchter) were compared using paired sample T-tests. In 
pre-specified subgroup analyses, the differential effects of baseline CCQ score, MRC 
scale and 6MWD were investigated.
RESULTS
Patients
In the Bocholtz study, 106 COPD patients according to GOLD classification were analyzed 
for baseline measurements, 59 patients in the intervention and 47 patients in the control 
group. In table 1, this initial COPD population is described. Subjects were aged 64 years, 
with an average post-bronchodilator FEV1 of 63% predicted (SD 19) and FEV1/FVC ratio 
of 0.56. There were no significant differences in demographic variables, smoking habits 
or lung function between intervention and control groups at baseline. Of the initial 
population of 106 patients, 86 patients (81%) completed follow up of two years (44 in 
the intervention group and 42 in the control group) and could be further analyzed.
Of the original group of 216 patients in the Kroonluchter cohort, 18% (39 persons) 
dropped out due to relocation, severe co-morbidity or unwillingness to fill out question-
naires repeatedly. Of the initial 216 patients, 104 (48%) were referred to a physiotherapy 
training program, based on MRC>2 or inactivity that necessitated an integrated ap-
proach. So far, 56 patients (54%) completed the 24 months 6MWD, and their data could 
be used for analysis. Table 2 shows the baseline characteristics of the initial cohort and 
the group that has finished 24 months follow-up. The mean age of the latter group was 
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69 years, with an FEV1/FVC ratio of 0.59, while their post-bronchodilator FEV1 of 65% was 
somewhat lower than in the total group (71%). 
Primary outcome Bocholtz study
Table 3 shows the long-term changes in CCQ scores in COPD patients in the interven-
tion and control groups of the Bocholtz study. Compared to baseline, a statistically 
significant change of -0.4 is sustained in the intervention group during 24 months, while 
the control group shows non-significant changes during 24 months. The pre-specified 
subgroup analysis of patients with baseline CCQ >1 shows a statistically significant 
and clinically relevant difference of -0.9, while the control group shows no significant 
improvement. In patients with MRC scores >2, the effect on CCQ score is tripled and 
shows a statistically significant and clinically relevant difference of -1.2, compared to a 
non-significant change of -0.02 in the control group. 
Table 1 Baseline characteristics of intervention versus control group in primary care COPD-patients of the 
Bocholtz Study
  Intervention (n=59) Control (n=47) p-value#
Age (yrs) 64.7 (10) 62.3 (9) 0.99
Gender (% male) 66.4 64.3 0.12
Current smoking (%) 33.9 46.8 0.08
Body Mass Index 25.8 (5) 26.0 (5) 0.75
FEV1 post-BD (%) 63.9 (21) 61.7 (17) 0.06
FEV1/FVC post-BD 0.55 (.10) 0.57 (.10) 0.72
MRC>2 (%) 38.6 33.3 0.32
CCQ 1.4 (1) 1.6 (1) 0.75
*all values are means (SD) except when stated otherwise;  #no significant difference between groups at baseline. 
Abbreviations: MRC, Medical Research Council Dyspnoea Score; CCQ, Clinical COPD Questionnaire
Table 2 Baseline characteristics of total versus 6MWD group in primary care COPD-patients of the 
Kroonluchter Cohort
Total (n=216) 6MWD (n= 56) p-value
Age (yrs) 67.1 (14) 69.2 (10) 0.11
Gender (% male) 42.1 37.3 0.38
Current smoking (%) 41.2 33.3 0.78
Body Mass Index 27.3 (6) 27.8 (5) 0.45
FEV1 post-BD (%) 70.5 (18) 64.5 (17) 0.002#
FEV1/FVC post-BD 0.61 (.12) 0.59 (.14) 0.098
MRC>2 (%) 45.8 51.9 0.24
6MWD (m) 364.0 (128) 354.6 (126) 0.44
*all values are means (SD) except when stated otherwise; #significant difference between groups at baseline
Abbreviations: MRC, Medical Research Council Dyspnoea Score; 6-MWD, 6- Minute Walking Distance
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Primary outcome Kroonluchter cohort
Table 4 shows the long-term changes in 6MWD in the Kroonluchter cohort at 3, 6, 12 
and 24 months. The 6MWD improves significantly and clinically relevant up to 93m 
at 12 months and remains at 83m during 24 months. In patients with MRC-scores >2, 
Table 3 Longterm effects of Integrated Disease Management on Health Status in primary care COPD 
patients of the Bocholtz Study 
Intervention Group
CCQ difference*/ 95% CI p-value
Control Group
CCQ difference**/ 95% CI p-value
All patients
12 mo -0.4 [-0.6, -0.2] 0.001 +0.01 [-0.2, 0.2] 0.9
24 mo -0.4 [-0.7, -0.1] 0.004 +0.02 [-0.4, 0.5] 0.9
Subgroup baseline CCQ>1
12 mo -0.8 [-1.1, -0.4] 0.001 -0.1 [-0.3, 0.08] 0.2
24 mo -0.9 [-1.2, -0.5] 0.001 -0.03 [-0.5, 0.5] 0.9
Subgroup baseline MRC>2
12 mo -0.9 [-1.4, -0.4] 0.002 +0.01 [-0.3, 0.3] 1.0
24 mo -1.2 [-1.8, -0.5] 0.004 -0.02 [-0.8, 0.8] 1.0
*paired samples T-test; p is considered significant at values<0.05; **MCID CCQ = -0.4 15 
Abbreviations: CCQ, Clinical COPD Questionnaire; MRC, Medical Research Council Dyspnoea Score
Table 4 Longterm effects of Integrated Disease Management on Exercise Tolerance in primary care COPD 
patients of the Kroonluchter Cohort
6-MWD difference *** compared to baseline  95% CI p-value
All patients
3 mo 38.3 [27.2, 49.4] <0.0001
6 mo 62.5 [47.4, 77.7] <0.0001
12 mo 93.5 [71.4, 115.6] <0.0001
24 mo 83.3 [60.0, 106.6] <0.0001
Subgroup baseline MRC>2
3 mo 52.1 [37.1, 67.2] <0.0001
6 mo 59.2 [40.8, 77.7] <0.0001
9 mo 93.0 [62.9, 123.1] <0.0001
12 mo 80.0 [44.7, 115.3] <0.0001
Subgroup baseline 6MWD<400m
3 mo 52.7 [38.9, 66.5] <0.0001
6 mo 78.2 [52.5, 103.9] <0.0001
9 mo 112.3 [77.9, 146.7] <0.0001
12 mo 101.4 [64.3, 138.6] <0.0001
*paired samples T-test; p is considered significant at values<0.05; **MCID 6MWD = 54m 17 
Abbreviations: 6-MWD, 6- Minute Walking Distance; MRC, Medical Research Council Dyspnoea Score
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6MWD differences are comparable in significance and clinical relevance, but seem to 
occur somewhat earlier, at 3 months. In patients with baseline 6MWD <400m, the 6MWD 
difference is 112 meters at 12 months and remains statistically significant and clinically 
relevant  at 24 months with effect sizes over 100 meters. 
DISCUSSION
Our studies demonstrate that IDM programmes can be successfully implemented in real-
life populations in primary care. Even after two years, considerable proportions of the 
patients involved in the programs still show significant and clinically relevant improve-
ments in health status and exercise tolerance. In patients with a baseline CCQ >1 and in 
patients with an MRC >2, the long-term effect on CCQ score seems to be doubled and 
even tripled, respectively. In patients with baseline 6MWD <400m, the 6MWD difference 
remains substantially large during two years, with effect sizes exceeding 100 meters. 
The typical structured program of PR in the secondary and tertiary care setting is usually 
of relatively short duration, ranging from 6 to 12 weeks.17  Positive results during up to 
3 months have been widely published6;17-19, but several clinical trials report that initial 
benefits of the intervention usually recede over time. Often, the effects above clinical 
relevance thresholds are lost again between 6 to 18 months follow-up.11;12;13;20;21
As a result, recommendations regarding prolonged duration of PR have been issued, 
and several studies have evaluated longer-term programs in more severe patients, 
with inconclusive results. Guell randomized 60 GOLD III COPD patients to 12 months of 
intervention or standard care and followed up for 2 years. Benefits on exercise tolerance, 
dyspnoea and quality of life were present, but diminished in the second year of follow-
up.22 In an RCT in moderate to very severe COPD patients, Berry concluded that an 18 
month exercise program resulted in greater improvements in self-reported disability 
and physical functioning when compared with a 3-month exercise program.4 Wijkstra 
and colleagues reported improvements in quality of life over 18 months in GOLD III 
patients following rehabilitation at home for three months, followed by once monthly 
physiotherapy sessions. The authors concluded however that change in quality of life 
was not associated with a change in exercise tolerance.23  Positive findings in selected 
patient groups from secondary and tertiary care, following a prolonged PR programme, 
were further confirmed by Troosters, Engstrom and Bendstrup, suggesting that struc-
tured, supervised exercise participation should be continued for extended periods in 
patients undergoing PR.24-26
To the best of our knowledge, this is the first publication describing long-term follow up 
results of IDM in primary care. Our positive results can be explained by two important 
differences, as compared to the mixed results summarized above. First, we studied the 
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effect of integrated disease management programs especially developed for primary 
care, which consisted of an interdisciplinary approach with different primary health care 
team members, aided by secondary care where needed. Furthermore, other PR stud-
ies included usually more severe COPD patients, while our programs were especially 
directed at the whole range of COPD patients, including those with milder stages of 
disease, but with sufficient symptom burden to justify intervention. 
Our results are probably more in line with the recent INTERCOM study, that included 
secondary care COPD-patients with less advanced airflow obstruction, but impaired 
exercise capacity. In this RCT, the intervention group received exercise training, edu-
cation, nutritional therapy and smoking cessation counselling in a community-based, 
multidisciplinary setting. Quality of life, functional exercise capacity and breathlessness 
remained significantly favourable in the intervention group versus usual care over the 
entire two-year intervention.27 
It is well-known that COPD patients have a less active lifestyle compared to healthy el-
derly persons.28  One study by Pitta showed that significant improvements in time spent 
walking in daily life was only obtained after 6 months of rehabilitation, but were not yet 
present at 3 months.29 These findings are mirrored in our Kroonluchter cohort results on 
the 6MWD, stressing the importance of implementing programmes at least 6 months 
to optimize the potential room to improve. It is likely that benefits achieved after fol-
lowing an exercise program tend to dissolve after the initial intervention and when the 
accompanying supervision terminates. Therefore, we successfully developed a training 
program which included an extra follow-up training of 1 hour per week after the initial 
6 months, intended to enhance social support in training groups and sustain results on 
the long term. It is likely that our clinically relevant and statistically significant results on 
the 6MWD at 24 months of follow up are the result of more prolonged supervision of 
physiotherapists and the offered peer-support in training groups. 
Our studies had several methodological limitations. The Bocholtz study was designed 
as a clinical controlled trial, but was not randomized, as it was primarily developed to 
measure a maximally achievable effect of an IDM program on a primary care practice 
level. Indeed, the study setting was thus chosen to include demographically compa-
rable villages that hardly interact in daily life, leading to a virtual absence of contamina-
tion between groups.12 The Kroonluchter cohort was based on lessons learned in the 
Bocholtz study, and was primarily developed as an implementation program in real-life 
setting. As a result, a power calculation was not conducted beforehand. Nevertheless, 
our significant 6MWD results at 24 months reached far beyond the MCID of 54 meters, 
demonstrating an adequate sample size. The first adequate batch of consecutive COPD 
patients completing 6MWD measurements at 24 months analyzed in this study may rep-
resent a selection of more motivated patients, although baseline characteristics differ 
little from the total group (see table 2). Indeed, we have observed that higher levels of 
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intrinsic motivation usually comes along with a higher burden of symptoms at base-
line. This may be part of the reason that indicators of disease burden (CCQ>1, MRC>2, 
6MWD<400m) do seem to increase chances of reaching clinically relevant effects on 
health status in mild to moderate COPD patients.  These results suggest potential useful-
ness for phenotypic profiling in a primary care COPD population, which we intend and 
recommend to study further.
Regaining control over one’s own disease state is probably a crucial factor in the success 
of both of our programs. During the IDM-program, improved feelings of self-efficacy 
and independency became notable in participating patients. Overall, greatest improve-
ments were found in patients with baseline MRC >2, and to a lesser extent in patients 
with CCQ>1. At this stage, lung function is still relatively well-maintained and thus 
patients perceive tangible change in symptom burden. When asked, they felt more ca-
pable of actually breaking through the vicious circle of inactivity, anxiety and increasing 
dyspnoea. This was prominently reflected in the patient group with a baseline 6MWD 
below 400 meter, achieving the most dramatic improvements in exercise capacity. This 
cut-off was in fact more sensitive than the 350 meters cut-off point applied in the BODE-
index, probably reflecting larger room for improvement in primary care COPD patients.30 
When COPD patients are treated with IDM at an earlier stage, it is likely that costs per 
patient will be lower, while larger groups of eligible patients can benefit. Further disease 
progression in terms of health status and exercise capacity will be positively influenced 
and, if sustained, even long-term deterioration of lung-function may be reduced. We 
have demonstrated that teams of general practitioners, physiotherapists and nurse 
practitioners, backed up by pulmonary physicians, can provide adequate IDM designed 
for primary care, as patients’ health status and exercise capacity improved substantially, 
even after two years of follow-up. In the future, we therefore recommend large pragmatic 
RCTs, addressing the costs and long-term effectiveness of large-scale IDM programs in 
primary care.
CONCLUSION
In this study, integrated disease management (IDM) improves and sustains health status 
and exercise capacity in primary care COPD-patients during two years follow-up. Im-
provements in health status are consistently higher in patients with CCQ >1 at baseline, 
being strongest in patients with MRC Dyspnoea score >2. Improvements in exercise 
capacity remain highest in patients with 6MWD < 400m at baseline and seem to occur 
earlier in patients with MRC Dyspnoea score >2.
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Favorable effects of formal pulmonary rehabilitation in selected moderate to severe 
COPD patients are well established. Few data are available on the effects and costs of 
integrated disease management (IDM) programs on quality of care and health status 
of COPD patients in primary care, representing a much larger group of COPD patients. 
Therefore, the RECODE trial assesses the long-term clinical and cost-effectiveness of IDM 
in primary care.
Methods/design
RECODE is a cluster randomized trial with two years of follow-up, during which 40 
clusters of primary care teams (including 1086 COPD patients) are randomized to IDM 
or usual care. The intervention started with a 2-day multidisciplinary course in which 
healthcare providers are trained as a team in essential components of effective COPD 
IDM in primary care. During the course, the team redesigns the care process and de-
fines responsibilities of different caregivers. They are trained in how to use feedback on 
process and outcome data to guide implement guideline-driven integrated healthcare. 
Practice-tailored feedback reports are provided at baseline, and at 6 and 12 months. 
The team learns the details of an ICT program that supports recording of process and 
outcome measures. Afterwards, the team designs a time-contingent individual practice 
plan, agreeing on steps to be taken in order to integrate a COPD IDM program into daily 
practice. After 6 and 12 months, there is a refresher course for all teams simultaneously 
to enable them to learn from each other’s experience. Health status of patients at 12 
months is the primary outcome, measured by the Clinical COPD Questionnaire (CCQ). 
Secondary outcomes include effects on quality of care, disease-specific and generic 
health-related quality of life, COPD exacerbations, dyspnea, costs of healthcare utiliza-
tion, and productivity loss. 
Discussion
This article presents the protocol and baseline results of the RECODE trial. This study will 
allow to evaluate whether IDM implemented in primary care can positively influence 
quality of life and quality of care in mild to moderate COPD patients, thereby making the 
benefits of multidisciplinary rehabilitation applicable to a substantial part of the COPD 
population. 
Trial registration: Netherlands Trial Register (NTR): NTR2268
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BACKGROUND
Chronic obstructive pulmonary disease (COPD) is a smoking-related pulmonary disorder, 
characterized by largely irreversible airflow obstruction, multisystemic manifestations 
and frequent co-morbidities.1 According to current guidelines, stable COPD is managed 
with a combination of different treatment components (e.g. smoking cessation, phys-
iotherapeutic reactivation, self-management, optimization of medication adherence)1, 
involving different healthcare providers. Currently, treatment is mostly guided by the 
severity of airflow limitation.2 However, COPD is a complex disease, with great variation 
in symptoms, functional limitations and co-morbidities as well as in progression towards 
more severe stages.3 Therefore, the existence of several clinically relevant phenotypes 
calls for a more personalized approach.4 Ideally, optimal care of COPD patients requires 
an individualized, patient-centered approach that recognizes and treats all aspects of 
the disease, addresses the systemic effects and co-morbidities, and integrates medical 
care among healthcare professionals and across healthcare sectors.5 Since professional 
treatment, hospital admissions and loss of work contribute to the economic burden of 
disease worldwide, there is much interest in systematically improving the quality of care, 
while reducing total costs for patients with COPD and other chronic illness. Integrated 
Disease Management (IDM) programs have proliferated as a means of improving the 
quality and efficiency of care. The most frequently applied IDM programs in COPD pa-
tients are pulmonary rehabilitation (PR) programs. According to a Cochrane systematic 
review, the effectiveness of PR on exercise tolerance and quality of life is well estab-
lished.7 In international reports and guidelines, it is acknowledged that PR is indicated 
for all individuals with COPD who have decreased exercise tolerance, exertional dyspnea 
or fatigue, and/or impairment of activities of daily living.1;8;9 However, widespread access 
is restricted, due to limited availability of resources and high costs.10-12 Furthermore, PR 
programs usually include only the more severe patients and last only for a limited pe-
riod of time13, while initial benefits seem to decline over time.14-18 After returning home, 
patients are frequently insufficiently motivated to continue a more physically active 
and healthy lifestyle. Unfortunately, general practitioners (GPs) are rarely involved in PR 
programs and, as a consequence, are often unable to support program methods after a 
rehabilitation phase has formally been concluded.13
We previously argued that when components of PR are integrated into a primary care 
IDM program, patients can be treated in their home environment. Primary care provid-
ers can then be (more) involved as direct coaches of this process.19-21 To establish such 
a program of combined interventions, the set-up of a multidisciplinary team is vital, 
in which different healthcare professionals participate and provide their share in the 
spectrum of the required care (Figure 1). Ideally, patients and healthcare providers are 
close partners in IDM, in order to better control daily symptoms and promote self-man-
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agement. Furthermore, strong cooperation between several disciplines in primary care 
and mutually agreeable collaboration with secondary and tertiary care are prerequisites 
for integrated chronic care.19 
Systematic reviews of disease management for COPD patients emphasise the need for 
well-designed, practical multicenter trials22;23, including broad representative patient 
samples24, with a wide range of physicians and settings to improve external validity.23 
Furthermore, authors of systematic reviews advocate studies designed to evaluate the 
long-term effectiveness of IDM23, and advise more health economic studies across dif-
ferent care settings.24  When considering the large number of eligible patients for IDM 
in the community, the potential impact is high. However, no trials have been published 
that are specifically targeted to measure the cost-effectiveness of IDM in patients re-
cruited in primary care. 
Figure 1 Components of an Integrated Disease Management program for COPD patients in primary care
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Therefore, the aim of the current RECODE (acronym for Randomized Clinical Trial on 
Effectiveness of integrated COPD management in primary care) cluster randomized 
clinical trial (NTR 2268) is to assess the cost-effectiveness of an IDM program for COPD 
patients in primary care in the Netherlands. Based on an earlier controlled clinical 
trial evaluating the effect of an IDM program in mild to moderate COPD, we found the 
greatest improvements on quality of life in patients with a MRC dyspnea score >2.25 As a 
result, we based our sample size estimates on the a priori planned subgroup of patients 
with MRC dyspnea score >2. This article describes the design, rationale and baseline 
results of this trial. 
METHODS
Study objective and design
The RECODE trial is a two-group parallel cluster-randomized clinical trial with a two-year 
follow-up, conducted in the primary care setting. Our objective is to evaluate the clini-
cal and cost-effectiveness of IDM for COPD patients in primary care. The intervention is 
delivered by the primary care team, including a GP, practice nurse, physiotherapist and 
dietician, with a consulting pulmonary physician at hand. To avoid contamination be-
tween treatment groups within practices, primary care practices are randomized rather 




Inclusion of GPs and patients started in September 2010 and was finished in September 
2011. Practices were considered as candidates if they were willing to create an integrated 
COPD management team, in which each member has responsibility for their respective 
areas of expertise. The practices had to include at least one GP, one practice or extramural 
respiratory nurse, and one physiotherapist specialized in COPD care. If multiple practices 
were collaborating (for example with one practice nurse), they formed one cluster which 
was used for randomization. Our recruitment goal was to enrol representative groups of 
primary healthcare providers from a broad spectrum of practices in order to enhance ex-
ternal validity. This study was embedded in the Leiden Primary Care Research Network 
(LEON), which is managed by the department of Public Health and Primary Care of the 
Leiden University Medical Center. This multi-center research network consists of some 
100 general practices in the western region of the Netherlands, in which these practices 
signed an agreement to collaborate in scientific research. 
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Patients
We included all patients who were diagnosed with COPD by their treating physician. 
We selected patients from electronic medical records (EMRs) of general practices. For 
all included patients, we attempted to verify the diagnosis by lung function according 
to the GOLD criteria1. If spirometry data were not available, patients were invited to 
participate for a formal lung function assessment, according to the ATS/ERS guidelines 
for spirometry26. Exclusion criteria consisted of terminally ill patients, dementia or 
cognitive impairment, inability to fill in Dutch questionnaires, and hard drug or alcohol 
abusers. We did not exclude patients if a pulmonary physician was considered the main 
healthcare provider. The GPs checked the selected patients against the formal inclusion 
and exclusion criteria before the recruitment procedure started. All patients provided 
written informed consent before participation in the study. 
Intervention
The intervention consists of an IDM program, which is implemented by a multidisci-
plinary team in general practice. The team consists of at least three members: the GP, 
the practice nurse, and a cooperating physiotherapist with specific certified training in 
COPD care. Depending on the team needs, a collaborating pulmonary physician and 
dietician were added to the intervention team.  
We trained the multidisciplinary teams of intervention practices in a two-day course dur-
ing 2010-2011. During this course, essential components of IDM for effective integrated 
COPD care in primary care were explained, trained and rehearsed and supervised. Ele-
ments of this course are further outlined in Table 1 and included a review of the advice 
from international guidelines, performing/interpreting spirometry and assessment of 
disease burden, and motivational interviewing to stimulate a healthier lifestyle includ-
ing more physical activity and smoking cessation. Furthermore, the healthcare providers 
were trained in adopting self-management action plans, including early recognition and 
treatment of exacerbations, encouragement of regular exercise and guideline-based 
physical reactivation, cooperation and collaboration with secondary care, and instruc-
tions in dietician support for nutritionally depleted patients. In addition, they were 
trained in how to use feedback on process and outcome data to guide and implement 
guideline-driven integrated healthcare. This CME course was developed according 
to recent national and international guidelines1;27 and was provided by teachers with 
hands-on experience with the program. At the end of the course, the team designed 
a time-contingent individual practice plan, agreeing on steps to be taken in order to 
integrate a COPD IDM program into daily practice. Intervention practices were free in 
the fulfilment of their individual plans, as long as they were feasible and relevant for 
the practice. After 6 and 12 months, there was a refresher course for the intervention 
practices.
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Web-based disease management application
During the course, the team learned the details of an ICT program that supports record-
ing of process and outcome measures by access to a flexible web-based IDM applica-
tion, named Zorgdraad (in English ‘Care Ties’). This application combined a patient and 
a healthcare provider portal. The patient portal provided patients with disease-specific 
easy written education, and allows personal goals and personal notes. The healthcare 
portal left space for a protocol for COPD follow-up guidance, quality of life scores, 
physiotherapy follow-up and examination, smoking cessation, medication records, and 
facilitates tailored benchmark reports at 6 and 12 months. These reports were generated 
by the researchers and sent to the practices to support prioritizing the healthcare needs. 
An experienced instructor provided the practices during the course with all informa-
tion about Zorgdraad. An account manager supported the practice nurse and GP on 
individual use of the program in daily practice. It was intended that practice nurses give 
the COPD patients directions for use on the patient-portal of Zorgdraad. 
All practices were in essence free in the usage of Zorgdraad, and in the fulfilment of their 
plans. Therefore, not all patients received all components of the program, but individual 
patient-specific care plans are negotiated by the team, in collaboration with the patient. 
The intensity of the IDM program depended upon the health status and needs of the 
patient, resulting in some patients receiving all interventions (e.g. smoking cessation, 
physiotherapy, nutritional support), while stable patients only had regular 6-monthly or 
Table 1. Components of IDM included in the RECODE course for multidisciplinary teams in primary care
DM interventions Example
Optimal medication adherence Tailoring of advices from international guidelines, 
e.g. frequent exacerbations necessitate inhaled 
corticosteroids; daily respiratory complaints necessitate 
long-acting bronchodilators
Proper diagnosis Performing and interpreting spirometry, assessment of 
disease burden using MRC and CCQ
Motivational interviewing Understanding and making use of patients’ personal 
goal in physical reactivation and lifestyle changes
Smoking cessation counselling Review of the recent literature, discussion of 
bottlenecks, applying behavioural techniques and drug 
therapy for smoking cessation 
Applying self-management plans Teaching self-management techniques, including early 
recognition and treatment of exacerbations
Guideline based physiotherapeutic reactivation Using a patients’ personal goal, referral for 
physiotherapeutic reactivation in patients with MRC 
score >2. 
Dietary interventions Early recognition and treatment of nutritionally 
depleted patients
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12-monthly follow-up by nurses. Implementation of the intervention was assessed at 24 
months (see “Outcomes”).   
Financial coverage of the intervention
We arranged with the local healthcare insurer that all RECODE patients with dyspnea on 
moderate or worse exertion (indicated by a Medical Research Council (MRC) score of >2) 
would be totally reimbursed for the intervention, including physiotherapy.
Usual care group
The control group consists of ‘usual care’ 28, which is based on the 2007 national primary 
care COPD guidelines27. Instead of the multidisciplinary RECODE course, the practice 
nurse received a course on technical performance of spirometry in primary care only, in 
order to divert attention from any of the IDM topics mentioned in Table 1. If the results 
of our study show that the IDM program could substantially improve the health-related 
quality of life of COPD patients, we will make the entire set of interventions available to 
the control group after the study has been completed.
Outcomes 
Time points
We follow patients at baseline, and at 6 and 12 months with a face-to-face interview. 
Blinded research nurses administer the questionnaires (Table 2) at specific time points. 
These interviews take place at the general practice or at the patients’ homes, using the 
web-based application Zorgdraad. At 9, 18 and 24 months we sent questionnaires by 
post. In addition, retrospectively the researchers extract data from the patients’ EMRs at 
24 months over the complete trial period, regarding prescribed medication. 
Primary endpoint is at 12 months, when we expect to detect the clinically relevant effect 
of the intervention20;29. Total study duration provides 24 months of follow-up, to assess 
whether benefits can be maintained. 
A. Patients
At baseline, we assessed socio-demographic factors (age, gender, socioeconomic status 
measured through level of education), marital status, lung function and co-morbidity. 
Primary outcome
The primary outcome measure in this study is health status as measured by the Clinical 
COPD Questionnaire (CCQ) at 12 months. This questionnaire is a disease-specific, 10-
item questionnaire that calculates an overall score and three domain scores: symptoms, 
functional state and emotional state. Patients are required to respond to each item on a 
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Table 2. Overview of measurements per time point in the RECODE study





CCQ X X X X X X
SGRQ-C X X X X X X
EQ-5D X X X X X X
SF-36 X X X X X X
Smoking behavior, guided smoking attempts X X X X X X
IPAQ X X X X X X
SMAS-30 X X X X X X
MRC-Dyspnea scale X X X X X X
Exacerbations X X
Costs of health care utilization by patients, part 
A: Health care use Questionnaire, including direct 
non-medical costs borne by patients/families
X X X X X X
Costs of productivity loss: Absence from work 
Questionnaire
X X X X X X
Costs of health care utilization by patients, part B: 
Data extraction from medical records (health care 
utilization, medical treatment)
X
PACIC X X X X X X
Health care providers
ACIC X X




IDM program information 
Development costs of the IDM program X (IG)
Implementation costs of the IDM program X (IG)
Performance indicators of practices (see Table 4) X X
ACIC: Assessment Chronic Illness Care; CCQ: Clinical COPD Questionnaire; EQ-5D: EuroQol-5D; IPAQ: International Physical 
Activity Questionnaire; MRC: Medical Research Counsil scale; PACIC: Patient Assessment Chronic Illness Care; SF-36: 
ShortForm-36; SGRQ-C: Saint Georges Respiratory Questionnaire; SMAS-30: Self Management Scale-30. IG=intervention 
group only
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7-point scale with 0 representing the best possible score and 6 representing the worst 
possible score. This instrument is proven to be sensitive and valid, and easy to admin-
ister in primary care. The minimal clinical important difference (MCID) is -0.4 points.30;31
Secondary outcomes
Secondary outcome measurements at 6, 9, 12, 18 and 24 months include (the question-
naire for each outcome is provided in brackets):
1. Measures of changes in health-related quality of life (disease-specific as well as 
generic), measured by : 
a. CCQ 
b. St. George Respiratory Questionnaire (SGRQ); designed to measure health impair-
ment in patients with asthma and COPD. The first part produces the symptom score 
and the second part the activity and impact score. A total score can also be calcu-
lated. We use a Dutch version of the SGRQ, and consider a -4 unit change as the MCID 
for within-group comparison.32
c. The Euro Qol-5D-3L is a generic, preference-based health-related quality of life 
questionnaire, with many applications in respiratory disease. It consists of 5 dimen-
sions to describe health (mobility, self-care, usual activities, pain/discomfort, and 
anxiety/depression) each item with three levels of functioning (e.g., no problems, 
some problems, and extreme problems). We used the value set derived from the 
Dutch general population that, when applied to the dimensions of the health state, 
result in a preference-based utility score that typically ranges from states worse than 
dead (<0) to 1 (full health), anchoring dead at 0. Besides the descriptive system and 
the off-the-shelf value sets, the EQ-5D includes a visual analog scale (VAS) where an 
individual rates his own health on a scale from 0 (worse imaginable health) to 100 
(best imaginable health).33;34  
a. Short-Form Health Survey (SF-36) is a 36-item questionnaire that measures two 
components (physical and mental component). The physical component consists of 
four domains of health: physical functioning, role limitations due to physical health, 
bodily pain and general health perceptions. The mental component consists of 
role limitations due to emotional problems, vitality, social functioning and mental 
health.35
2. Measures of change in patients’ lifestyle, illness behavior and knowledge:
a. Smoking behavior, guided smoking attempts;
b. Taking initiatives, investment behavior and level of self-efficacy, as measured by the 
Self-Management Scale-30 (SMAS-30)36;
c. Physical activity, as measured by the International Physical Activity Questionnaire 
(IPAQ) short form. This is an instrument designed primarily for population surveil-
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lance of physical activity among adults. The items in this short form are structured 
to provide separate scores on walking, moderate-intensity and vigorous-intensity 
activity. The total score is computed by multiplying the duration (in minutes) and 
frequency (days) of walking, moderate-intensity and vigorous-intensity activities by 
its energy requirement to yield a score in Metabolic Equivalent Time (MET) minutes.
3. Measures of change in intermediate patient-related outcomes: 
a. Dyspnea, measured by the MRC Dyspnoea Scale37
b. Exacerbations: moderate (oral prednisone and/or antibiotic courses), severe (hospi-
talizations). These data were retrospectively extracted from EMRs at 24 months, over 
the entire follow-up period. 
4. Measures of change in healthcare utilization and costs:
a. Development and implementation costs of the program: time and material resources 
associated with the training of the healthcare providers and the ICT support (mea-
sured at 24 months).
b. Costs of healthcare utilization by patients: including all COPD and non-COPD related 
cost of a) hospitalization, b) medication, c) caregiver contact, and d) revalidation. 
 Retrospectively we extract data from EMRs at 24 months over the complete trial 
period, regarding prescribed medication. 
c. Direct non-medical costs borne by patients/families, e.g. travel costs. Costs of 
productivity loss due to absenteeism/presenteeism at work. This was measured at 
baseline, and at 6, 9, 12, 18 and 24 months.
5. Measures of change in care delivery process: level of care integration according to 
patients, measured by the Patient Assessment Chronic Illness Care (PACIC).38This 
questionnaire was self-reported by patients in both groups and was administered at 
baseline, and at 6, 9, 12, 18 and 24 months. 
B. Healthcare providers
The Assessment Chronic Illness Care (ACIC) questionnaire, which is a tool to measure 
the level of care integration according to healthcare providers39, was sent to primary 
care providers at baseline and is evaluated at 12 months. Furthermore, we use a self-
designed questionnaire at 12 months (“Satisfaction, involvement and implementation 
of the IDM program”) for the primary care team, to measure the level of involvement 
and implementation of the practice teams with the RECODE intervention at 12 months. 
This questionnaire comprises questions on the number and type of healthcare providers 
which were involved in the program, the types of team meetings and local appointments, 
and the usage of tailored benchmark reports. Furthermore, we requested the number 
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of patients involved in the intervention, and the numbers of components implemented 
in daily practice. Overall, the healthcare providers are asked to rate the intervention on 
a 5-point scale, and we ask for details on possible bottlenecks and problems regarding 
implementation. 
C. Current level of care of the practices at baseline 
The current level of COPD care was assessed at baseline in all general practices to be able 
to report any difference in quality of care at 12-months follow-up. Therefore, from the 
EMRs we extracted the following performance indicators: registration of smoking status 
and stop-smoking advice, registration of body mass index, assessment of spirometry 
and inhalation technique in the last year, the number of patients with monitored func-
tioning by means of the CCQ, MRC, or the number of patients with controlled physical 
activity in the last year.
Sample size calculation
The primary outcome is the difference in change in the CCQ score between baseline and 
12 months between both groups. We used methods for standard sample size estimates 
for trials that randomised at the level of the individual40 adjusting for clustering by inflat-
ing sample size estimates by the design effect given by 1+(n-1)ρ, where n is the average 
cluster size, and ρ is the estimated intraclass correlation coefficient (ICC).41 Sample size 
estimates are based on the mean difference in CCQ between intervention and control 
group. Using the minimal clinically important mean difference for the CCQ30, and the 
upper value of 0.05 from a range of ICC values identified in studies involving the older 
person in primary care42, power calculations indicate that 40 clusters of practices with an 
average of 27 participants per cluster are required. To allow for subgroup analysis in MRC 
scores 1-2 versus 3-5, in total 1080 participants are need to be randomized to achieve a 
power of at least 80% with alpha levels of 0.05, including a participant loss to follow-up 
of 10% or a loss of 4 clusters at 12 months. 
Randomization
Cluster randomization was at the level of the primary care team. The first author recruited 
the practices, and the selected participants were checked by the GP against formal in-
clusion and exclusion criteria before the intervention started. To enhance comparability 
between the intervention and control group, the clusters were matched and randomized 
by a researcher who was blinded to the identity of the practices. Matching was into pairs 
according to the following criteria: (i) percentage of patients from ethnic minorities, (ii) 
type of practice, (iii) practice location (urban/rural), (iv) age of GP, and (v) gender of the 
GP. Subsequently, the matched practices were randomized to the intervention group or 
the control group by using a computer-generated random number list. 
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Informed consent
Informed consent was provided by the GPs and the patients. The informed consent was 
acquired before the course took place and the practices started with their intervention. 
Blinding
Because of the nature of the intervention, it is not possible to blind patients and primary 
care providers to practice group allocation. Therefore, blinded research nurses assess 
the outcomes. Patients are instructed not to report on their type of management to the 
outcome assessors. 
Data analysis at baseline
Non-participation analysis at baseline
We recruited potential participants with an invitation letter including a postal CCQ 
questionnaire. Returned questionnaires were analysed to investigate if there were dif-
ferences between participants and patients who fulfilled inclusion criteria, but refused 
to participate in the trial (non-participants). We compared differences on CCQ scores, sex 
and age using independent t-tests and chi-square tests. 
Analysis plan 
Analysis of effectiveness at 12 and 24 months
The final analysis of the trial will be carried out on an intention-to-treat basis. The free-
dom of the clusters to fill in the precise implementation of the intervention will probably 
relate to the (cost)-effectiveness of the intervention and, therefore, the clustering of 
patients in GP practices should be taken into consideration in the analysis.43 Therefore, 
the results will be investigated with respect to the differences in intensity between and 
within clusters over time using multi-level analysis. 
Pre-planned subgroup analyses
We will study the influence of age, sex, disease burden (MRC score 1-2 vs. 3-5), disease 
severity (GOLD stage), and socioeconomic status. The trial was specifically powered on 
the MRC 1-2 vs. 3-5 subgroup analyses; see ‘Sample size calculation’. 
Economic evaluation at 12 and 24 months
The economic evaluation will be performed according to the internationally agreed 
guidelines44 and the national guidelines for pharmacy-economic research.45 We will cal-
culate the costs from a healthcare perspective and a broad societal perspective, in order 
to facilitate decision making. The healthcare perspective will include all costs covered by 
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the healthcare sectors budget: development, implementation and healthcare utilization 
costs. The costs from societal perspective will include travel and productivity costs in ad-
dition to the costs from the healthcare perspective to capture (almost) all costs related 
to the intervention, irrespective of who actually bears them. 
The healthcare utilization costs (excluding medication costs), travel costs and produc-
tivity costs of patients will be calculated using questionnaires at different time points 
(Table 2). These questionnaires will collect self-reported cost-related data by patients 
using a recall period of three months. Additionally, the type and amount of medication 
from the individual patients will be collected from the GP information systems. The 
unit costs per medication prescription will be based on the GIP Databank.45 Time and 
material resources associated with the training of the healthcare providers, the multi-
disciplinary team meetings in the GP practices, and the ICT support will be estimated 
based on course attendance, computer-documented minutes of ICT use, treatment 
plans, and professional self-report. Finally, the productivity costs will be estimated using 
the friction method, which implies that the costs of absenteeism will occur only for a 
fixed (friction) period ending at the moment that the employee is replaced.46
Cost-effectiveness (CEA) and cost-utility analyses (CUA)
The relation between the costs and the estimated health outcomes is expressed in 
cost-effectiveness ratios: (1) costs per QALY, (2) costs per exacerbation prevented, (3) 
costs per patient with a clinically relevant improvement of at least 0.4 units on the CCQ, 
(4) costs per patient with a clinically relevant (4 units) improvement on the SGRQ, and 
(5) costs per patient with a 1 point improvement on the MRC dyspnea scale. Adopt-
ing such a wide range of outcome measures in the economic evaluation is in line with 
recent guidelines of a joint ATS/ERS task force on outcome measurements in COPD that 
recommend taking a multi-outcome approach.47 At the same time, comparison with the 
cost-effectiveness of other interventions for other diseases is made possible through 
the calculation of costs per QALY. Uncertainty around cost-effectiveness ratios will be 
dealt with in probabilistic sensitivity analysis in which costs and health outcomes will be 
bootstrapped and plotted on cost-effectiveness planes from which cost-effectiveness 
acceptability curves will be drawn.48-50 In additional ‘net monetary benefits51, will be 
calculated using different thresholds of the willingness to pay for a QALY and it will be 
investigated which patient, practice and team characteristics are related to the size of 
the net monetary benefits. The economic evaluation will compare differences in costs to 
differences in effects (CEA) and quality adjusted life-years (CUA). The analysis will have a 
12 and 24-months time horizon. Sensitivity analyses will be performed on the perspec-
tive (societal versus healthcare) and the applied utility measure (Dutch EQ5D). 
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BASELINE RESULTS
Primary care practices 
The characteristics of the enrolled 54 general practices, which formed 40 clusters, are 
shown in Table 3. Numbers of included patients per participating cluster ranged from 
11 to 79 patients. Most practices were single-handed (44%) or one or more partner 
practices (41%). Of all the practices, 50% were healthcare centers. The enrolled practices 
included a total of 76 participating GPs; the majority (61%) were males with a mean age 
of 50 (range 35-62) years and 16 (SD 8.2) years of practicing. 
Current level of care of the practices
We assessed the current level of COPD care at baseline in all general practices to be able 
to report any difference in quality of care after 12 months. Results at baseline are shown 
in Table 4. Almost half of the RECODE patients (53%) have a registered smoking status; 
however, a standard spirometry test in the last year was less common, with only (12%) 
of the patients receiving spirometry. 
Patient recruitment
Figure 2 shows the study flow chart until baseline. In total, 2886 patients were se-
lected in 40 clusters of which 617 (21%) patients were excluded by their GP. Most of 
these excluded patients were registered as a COPD patient in the EMR; however, after 
Table 3. Characteristics of included primary care practices in the RECODE study
General practices
Number of GP practices 54
Number of clusters 40
Number of included patients per participating cluster, range 11-79
Type of practice, %
     Single-handed practice 44
     One or more partner practice 41
     Healthcare centre 15
Practice location, % urban 72
Patient practice population, n (range) 3418 (1750-16907)
Ethnic minorities, % 15
General practitioners
Number of participating GP’s 76
Gender GP, % male 61
Age GP, years (range) 50 (35-62)
Years practicing, years (SD) 16 (8.2)
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Table 4. Description of current level of care of included GP practices: distribution of the performance 
indicators of the practices
Measurement category Process indicator % (SD)
Smoking % RECODE patients with registered smoking status 53 (27.9)
% RECODE patients that are registered smokers 35 (19.3)
%RECODE patients, which are registered smokers with stop-smoking 
advice in the last year
35 (34.3)
BMI % RECODE patients of which the BMI is measured in the last year 42 (23.8)
Treatment & monitoring % RECODE patients with inhalation technique controlled in the last year 13 (20.3)
% RECODE patients with a spirometry test in the last year 12 (14.9)
% RECODE patients with monitored functioning with a structured method ( 
CCQ or MRC) in the last year
28 (27.4)





































Excluded by GP (N=333):
* Not meeting inclusion criteria (n=301): 
  - terminally ill (n=45)
  - dementia (n=76)
  - cognitive impairment/addicts (n=15)








Excluded by GP (N=284):
* Not meeting inclusion criteria (n=241): 
  - terminally ill (n=46)
  - dementia (n=41)
  - cognitive impairment/addicts (n=27)
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* No interest (n=99) 




































Figure 2. Flowchart of the recruitment to the baseline assessment of the RECODE study
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evaluation they turned out to be mislabelled by their GP. After exclusion, 2269 patients 
were invited to participate, of which 48% participated (response 48%). Most patients 
indicated no reason for refusing (71%), while others expressed no interest (16%), did not 
consider themselves to be a COPD patient (6%), or reported not having troublesome 
COPD symptoms (6%). In total, we have been able to allocate 1086 COPD patients at 
baseline: 554 participants to the intervention group and 532 participants to the control 
group. Patients were included from September 2010 until September 2011.
Non-participation analysis
As we invited all eligible participants for this trial with an invitation letter with an at-
tached CCQ questionnaire, we were able to determine any differences between partici-
pants of the trial and COPD patients eligible but declining randomization, in order to 
assess external validity (Table 3). Of all eligible patients who were invited to participate, 
1549 questionnaires had analyzable data. We received a higher response rate (961 vs. 
588) of returned CCQ questionnaires in the group of patients willing to participate in the 
trial, compared to patients eligible but declining randomization. There was no difference 
in age between both groups. Significantly more men (54.7%) are participating in the 
RECODE trial compared to the proportion of men in patients who declined participation 
(46.9%). Furthermore, participants in the trial reported significantly more symptoms and 
disabilities on their functional and mental state, which was reflected in a mean total CCQ 
score of 1.8 (1.1), compared to 1.5 (1.1) in non-participants. 
Baseline characteristics COPD patients
Table 6 presents the baseline demographic and clinical characteristics of the included 
COPD population. Enrolled subjects were mainly elderly (ex) smokers, and had mod-
erate COPD which is reflected by a mean post-bronchodilator FEV1 of 68% predicted. 
We included COPD patients with substantial co-morbidities: 36.8% had a diagnosis of 
Table 5. Characteristics and comparison of participants and non-participants of the RECODE trial 
Participant (n=961)* Non-participant (n=588) p-value
Age, years (SD) 68.7 (11.0) 67.8 (11.5) 0.162
Males, % 54.7 46.9 0.003
CCQ
     Symptoms 2.4 (1.2) 1.9 (1.2) <0.001
     Functional state 1.8 (1.3) 1.5 (1.4) <0.001
     Mental state 0.9 (1.2) 0.7 (1.2) <0.001
     Total score 1.9 (1.1) 1.5 (1.1) <0.001
*Values are means (S.D.) unless stated otherwise. ** Of the 1086 RECODE patients, there were 961 CCQ questionnaires 
available at the time of initial invitation.  
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hypertension, 16.1% suffered from major cardiovascular disease, 14.7% had diabetes 
and 9.9% had a combined diagnosis of depression. Mean SGRQ total score was 35.6 
(20.5) and mean CCQ total score was 1.5 (0.97). The proportion of patients with dyspnea 
on moderate exertion or worse (MRC score >2) comprised one third of the study popula-
tion. 




Age, y 68.3 (11.2)
Employment, % 28.3
Low education, % 40.3
Pulmonary function¹
     Predicted FEV1** % 67.8
     FER*** % 57.7
GOLD-stage, %****
     I   Mild 24.6
     II  Moderate 53.2
     III Severe 19.4
     IV Very severe 2.9
Smoking status, %
     Current 36.7
     Former 53.2
     Never 10.1
Co-morbidities
     Major cardiovascular disease, % 16.1
     Hypertension, % 36.8
     Diabetes, % 14.7
     Depression, % 9.9
     Charlson co-morbidity index 2.3 (1.3)
CCQ 
     Symptoms 2.09 (1.21)
     Functional state 1.40 (1.22)
     Mental state 0.51 (0.98)
     Total score 1.50 (0.97)
MRC
    score ≤2. % 66.6
    score >2. % 33.4
    MRC score (mean) 2.01 (1.28)
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DISCUSSION AND COMPARISON WITH OTHER STUDIES
Optimal COPD management continues to be an important area of research, as the 
worldwide prevalence is growing and costs will rise in coming decades. Furthermore, in 
contrast to asthma patients, medication has demonstrated to have limited effect in the 
management of COPD patients. IDM for chronic diseases has the potential to influence 
health status, while reducing total costs.6 However, the (cost) effectiveness of IDM in 
primary care COPD patients remains unknown, due to a paucity of randomized clinical 
trials in this field. This article presents the design and baseline results of the RECODE 
trial, which aims to assess the (cost) effectiveness of IDM for COPD patients in primary 
care.
We have chosen a cluster-randomized design to prevent cross-contamination of the 
IDM intervention within a practice. In order to enhance comparability between the 
intervention and control group at baseline, clusters were matched by stratification 
and randomized by a blinded researcher. We were able to allocate a broad sample of 
SGRQ
    Symptom 50.5 (20.9)
    Activity 47.8 (29.5)
    Impact 23.3 (19.6)
    Total 35.6 (20.5)
EQ-5D
     Total score 0.74 (0.26)
     EQ-VAS 67.0 (17.4)
SF-36
    Physical 38.3 (10.8)
    Mental 48.6 (10.4)
IPAQ
    Total MET minutes 2925 (4683)
    High physical activity, % 11.1
    Moderate physical activity, % 0.6
    Low physical activity, % 88.4
Self-management
    Taking initiatives 57.0 (17.9)
     Investment behavior 60.4 (17.6)
     Self-efficacy 65.3 (17.4)
*Values are means and corresponding standard deviations (SD) unless stated otherwise. **FEV1 predicted: Forced 
expiratory volume in 1 second, post-bronchodilator, predicted according to age and height. ***FER: forced expiratory 
ratio (FEV1 / FVC x 100%), FVC: forced vital capacity. ****Mild= FEV1 > 80%, Moderate= 50%≤ FEV1 < 80%, Severe= 30%≤ 
FEV1 <50%, Very severe= FEV1<30% 
1. Lungfunction was missing in 66 patients (34 control patients; 32 intervention patients).  
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1086 COPD patients (ranging from mild to very severe patients) with a response rate of 
participants of almost 50%. We can conclude from our non-participation analysis that 
we have recruited a sufficient proportion of patients with considerable complaints, and 
thus room for improvement. Furthermore, the included practices showed great diversity 
in the kind of practice, practice size and distribution of ethnic minorities, thereby con-
tributing to high external validity. 
To date, previous clinical trials of disease management or home-based rehabilitation 
trials in primary care have revealed encouraging results on quality of life.52-56 Based on 
an earlier example of a published protocol57, we compared several aspects of our cur-
rent study to the previously conducted randomized trials which aimed to evaluate the 
effectiveness of such programs in primary care or in the home-based setting (Table 7).
Selection of patients 
In respiratory medicine there is a lack of research on mild to moderate COPD patients, 
despite that over 80% of COPD patients suffer from this stage of disease and are often 
treated in primary care. Moreover, it has been shown that treatment decisions for asth-
ma and COPD patients are usually based on studies including a very small and highly 
selected proportion of the real patient population; this indicates the need for more 
real-life studies targeted at the true population, and applying less exclusion criteria.58 
Former trials included a highly selected severely ill patient population52;53 or recruited 
their patients in secondary care56; overall, this is not an uncommon phenomenon in 
primary care COPD trials. 
Limited follow-up
Most studies presented data up to 12 months follow-up, while limited information is 
available on studies with long-term (18 or 24 months) follow-up. Gottlieb et al. evalu-
ated the effect of an intensive exercise and educational program in patients with moder-
ate COPD during 18 months of follow-up.54 Although an effect was found on walking 
distance and quality of life, the effect on quality of life disappeared over 18 months. 
However, this result should be interpreted with caution, as the intensive rehabilitation 
program lasted only 7 weeks, which was followed by a maintenance phase including a 
monthly session focusing on ways of incorporating exercise in daily life. Furthermore, 
the authors acknowledged many dropouts before randomization, at randomization 
and during rehabilitation, potentially introducing bias and indicating substantial loss 
of power.54 Another study evaluated the efficacy of a community-based COPD manage-
ment program in less advanced (GOLD 2 and 3) COPD patients during 24 months follow-
up. The SGRQ score initially improved in the intervention group compared to the control 
group. At 12 months, scores in the intervention group had returned to baseline, whereas 
in the usual care group it remained stable up to 12 months and worsened thereafter.56 






























































































































































































































































































































































































































































































































































































































































































































































































































Due to the nature of the intervention, blinding of participants and patients to the 
intervention is usually impossible. However, blinding of an outcome assessor can sub-
stantially diminish the risk of bias. All the above-mentioned studies, except for the trial 
of Wetering et al.56, failed to introduce blinded outcome assessors or did not report this 
as such. In the study of Rea et al.55, randomization was also clustered, comparable to our 
study; however, statistical analysis was at the level of the patient, thereby not taking 
the clustering coefficient in account. Furthermore, the authors failed to allocate five 
practices to the correct treatment group. 
Planned subgroups
Finally, this study differs from the other studies in that we based our sample size esti-
mates on the a priori planned subgroup of patients with a MRC dyspnea score >2. We 
earlier reported that we found the greatest improvements on quality of life in these 
patients.25 It is probably that lung function is still relatively well maintained at this stage, 
while patients experience considerable dyspnea and an impaired quality of life.20 As a 
result of this pre-planned subgroup power analysis and to compensate for the intra-
clustering, we allocated almost 1100 patients in the present trial according to protocol. 
As can be seen in Table 7, this number is much higher than that of earlier studies in this 
field.
CONCLUSION
It is acknowledged that not all patients who potentially benefit from an exercise train-
ing program, pulmonary rehabilitation, or smoking cessation intervention are actually 
receiving this type of support in daily practice. It is likely that costs will be lower when 
patients are detected and persuaded to change their lifestyle at an earlier stage, pos-
sibly reducing health decline and disease progression in the long term. To the best of 
our knowledge, this is the first and largest cluster randomized trial to evaluate the cost 
and clinical effectiveness of IDM in primary care COPD patients. The results of this study 
will provide insight into the clinical and cost-effectiveness of IDM in primary care COPD 
patients, also on the long term.
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Objective To investigate the long term effectiveness of integrated disease management 
delivered in primary care on quality of life in patients with chronic obstructive pulmo-
nary disease (COPD) compared with usual care.
Design 24 month, multicentre, pragmatic cluster randomised controlled trial.
Setting 40 general practices in the western part of the Netherlands.
Participants Patients with COPD according to GOLD (Global Initiative for COPD) criteria. 
Exclusion criteria were terminal illness, cognitive impairment, alcohol or drug misuse, 
and inability to fill in Dutch questionnaires. Practices were included if they were willing 
to create a multidisciplinary COPD team.
Intervention General practitioners, practice nurses, and specialised physiotherapists in 
the intervention group received a two day training course on incorporating integrated 
disease management in practice, including early recognition of exacerbations and self 
management, smoking cessation, physiotherapeutic reactivation, optimal diagnosis, 
and drug adherence. Additionally, the course served as a network platform and collabo-
rating healthcare providers designed an individual practice plan to integrate integrated 
disease management into daily practice. The control group continued usual care (based 
on international guidelines).
Main outcome measures The primary outcome was difference in health status at 12 
months, measured by the Clinical COPD Questionnaire (CCQ); quality of life, Medical 
Research Council dyspnoea, exacerbation related outcomes, self management, physical 
activity, and level of integrated care (PACIC) were also assessed as secondary outcomes.
Results Of a total of 1086 patients from 40 clusters, 20 practices (554 patients) were 
randomly assigned to the intervention group and 20 clusters (532 patients) to the usual 
care group. No difference was seen between groups in the CCQ at 12 months (mean 
difference –0.01, 95% confidence interval –0.10 to 0.08; P=0.8). After 12 months, no 
differences were seen in secondary outcomes between groups, except for the PACIC do-
main “follow-up/coordination” (indicating improved integration of care) and proportion 
of physically active patients. Exacerbation rates as well as number of days in hospital 
did not differ between groups. After 24 months, no differences were seen in outcomes, 
except for the PACIC follow-up/coordination domain.
Conclusion In this pragmatic study, an integrated disease management approach de-
livered in primary care showed no additional benefit compared with usual care, except 
improved level of integrated care and a self reported higher degree of daily activities. The 
contradictory findings to earlier positive studies could be explained by differences between 
interventions (provider versus patient targeted), selective reporting of positive trials, or 
little room for improvement in the already well developed Dutch healthcare system.
Trial registration Netherlands Trial Register NTR2268.
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BACKGROUND 
Chronic obstructive pulmonary disease (COPD) is a disabling respiratory disease af-
fecting millions of people worldwide.1 Although no medical treatment can modify the 
course of the disease, multiple interventions are available to improve the wellbeing of 
patients and to reduce unnecessary hospital admissions due to exacerbations. However, 
these interventions are underused or suboptimally implemented.2 Irregular exacerba-
tions, fluctuating symptoms, and various disabilities require a collaborative interaction 
between actively involved patients and a proactive multidisciplinary team.3 Such 
interaction is promoted by integrated disease management programmes developed in 
response to the evidently unsuccessful reactive response to disease progression.2
Recently, we published a Cochrane systematic review showing clinically relevant effects 
on disease specific health related quality of life and exercise capacity of COPD patients 
following an integrated disease management programme for at least three months.4 The 
review also showed that integrated disease management reduced respiratory related 
hospital admissions and days in hospital. This led to potential savings in healthcare costs, 
as shown in a second review.5 Interestingly, the effects and cost savings increased with 
severity of COPD. As COPD is a disease with increasing prevalence, and general practi-
tioners and family physicians treat most patients, well designed studies of pragmatic 
integrated disease management programmes in primary care are essential. However, in 
COPD trials, the participants commonly comprise a small and selected fraction of the real 
world population, resulting in leading medical journals calling for studies in more rep-
resentative patient populations.6;7 The few studies of integrated disease management in 
primary care recruited patients in secondary care,8-11 consisted of palliative programmes 
for severe patients,12;13 had a short duration of intervention,9-12;14 or did not correct for 
cluster analysis.15 The true effect of integrated disease management in primary care thus 
remains inconclusive. Therefore, the aim of this large pragmatic RECODE (randomized 
clinical trial on effectiveness of integrated COPD management in primary care) cluster 
randomised trial was to assess whether integrated disease management implemented 
in primary care is effective in improving the quality of life of COPD patients.
METHODS 
This study was performed in accordance with the study protocol.16
Study design and patients
We did a 24 month, cluster randomised controlled trial in which general practitioners 
were randomly assigned to the intervention (integrated disease management) or usual 
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care. General practitioners were recruited from the western part of the Netherlands. 
Patients in both groups received an information leaflet stating that the aim of the study 
was to improve treatment of COPD in primary care and that general practitioners were 
randomised to two groups. All general practitioners and all participants gave written 
informed consent. Eligible participants had a diagnosis of COPD, according to GOLD 
(Global Initiative for COPD) guidelines.1 For all included patients, we attempted to verify 
the diagnosis by lung function tests. If spirometry data were not of sufficient quality or 
not available, patients were invited to participate for a lung function assessment, ac-
cording to the American Thoracic Society/European Respiratory Society guidelines for 
spirometry.17 Exclusion criteria were terminal illness, cognitive impairment, hard drug or 
alcohol misuse, and inability to fill in questionnaires. Recruitment of practices started in 
September 2010 and was finished in September 2011.
Intervention
The intervention was delivered at the cluster level. General practitioners, practice 
nurses, and specialised physiotherapists in the intervention group received a two day 
training course on incorporating integrated disease management in practice. Option-
ally, an additional team member (such as a dietitian or pulmonary specialist) could 
attend the course if they expressed interest. Elements of the course included perform-
ing/interpreting spirometry, assessment of disease burden, review of advice from 
international guidelines, motivational interviewing to stimulate a healthier lifestyle, and 
smoking cessation. Furthermore, the healthcare providers were trained in adopting self 
management action plans, including early recognition and treatment of exacerbations, 
encouragement of regular exercise and guideline based physical reactivation, coopera-
tion with secondary care, and instructions in nutritional support. The secondary aim of 
the course was to provide a network platform for team members.
At the end of the second day, each practice team designed a specific time contingent 
plan in a group discussion with their multidisciplinary members. They decided which 
elements of integrated care they wanted to start implementing first, who would be 
responsible for which part of the interventions, and which steps to take to integrate 
integrated disease management into their daily practice. The practice plan they agreed 
to depended not only on the chairperson and the capacity of the team but also on the 
COPD care already provided at baseline and the priorities and feasibility in their practice. 
They received advice on the content and feasibility of their plan from the experts who 
guided the training. After six and 12 months, the intervention practices had a refresher 
course.
During the course, the team learnt the details of a web based decision support system 
for audit and feedback with patients’ and professionals’ portals, named Zorgdraad (“care 
ties”). The teams received practice tailored benchmark reports at baseline and at six and 
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12 months. All practices were free to determine and follow their individual plans and 
could choose to implement the Zorgdraad programme. The intensity of the integrated 
disease management programme for individual patients depended on health status, 
personal needs, and preferences, as well as on the capacity of the general practice 
team. As a result, patients with severe disease or at high risk were encouraged to receive 
multiple interventions, whereas other (for example, stable) patients had only regular 
control visits. All patient care was covered by the basic health insurance package that 
is compulsory in the Netherlands, except physiotherapy, which was additionally reim-
bursed for all RECODE patients with a Medical Research Council dyspnoea score above 2.
Healthcare providers in the control group were asked to continue their usual care, based 
on Dutch general practice COPD guidelines, in line with GOLD guidelines.1 The practice 
nurses in the usual care group received a course on technical performance of spirometry 
only, to divert attention from topics related to our intervention.
Randomisation and masking
To enhance comparability, a blinded researcher (NHC) stratified and matched participat-
ing clusters according to the following criteria: percentage of patients in practice from 
ethnic minorities, type of practice (single handed, one or more partner practice, or 
healthcare centre), practice location (urban/rural), age of general practitioner, and sex of 
general practitioner. Following this procedure, the same blinded researcher randomised 
matched clusters in pairs by using a computer generated list in four blocks of 10. Because 
of the nature of the intervention, participating healthcare providers and patients could 
not be blinded. Therefore, blinded research nurses assessed outcomes to minimise 
detection bias. Patients were instructed not to report on their type of management to 
these research nurses.
Outcomes
All outcomes were assessed at the level of the individual participant and are reported 
in Supplementary table 1. The primary outcome was change in health related quality 
of life on the Clinical COPD Questionnaire (CCQ)18 at 12 months. Secondary outcomes 
were change in health related quality of life as measured by the St George’s Respira-
tory Questionnaire (SGRQ)19, Euro Qol-5D (EQ-5D)20, and Short Form 36 (SF-36)21. In 
addition, we measured MRC dyspnoea22, Self-Management Ability Scale-30 (SMAS-30) 
23, daily physical activities (International Physical Activity Questionnaire; IPAQ24), level 
of care integration according to patients, measured by the Patient Assessment Chronic 
Illness Care (PACIC)25, smoking behaviour, and healthcare usage (including hospital 
admissions and moderate/severe exacerbations). Blinded research nurses administered 
these questionnaires at baseline and at six and 12 months. Postal questionnaires were 
sent at nine, 18, and 24 months. We extracted data on moderate exacerbations over 
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Table 1 Baseline characteristics of chronic obstructive pulmonary disease patients included in RECODE 







Mean (SD) age (years) 68.2 (11.3) 554 68.4 (11.1) 532
Male sex 280 (50.5) 554 305 (57.3)* 532
Employment 140 (27.7) 505 142 (28.8) 493
Low education 195 (39.2) 498 195 (41.5) 491
Mean (SD) FEV1 % predicted 67.7 (20.3) 522 67.9 (20.5) 498
GOLD stage:
 I—mild 116 (25.3) 458 97 (23.7) 409
 II—moderate 241 (52.6) 458 220 (53.8) 409
 III—severe 87 (19.0) 458 81 (19.8) 409
 IV—very severe 14 (3.1) 458 11 (2.7) 409
Current smoker 179 (34.8) 515 196 (38.7) 506
Relevant comorbidities:
 Major cardiovascular disease 81 (14.6) 522 94 (17.7) 515
 Hypertension 196 (35.4) 522 204 (38.3) 515
 Diabetes 81 (14.6) 522 79 (14.8) 515
 Depression 54 (9.8) 522 54 (10.1) 515
Mean (SD) CCQ score:
 Total 1.5 (1.0) 553 1.5 (1.0) 527
 Symptoms 2.1 (1.2) 554 2.1 (1.2) 531
 Functional 1.5 (1.2) 553 1.3 (1.2)* 531
 Mental 0.5 (1.0) 554 0.5 (1.0) 527
Mean (SD) SGRQ score:
 Total 36.7 (21.1) 551 34.5 (19.8) 529
 Symptoms 51.6 (20.8) 554 49.3 (20.9) 530
 Activities 49.4 (29.9) 551 46 (29) 531
 Impact 24 (20.2) 554 22.7 (19) 530
Mean (SD) MRC total score 2.0 (1.3) 553 2.0 (1.3) 529
MRC score >2 194 (35.1) 553 167 (31.6) 529
Mean (SD) EQ-5D score 0.74 (0.25) 546 0.73 (0.28) 528
Mean (SD) EQ-5D VAS score 66.6 (17.6) 554 67.3 (17.3) 532
Mean (SD) SF-36 score, physical 
component
38 (10.9) 512 38.6 (10.7) 503
Mean (SD) SF-36 score, mental 
component
48.3 (10.5) 512 48.9 (10.3) 503
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the complete trial period from electronic medical records at 24 months. We defined a 
moderate exacerbation as a worsening of daily symptoms that led a patient’s physician 
to prescribe systemic corticosteroids, antibiotics, or both, without hospital admission. A 
severe exacerbation occurred when worsening symptoms required a hospital admission.
Statistical analysis
We based sample size estimates on the mean difference in CCQ score between inter-
vention and control groups at 12 months. We used methods for standard sample size 
estimates for trials that randomise at the level of the individual,26 adjusting for clustering 
by inflating sample size estimates by the design effect given by 1+(n–1)ρ, where n is 
the average cluster size and ρ is the estimated intra-class correlation coefficient.27 Using 
the minimal clinically important mean difference of 0.4 for the CCQ,28 with a standard 
deviation of CCQ equal to 0.49 at 12 months, and the upper value of 0.05 from a range 
of intra-class correlation coefficient values identified in primary care studies,29 power 
Mean (SD) SMAS score
 Taking initiatives 56.8 (17.8) 518 56.9 (17.4) 509
 Investment behaviour 61.4 (16.8) 517 59.3 (17.9) 511
 Self-efficacy 65.7 (17.2) 516 64.3 (17.6) 512
Mean (SD) IPAQ, total MET 
minutes
2925 (4574) 546 2925 (4798) 526
IPAQ, high/moderate 54 (10.0) 541 70 (13.4) 523
IPAQ, low 487 (90.0) 541 453 (86.6) 523
Mean (SD) PACIC score:
 Total 2.3 (0.9) 436 2.2 (0.8) 437
 Activation 2.3 (1.3) 435 2.1 (1.2) 435
 Delivery system design 2.9 (1.2) 432 2.8 (1.1) 436
 Goal setting 2.1 (1.0) 431 2.0 (0.8) 433
 Problem solving 2.2 (1.2) 430 2.1 (1.0) 433
 Follow-up/coordination 1.8 (0.9) 433 1.8 (0.8) 431
Mean (SD) exacerbations:
 Moderate exacerbation rate 
(12 months)
0.4 (0.8) 554 0.3 (0.8) 532
 Severe exacerbation rate (3 
months)
0.02 (0.2) 554 0.02 (0.2) 532
 Hospital admission days (3 
months)
6 (2.1) 554 8.6 (4.7) 532
CCQ=Clinical COPD Questionnaire; GOLD=Global Initiative for Chronic Obstructive Pulmonary Disease; EQ-5D=Euro 
Qol-5D; FEV1=forced expiratory volume in 1 second; IPAQ=International Physical Activity Questionnaire; MRC=Medical 
Research Council; MET=Metabolic Equivalent of Task; PACIC=Patient Assessment Chronic Illness Care; SF-36=Short Form 
36; SGRQ=St George’s Respiratory Questionnaire; SMAS=Self-Management Ability Scale.
*Statistically significant difference between intervention and usual care groups. 
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calculations indicated that we needed 40 clusters of practices with an average of 27 
participants per cluster. To allow for subgroup analysis of MRC scores 1-2 versus 3-5, a 
total of 1080 participants were needed to achieve a power of at least 80% with α levels 
of 0.05, including a loss to follow-up of 10% of participants or a loss of four clusters at 
12 months.
The primary effectiveness analysis was an intention to treat analysis of the difference 
in mean CCQ score between groups at 12 months. Because of repeated measurements 
for all patients, we used linear mixed model analyses to assess differences within and 
between groups for all continuous outcomes, correcting for baseline scores, age, sex, 
proportion of patients with MRC score above 2, and clustering of patients per general 
practice. We used baseline scores as a dependent variable, the cluster was represented 
by a random effect, and the within patient covariance structure was unstructured. 
For dichotomous outcomes, we used logistic link generalised linear mixed models for 
repeated measurements to analyse differences within and between groups at all time 
points, correcting for the same covariates. We compared differences in two year moder-
ate and severe exacerbation counts by using the negative binomial model30, correcting 
for age, sex, MRC score above 2, exacerbation rate in the year before baseline, and 
clustering of patients per practice. This model returns incidence rate ratios, which in 
this case are exacerbation rates. On the basis of the literature, we did a priori defined 
subgroup analyses on the primary outcome of CCQ at 12 months16.
RESULTS 
Patients
Figure 1 shows the screening, randomisation, and follow-up of patients31. Supplementary 
figure 1 shows the drop-out at the several time points. Table 1 summarises the baseline 
characteristics of the patients. Supplementary table 2 demonstrates the characteristics 
of the general practices. Dropout rates at 12 months (9% intervention v 11% usual care) 
and 24 months (24% v 26%) were similar in the two groups. Patients who dropped out at 
24 months were significantly older (P=0.002) and had worse scores on the CCQ, EQ-5D, 
PACIC, SF-36, SGRQ, and MRC questionnaires at baseline. Thirty two patients died in the 
intervention group and 28 in the usual care group. Causes of death were comparable be-
tween groups (P=0.54): COPD related (28% intervention; 36% usual care), cardiovascular 
disease (16%; 14%), and malignancies (16%; 21%). In 40% of the intervention patients 
and in 29% of the usual care patients, the cause of death was unknown.
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Primary outcome
We found no statistically significant difference between the intervention and usual care 
groups in the CCQ score at 12 months (mean difference –0.01, 95% confidence interval 
–0.10 to 0.08; P=0.8) (Table 2; Figure 2)
Secondary outcomes and subgroup analyses
At 6, 9, 18, and 24 months, we found no statistically significant difference between 
intervention and usual care in the CCQ score (Figure 2). At 12 months, the change from 
baseline in SGRQ, EQ-5D, SF-36, MRC, and SMAS scores was not significantly different 




Usual care (n=1114 invited patients)Intervention (n=1155 invited patients)
Informed consent (n=532)Informed consent (n=554)
Baseline (n=532)Baseline (n=554)
24 months (n=391)24 months (n=419)
Randomised (n=40 clusters)
Patients declined (n=601):
  No interest (n=99)
  No problems with COPD (n=31)
  Comorbidity (n=32)
  Unknown (n=435)
  Died (n=1)
  Other (n=3)
Patients declined (n=582):
  No interest (n=95)
  No problems with COPD (n=38)
  Comorbidity (n=35)
  Unknown (n=407)
  Died (n=1)
  Other (n=6)
Lost to follow-up (n=135):
  No interest (n=18)
  No problems with COPD (n=9)
  Comorbidity/terminally ill (n=24)
  Unknown (n=50)
  Died (n=32)
  Other (n=2)
Lost to follow-up (n=141):
  No interest (n=30)
  No problems with COPD (n=9)
  Comorbidity/terminally ill (n=30)
  Unknown (n=41)
  Died (n=28)
  Other (n=3)
Excluded by GP (n=333):
  Did not meet inclusion criteria (n=301):
    Terminally ill (n=45)
    Dementia (n=76)
    Cognitive impairment or addicts (n=15)
    No COPD (n=165)
  Died (n=9)
  Other (n=23)
Excluded by GP (n=284):
  Did not meet inclusion criteria (n=241):
    Terminally ill (n=46)
    Dementia (n=41)
    Cognitive impairment or addicts (n=27)
    No COPD (n=127)
  Died (n=9)
  Other (n=24)
  Unknown (n=10)
Figure 1. Flow diagram of RECODE study
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between the intervention and usual care groups (Table 2). The proportion of patients 
with moderate or high activity levels at 12 months as measured with the IPAQ improved 
significantly in the intervention group compared with the usual care group (mean 
difference 10.1; P<0.001). The PACIC domain “follow-up and coordination,” measuring 
Table 2 Clinical outcomes: within and between group differences at 12 months, corrected for age, sex, 
baseline score, and MRC score >2. Values are mean (95% CI) unless stated otherwise
Outcome Intervention 
(n=554; 20 clusters)





CCQ total score –0.03 (–0.09 to 0.03) 0.03 (–0.03 to 0.09) –0.01 (–0.10 to 0.08) 0.80
CCQ—symptoms domain –0.07 (–0.15 to 0.02) –0.10 (–0.19 to 0.01) 0.03 (–0.09 to 0.15) 0.59
CCQ—functional domain 0.16 (0.08 to 0.25) 0.21 (0.12 to 0.29) –0.04 (–0.16 to 0.07) 0.48
CCQ—mental domain –0.09 (–0.16 to –0.02) –0.06 (–0.14 to 0.01) –0.03 (–0.13 to 0.07) 0.57
SGRQ total score –0.40 (–1.46 to 0.65) 0.33 (–0.78 to 1.43) –0.73 (–2.25 to 0.78) 0.34
SGRQ—symptoms domain –0.75 (–2.43 to 0.93) 0.22 (–1.52 to 1.96) –0.97 ( –3.33 to 1.39) 0.42
SGRQ—activities domain 0 ( –1.51 to 1.50) 1.25 ( –0.32 to 2.82) –1.25 ( –3.41 to 0.90) 0.26
SGRQ—impact domain –0.31 (–1.46 to 0.85) –0.35 (1.96 to 5.33) 0.04 ( –1.61 to 1.70) 0.96
MRC dyspnoea score 0.23 (0.14 to 0.33) 0.19 (0.09 to 0.29) 0.04 (–0.09 to 0.18) 0.52
EQ-5D –0.04 (–0.06 to  –0.02) –0.01 (–0.03 to 0.01) –0.03 (–0.06 to 0) 0.07
EQ-5D VAS score –1.71 (–2.95 to 0.46) –1.92 (–3.21 to –0.63) 0.21 (–1.44 to 1.87) 0.80
SF-36—physical domain –1.1 (–1.82  to  –0.38) –0.48 (–1.23 to 0.26) –0.61 (–1.61 to 0.39) 0.23
SF-36—mental domain 0.73 (–0.07 to 1.54) 0.09 (–0.74 to 0.92) 0.64 (–0.45 to 1.73) 0.25
SMAS—taking initiatives –1.27 (–2.5 to 0) –1 (–2.3 to 0.33) –0.28 (–2.00 to 1.43) 0.75
SMAS—investment behaviour –1.5 (–2.75 to –0.25) –1.43 (–2.73 to –0.12) –0.07 (–1.78 to 1.63) 0.93
SMAS—self-efficacy –1.17 (–2.39 to 0.05) –0.38 (–1.65 to 0.89) –0.79 (–2.47 to 0.88) 0.35
IPAQ—total MET minutes –44 (–475 to 387) –438 (–886 to 11) 393 (–179 to 965) 0.18
IPAQ—high/moderate (%) 32.2 22.1 10.1 <0.001
PACIC—total score –0.02 ( –0.11 to 0.08) –0.08 (–0.18 to 0.02) 0.06 (–0.06 to 0.19) 0.31
PACIC—activation –0.03 (–0.16 to 0.1) –0.5 (–0.19 to 0.08) 0.03 (–0.14 to 0.19) 0.76
PACIC—delivery system design –0.20 (–0.32 to –0.8) –0.27 (–0.40 to –1.30) 0.07 (–0.10 to 0.23) 0.43
PACIC—goal setting 0.04 (–0.06 to 0.13) –0.08 (–0.18 to 0.03) 0.11 (–0.10 to 0.25) 0.10
PACIC—problem solving 0.02 (–0.09 to 0.14) –0.02 (–0.14 to 0.1) 0.04 (–0.10 to 0.19) 0.58
PACIC—follow-up/coordination 0.13 (0.04 to 0.21) –0.02 (–0.11 to 0.07) 0.15 (0.04 to 0.26) 0.01
Current smokers (%) 48.6 51.7 3.1 0.56
Hospital admission days 10.5 (7.6 to 13.3) 10.7 (7.4 to 14.0) 0.2 (–4.3 to 4.3) 0.92
Moderate exacerbations (rate) 0.58 (0.45 to 0.75) 0.48 (0.37 to 0.62) 1.22 (0.97 to 1.54)* 0.09
Severe exacerbations (rate) 0.13 (0.08 to 0.21) 0.10 (0.06 to 0.18) 1.20 (0.78 to 1.84)* 0.42
CCQ=Clinical COPD Questionnaire; EQ-5D=Euro Qol-5D; IPAQ=International Physical Activity Questionnaire; MET= 
Metabolic Equivalent of Task; MRC=Medical Research Council; PACIC=Patient Assessment Chronic Illness Care; SF-
36=Short Form 36; SGRQ=St George’s Respiratory Questionnaire; SMAS=Self-Management Ability Scale.
Values are corrected for clustering, age, sex, score at baseline, and MRC score >2.
*Means rate ratio.
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improvement in follow-up structure of COPD patients, was significantly higher in the 
intervention group at 12 months (mean difference 0.15; P=0.01). The proportion of cur-
rent smokers, as well as moderate and severe exacerbation rates and hospital admission 
rates, did not differ (Table 2).
After 24 months of follow-up, the PACIC follow-up and coordination domain remained 
significantly higher in the intervention group (data not shown; mean difference 0.15; 
P=0.03). The other secondary outcomes did not differ significantly between groups at 24 
months. Subgroup analyses showed no statistically significant effect of the intervention 
in any of the a priori defined subgroups (Table 3). We performed additional, a posteriori 
defined subgroup analyses, which demonstrated no significant effect of the interven-
tion. (Supplementary table 3)
DISCUSSION 
This cluster randomised trial examined a pragmatic set of interventions aiming to es-
tablish an integrated disease management programme, delivered by a multidisciplinary 
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Figure 2. Change in Clinical COPD Questionnaire (CCQ) score at 6, 9, 12, 18, and 24 months, corrected for 
age, sex, baseline, CCQ score, and MRC score above 2. 
Error bars represent standard errors. Score lower than 0 means improvement compared with baseline
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in quality of life, exacerbation related outcomes, self management, or MRC dyspnoea 
scores. However, significantly more patients in the intervention group had a self re-
ported higher degree of daily activities, and the level of follow-up and coordination of 
the COPD patients improved.
Interpretation of findings
The results from our study were contrary to our expectations and to the positive results 
of the Cochrane systematic review.4 Several reasons might explain the difference in find-
ings.
Firstly, our intervention was implemented at the level of the healthcare provider, 
whereas earlier studies were of patient targeted interventions. We specifically chose to 
study a pragmatic intervention that was developed on the basis of positive results of a 
controlled primary care study and implementation project.32;33 In these times of heavy 
workload in primary care, we gave the integrated disease management teams respon-
sibility to develop their individual practice plans tailored to their own needs, to ensure 
ongoing implementation after the study was finished. This is clearly in contrast to other 
integrated disease management studies that applied patient targeted interventions 
and operated under more intensively supported, time consuming, and strictly regulated 
conditions.4 Therefore, a suboptimal intensity, but more realistic, implementation of the 
Table 3 Subgroup analyses: difference between intervention and usual care groups in change from baseline to 












valueNo Mean (SE) No Mean (SE)
Full cohort 554 0.02 (0.03) 532 0.03 (0.03) –0.01 (0.04) 0.82
Sex: 0.3
 Male 280 0 (0.06) 305 0 (0.06) 0 (0.05) 0.99
 Female 274 0.01 (0.04) 227 0.03 (0.03) –0.02 (0.05) 0.66
Age: 0.15
 <65 years 212 0.17 (0.09) 199 0.15 (0.09) 0.02 (0.05) 0.71
 ³65 years 342 0 (0.04) 333 0.03 (0.03) –0.03 (0.05) 0.54
GOLD stage: 0.47
 I-II 357 –0.29 (0.07) 317 –0.33 (0.07) 0.04 (0.05) 0.46
 III-IV 101 0.03 (0.06) 92 0.03 (0.04) 0 (0.07) 0.96
MRC score: 0.2
 £2 359 0.03 (0.04) 362 0.03 (0.03) 0 (0.05) 0.97
 >2 194 1.10 (0.07) 167 1.13 (0.06) –0.03 (0.06) 0.63
Lower CCQ score means better quality of life. Values are corrected for clustering, age, sex, score at baseline, and MRC 
score >2.
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intervention may have contributed to the difference in effect between this study and 
earlier studies.
Secondly, in the intervening years, COPD care in the Netherlands has substantially 
evolved, which was partially unforeseen. Probably one of the most important triggers 
for general practitioners to start implementing integrated disease management was the 
start of a bundled payment system in 2010, which was our first study year. Although 
nationwide implementation of integrated disease management of COPD is still lacking, 
several regional projects have been started during recent years.34;35 Nowadays, COPD 
care has a better prepared delivery system with structured collaboration between 
healthcare professionals, more and better equipped nurses, and the development of 
clinical information systems to support the professional and the patient.36 Therefore, the 
considerable drive by health policies and providers to improve COPD care could have 
stimulated general practitioners in the usual care group to start implementing integrat-
ed disease management as well. The absence of effect due to already high levels of care 
was pointed out in other well designed Dutch and English primary care trials, studying 
components of COPD care.36-38 In contrast, a community based integrated intervention 
for early prevention and management of COPD in a Chinese setting, with a potentially 
larger room for improvement, showed a significant effect on smoking cessation rates 
and improvements in knowledge.39
Thirdly, studies with positive results are more likely to be published, and in high impact 
journals. In contrast to trial settings, healthcare providers trying to implement COPD 
programmes in daily life often experience problems with poor adherence or non-
response, owing to lack of time, motivation, or cooperation of patients. This mismatch 
was illustrated by Bjoernshave et al, who showed that the populations included in the 
Cochrane systematic review of pulmonary rehabilitation were highly motivated and 
not representative of the target population, as 75% of the initially suitable patients 
were omitted owing to exclusion or drop out.40 Additionally, positive trial results have 
a higher chance of being referred to in guidelines. For example, the recent American 
Thoracic Society/European Respiratory Society statement41 recommends offering 
pulmonary rehabilitation to patients with milder COPD on the basis of results of two 
positive trials,8;42 whereas negative trials were not taken into consideration when these 
recommendations were formulated.14;43
Strengths and weaknesses of study
To best of our knowledge, this is the largest trial to date assessing the effectiveness of 
integrated disease management in primary care. Important features of this study are 
the long term follow-up and the inclusion of a sizeable real world, heterogeneous study 
population,6;7 which provided sufficient power to study differences in effect in subgroup 
analyses. Additionally, this pragmatic study included a wide range of outcomes relevant 
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to primary care, including objective outcomes (moderate and severe exacerbation 
rates) and subjective measures (quality of life).7 We applied sophisticated regression 
techniques to facilitate the analysis of clustered longitudinal data.
After 24 months, dropout rates were low but selectively higher in patients with worse 
baseline scores. This raises questions of generalisability, although after correction for 
baseline scores no evidence existed for health benefits of the intervention at all, indicat-
ing that dropout is unlikely to have biased the result.
Blinding of participants and clinicians for this type of intervention was impossible. In an 
attempt to minimise bias, blinded research nurses collected the data and patients were 
instructed not to talk about their type of intervention. Although pairing and randomisa-
tion of the practices was done by a member of the research team, he was provided only 
with the characteristics of the practices (age and sex of general practitioner, type of 
practice). He was blinded to the identity of the practices and had no contact with the 
general practitioners.
The included practices were diverse in terms of setting, practice size, distribution of 
ethnic minorities, and level of COPD care at baseline.16 We corrected for most practice re-
lated factors by matching and stratification. However, a pre-existing high level of COPD 
care at baseline may have limited the potential for further improvement in already well 
developed practices. Additionally, because of the complex character of the interven-
tion and the pragmatic study design, we were unable to assess the effect of individual 
components of the intervention.
Implications for practice
We found that an integrated disease management programme implemented in primary 
care did not improve quality of life and exacerbation related outcomes in a representa-
tive group of Dutch primary care patients with COPD. We observed an improved level of 
follow-up and structure of COPD care, as measured with the Patient Assessment Chronic 
Illness Care in the intervention group over the two year period, indicating important 
changes at an organisational level. However, this did not translate into differences in 
health outcomes. When interpreting the unforeseen findings of our study, policy mak-
ers and healthcare professionals should take into account the fact that primary care for 
COPD in the Netherlands is already at a high standard and has further evolved during 
the years of our intervention. Effect sizes might be greater in countries where primary 
care is less well developed.
On the basis of our experiences, an intervention directed at healthcare providers cannot 
be recommended for the generality of COPD patients. We advise application of more 
intensive, but still pragmatic programmes aiming at a selection of patients with a higher 
burden of disease and thus larger room for improvement. Exercise can be recognised as 
a compulsory element of integrated disease management.4 However, healthcare provid-
RECODE: trial results 203
ers and insurers should realise that patients with mild disease often lack the motivation 
or do not feel the need (yet) to commit to an intensive (and expensive) integrated care or 
exercise programme.14 Therefore, resources are probably better spent if patients with a 
higher burden of disease are firstly thoroughly assessed and stratified for risk, after which 
a personalised treatment plan is made using a shared decision making process between 
patient and physician. The individual patient’s needs, preferences, and personal goals 
should play a key role in this process. Finally, we should take into account the fact that 
COPD is only one of the several chronic conditions we manage in primary care. There-
fore, a more fruitful approach might be to consider integrated care for a suite of long 
term conditions with a high burden of disease, of which COPD is one component. The 
absolute number of patients eligible for this selective approach is probably relatively 
low, which makes having proper case management interventions in place possible.
Conclusion
In this study, integrated disease management incorporated in primary care was not 
effective in improving quality of life. The contradictory findings to earlier positive stud-
ies could be explained by differences between interventions (provider- versus patient 
targeted), selective reporting of positive trials, or little room for improvement in the well 
developed Dutch healthcare system.
WHAT THIS PAPER ADDS
What is already known on this subject
In a Cochrane systematic review, integrated disease management programmes for 
chronic obstructive pulmonary disease (COPD) showed clinically relevant effects on 
quality of life and exercise tolerance and reductions in admissions and hospital days
However, most studies were in patients with severe COPD, and the studies in primary 
care recruited patients in secondary care, consisted of palliative programmes for severe 
patients, had a short duration of intervention, or did not correct for cluster analysis
What this study adds
Integrated disease management incorporated in primary care was not effective in 
improving quality of life or exacerbation related outcomes, such as hospital admissions 
and hospital days
The contradictory findings to earlier positive studies could be explained by differences 
between interventions (provider versus patient targeted), selective reporting of positive 
trials, or little room for improvement in the well developed Dutch healthcare system
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A healthcare provider directed intervention cannot be recommended for the general 
population of COPD patients
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In the last decade, integrated disease management (IDM) programmes for patients with 
chronic obstructive pulmonary disease (COPD) have been developed and implemented 
worldwide. In the studies included in this thesis, we evaluated IDM for COPD from dif-
ferent perspectives. More specifically, we aimed to study if IDM is effective in improving 
health outcomes in patients with COPD. 
Main results
In Chapters 1 and 3, we provided a framework for our research question. In Chapters 2 
and 6, we evaluated two individual components of IDM: optimal medication and self-
management. In Chapter 4, in our Cochrane systematic review, we summarized all the 
published evidence on IDM. This review showed that, after following a programme of 
three months, both quality of life and exercise tolerance improved, while hospitalisa-
tions and hospital days were reduced. The number needed to treat in a programme to 
prevent one hospital admission was calculated to be 15. Therefore, we can conclude 
that it is feasible to apply these programmes in a clinical setting. In Chapter 7, we dem-
onstrated the results of IDM in primary care COPD patients in a controlled clinical trial 
(the Bocholtz study) and implementation project (Kroonluchter). At 24 months follow-
up, the improvements in quality of life and exercise tolerance were still well sustained. 
Based on those positive findings, we designed the RECODE trial to confirm our findings 
in a pragmatic cluster randomised trial in primary care (Chapter 8). In a team setting, 
we trained healthcare providers during a two-day course to deliver IDM. The training 
was based on the positive experiences of the Bocholtz and Kroonluchter projects, and 
included several evidence-based elements of COPD care (including smoking cessation, 
motivational interviewing and physiotherapeutic reactivation), targeted at individual 
treatment goals. However, contrary to our expectations, we found no difference be-
tween IDM and usual care in our outcomes at 12 and 24 months follow-up (Chapter 9). 
In addition, a survey was conducted to examine the experiences of healthcare providers 
who have been working for several years in well-established multidisciplinary teams 
across the UK (Chapter 5). They valued working in a team as very satisfying and useful, as 
their meetings not only served to improve communication but also facilitated education 
and teaching. Especially nurses and physiotherapists reported that they felt highly sup-
ported in their decisions by being able to discuss their patients in a holistic way.
Then, the question arises: what can we learn from all these studies and experiences? In 
this chapter we reflect on the different aspects of integrated care (i.e. type of interven-
tion, study population, context and outcomes) that can contribute to the (more or less) 
success of a programme. In addition, we discuss the implications for routine clinical 
practice and make some recommendations for future research.
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IDM: WHICH INTERVENTION OR COMPONENTS ARE MOST EFFECTIVE?
The twenty-six studies included in the Cochrane review (Chapter 4) evaluated the effect 
of IDM on a number of different outcomes. However, due to the variations in healthcare 
providers, components, settings, context and patient populations, this led to a large 
body of evidence in which different combinations were tested. Therefore, it is difficult 
to interpret which intervention is most successful and to provide a blueprint of an ideal 
programme. However, a number of key components can be identified in the literature, 
which should be considered to be included or excluded when implementing an IDM 
programme.
Exercise training or physiotherapeutic reactivation can be considered a cornerstone of 
IDM, as studies focusing mainly on exercise revealed clinically relevant improvements 
in health-related outcomes (Chapter 4). These beneficial effects were already widely 
acknowledged in pulmonary rehabilitation programmes.1;2 However, these programmes 
were usually tested in more severe patients in tertiary care clinics. Besides application in 
highly specialized settings, such as rehabilitation centres, there is evidence that training 
is safe in the home-based or community setting.3-9 This is in line with Chapter 7, in which 
we demonstrated that twice-weekly training in the community, if applied for at least 
three months, is both feasible and effective. Nevertheless, in daily practice the use of 
pulmonary rehabilitation is limited by insufficient motivation or compliance of patients, 
high drop-out rates, or financial problems (Chapter 3). Especially in the early stages, 
patients often consider that the disease is not disabling enough to necessitate reha-
bilitation. We observed this phenomenon in the RECODE study, in which the majority of 
patients were not referred for, or declined participation in an exercise programme, even 
though we had arranged sufficient funding and facilities (Chapter 9). Similarly, in the 
INTERCOM trial, in which COPD patients with less severe lung function impairment were 
trained in the community, the two-year drop-out rates among patients who started the 
programme were 25% in the intervention group compared with 16% in the usual care 
group.3 Whether or not exercise training is effective in patients with milder disease still 
remains unclear, as some studies demonstrated benefits3;10 while others revealed no 
effect.11-13 In short, we can conclude that exercise training can be beneficial in patients 
with mild and moderate disease with considerable dyspnoea (Chapter 7); however, more 
focus is required on feasible and cost-effective strategies that will increase motivation 
and adherence to a programme in this patient group.
In contrast, the evidence for exacerbation-related self-management for COPD patients 
is currently fragmented.14 This was highlighted in Chapter 6, as well as in the subgroup 
analyses of our Cochrane review (Chapter 4). Although initially regarded as an effective 
way to reduce costs related to hospitalisations and hospital days, an increasing number 
of negative trials15-19 now has raised serious concern as to whether self-management is 
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safe and effective. To explain this, in Chapter 6 we further explored the characteristics of 
the negative and positive studies. Although self-management is probably not suitable 
for all patients, it tends to be beneficial in a subgroup of ‘successful self-managers’, repre-
senting about 40% of patients with COPD.16;18 This subgroup was characterised by being 
of relatively younger age, living with others, having severe airflow obstruction, and 
having cardiac comorbidity.16;18 We concluded that patients in the negative trials might 
not be adequately supported. Therefore, it is important to involve a key-person at place 
that could offer support in making treatment decisions. In routine clinical practice, guid-
ance could be accomplished by a well-trained practice nurse or, in the case of multiple 
chronic diseases, by a case manager. It is recommended to involve a dedicated family 
member (or friend) in the exacerbation action plan, so that patients do not feel alone 
when faced with difficult treatment decisions (Chapter 6). Early recognition and treat-
ment of exacerbations is an important aim of a self-management action plan. Probably 
the most effective measure consists of exacerbation management in order to reduce a 
delay of treatment. This could be achieved by simply explaining to patients that a short 
course of oral steroids (including a leaflet with instructions) is particularly effective dur-
ing the first 72 hours.20 Practices that can facilitate prompt access to this simple care, 
within this time span, can achieve success in treating exacerbations as early as possible.
Besides self-management, telehealth is suggested as another solution to involve patients 
in their own treatment decisions. However, two systematic reviews demonstrated con-
flicting results of this intervention in COPD patients.21;22 Another recent trial found that 
telehealth integrated in clinical services did not improve health outcomes, whereas the 
workload and costs increased.23 In addition, the largest pragmatic study to date tested a 
‘whole system demonstrator’ in COPD, diabetes and heart failure patients, with no effect 
on quality of life, costs and psychological outcomes.24 In our trial, although we did not 
implement a true telehealth intervention, we encouraged the intervention practices 
to use a supportive web-based system, intended to facilitate communication by use of 
a patient and professional portal. Although most practices were initially enthusiastic 
about using the system, the overall uptake among providers and patients remained 
low. The most often mentioned reasons for this low uptake were instability of the ap-
plication, disinterest of patients for the portal, and a need to duplicate information into 
separate ICT systems. Therefore, we can conclude that the added value of telehealth in 
COPD for routine practice is limited, the applications need to be thoroughly developed 
and tested, and resources are probably better spent on evidence-based interventions 
such as smoking cessation or exercise. 
What are further options to improve the care of COPD patients in the Netherlands? Other 
recent initiatives developed in the UK have received interest in the Netherlands, as they 
have the potential to decrease admissions or hospital days. For example, the so-called 
‘discharge care bundles’ (administered by nurses on respiratory wards) consist of short 
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lists of evidence-based practices:  smoking cessation, pulmonary rehabilitation refer-
ral, education for exacerbations, inhalation technique instructions, and a follow-up call 
after 48 hours of discharge to check the health status.25 The initial results presented in 
a research update in the journal ‘Thorax’ seem promising, as readmissions have tended 
to decrease and the uptake of evidence-based interventions by patients has increased.25 
Other innovating approaches include the ‘hospital-at-home’ or rapid response teams, 
which can transfer the care for exacerbations from the hospital to the home.26 In the 
Netherlands, within a study setting, the hospital-at-home concept has proven to be a 
safe alternative for usual care.27 It would be interesting to examine the long-term value 
of these initiatives in routine practice. There might be a role for nurses employed by 
home care organisations, who could be trained to deliver this specialised type of home 
care. Unfortunately, implementation of these initiatives is hampered by lack of financial 
coverage by health insurance, as hospitals are currently unable to fund this type of 
outreach care. In addition, as the introduction of the hospital-at-home has implications 
for the treating professionals, we need to explore whether general practitioners or 
pulmonary specialists are willing to assume responsibility for outreach care at home.28 
In addition, we need to explore how best to implement programmes in daily practice. 
For example, in our RECODE trial, we trained the healthcare providers without targeting 
the intervention directly at the patients; consequently, we had little influence on the 
teams’ actions and relied on their own initiatives. This approach has now proven to be 
less successful compared with other studies in which the interventions were directed to 
patients; as illustrated by the Cochrane systematic review (Chapter 4), the Bocholtz and 
Kroonluchter studies (Chapter 7) and the INTERCOM trial.3 However, some critical barri-
ers might exist that hinder the translation of an intervention targeted at the healthcare 
provider to the actual implementation of integrated care. We have planned an addi-
tional study to investigate the diversity in uptake of our intervention (data therefore 
not yet available). Another critical factor for success may be the presence of a dedicated 
leader who feels responsible for the continuity of the programme. Organising weekly or 
monthly team meetings, in which the derived goals are discussed with all team mem-
bers, is considered the key to successful long-term implementation (Chapter 5).  
IDM: FOR WHOM IS IT EFFECTIVE?
Our Cochrane systematic review provides evidence that an intensive IDM programme of 
at least three months duration is effective in improving health outcomes in patients with 
more severe COPD. However, whether these programmes are also effective in primary 
care populations with a considerable proportion of mild and moderate patients remains 
less clear. We found conflicting results in our own studies (Chapters 7 and 9). Unfortu-
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nately, there is a lack of research on this topic in primary care. Because previous studies 
were restricted to subsets of primary care patients, such as only moderate and severe 
patients3;29;30, this makes interpretation less clear. Therefore, to confirm or refute our find-
ings, more research is needed that covers the whole range of primary care patients, with 
sufficient numbers of patients in each disease category.
Unfortunately, it is a common phenomenon in the literature that the efficacy of therapies 
is usually tested in more severely affected patients, in COPD as well as in other chronic 
diseases. This is not surprising, as room for improvement is usually greater in patients 
with more symptoms and frequent exacerbations; moreover, this large room for im-
provement increases the chance of positive findings. This long-standing issue is further 
examined in Chapter 2; here we investigated whether patients included in the six largest 
pharmaceutically-sponsored studies were representative of patients treated in primary 
care. The study revealed that the tested populations were highly selected and differed 
from primary care patients in terms of lung function, gender, exacerbations and quality 
of life. In addition, other research31 revealed a similar selection of patients included in a 
Cochrane systematic review on pulmonary rehabilitation.1 Patients that were included 
were not representative of the target population, as nearly half of the contacted patients 
were not offered screening if they were eligible to participate in the programme, and 
one third of the contacted patients finally completed the programme.31 In contrast, in 
our pragmatic RECODE trial, due to our limited number of exclusion criteria, only 11% of 
all registered primary care COPD patients were not eligible to participate.
In addition, selection bias among participants is further complicated by publication 
bias: positive studies have a higher chance of being published in higher impact journals 
and, therefore, receive more attention from the public, policymakers and guideline 
developers. Consequently, treatment recommendations and guidelines rely on selec-
tive information. As a result, general practitioners (who deal with the majority of COPD 
patients) are left to make treatment decisions based on studies not targeted at their 
own population. Therefore, current guideline developers and trialists should continue 
to emphasise the importance of more studies conducted among milder patient groups. 
This is required not only because mild and moderate patients form 75% of the total 
COPD population, but also because low physical activity, comorbidities, exacerbations, 
anxiety and depression are evidently also apparent in milder stages.2;32  
Until there is more certainty regarding the effectiveness of IDM and its components in 
milder stages, it seems clinically plausible and potentially most (cost-)effective to start 
an IDM programme in primary care in a subset of patients with considerable complaints 
(i.e. frequent exacerbators, patients with more symptoms, patients with diminished 
exercise tolerance), who are sufficiently motivated. When these programmes have found 
their way in primary care, inclusion criteria could be broadened to include milder pa-
tients. However, this will only be of value if such grouping provides clinically meaningful 
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categories of patients that will guide treatment (by predicting treatment success) more 
effectively.32
IDM: TIMING, ROOM FOR IMPROVEMENT AND OUTCOMES
When interpreting the results of studies that examine the effectiveness of IDM, we should 
consider the moment when the studies were developed. The yield of a newly developed 
programme is evidently higher in less developed settings and during the first years of in-
tervention. For example, when tested in 2003 in Canada, the integrated care programme 
of Bourbeau et al. showed dramatic improvements in health-related outcomes.33 When 
(a few years later) the same intervention was replicated in the Netherlands15 and in the 
USA19, the results were less favourable. Thus, the success of a programme is probably not 
only dependent on the setting, but also on the relative timing of interventions amongst 
each other. Similarly, we had successful results in 2005 with our IDM programme, when 
COPD care was less well organised and with considerable underdiagnosis and under-
treatment, whereas we demonstrated no effect in our trial starting in 2010. 
The interpretation of early trial results is complicated also for other reasons. In all 
developed countries, the care for COPD patients has changed considerably over the 
last decade. In the Netherlands, the need for a transfer of care from a secondary to a 
primary setting became increasingly more apparent, which (in 2010) was followed by 
the introduction of a bundled payment system.34;35 According to this system, insurers 
pay a single fee to a ‘care group’ (usually exclusively general practitioners) to cover a 
full range of COPD care services for a fixed period. For the various components of care, 
the care group either delivers the services itself or subcontracts to other care providers 
(physiotherapy, nutritional support, pulmonary specialists consultations). The price for 
the bundle of services is freely negotiated by insurers and care groups; similarly, the fees 
for the subcontracted providers are negotiated by the care group and the providers.34 
A nationwide implementation of COPD IDM is still lacking, but several regional projects 
have been initiated.35;36 Nowadays, almost all practices have some kind of structured 
COPD care, including a practice nurse that performs spirometry and provides regular 
follow-up and monitoring. Although difficult to distinguish, the increased awareness 
and willingness to implement integrated care was also clearly apparent to the general 
practitioners in our usual care group, as our trial was conducted between 2010 and 
2013; this could have reduced the contrast between the groups in the RECODE trial. 
Other recent trials studying components of COPD care in English and Dutch primary 
care settings, with the same absence of effect, illustrate the influence of already high 
levels of usual care in these countries and settings.15;17;23 
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Recent developments in the Netherlands are likely to stimulate further implementation 
of integrated care for COPD. The Lung Alliance Netherlands started the National Action 
Programme on Chronic Lung Diseases, which aims to achieve less burden/deaths, and 
costs for asthma and for COPD. In 2015 the Dutch government plans to change the 
reimbursement structure of GP care, i.e. care for chronic diseases in primary care will 
be financed by only one payment per patient that covers all multidisciplinary care, and 
single consultations by practice nurses will no longer be reimbursed.37 These new plans 
will further motivate GPs to form care groups and multidisciplinary settings for COPD. In 
addition, healthcare insurers are encouraged to provide additional financial incentives 
for new innovations such as self-management and e-health. Similarly, those develop-
ments will further stimulate integrated care, leaving even less room for contrast with 
usual care in a study setting.
In addition, when implementing or testing IDM or other complex interventions, we need 
to consider what the best outcomes are to measure an effective IDM approach. In our 
study carried out in the UK, experienced team members acknowledged that this re-
mains very difficult (Chapter 5). The participants suggested outcomes that were mostly 
related to underlying changes of the system: e.g. satisfaction of the team or the patient, 
decreases in healthcare resources, or the number of interventions implemented. In 
clinical trials, the outcomes are usually both functional (such as quality of life), as well as 
objective (exacerbations, mortality). Satisfaction of patients with the overall system or 
the physician can have an influence on their functional outcomes. Therefore,  concern 
about bias is diminished when findings from both objective and subjective measures 
are consistent.38 In our RECODE trial, we attempted to provide insight into underlying 
behavioural and organisational changes, by using outcomes such as self-management 
(SMAS), smoking behaviour, and integration of care according to the patient (PACIC) 
and providers (ACIC). Usually, compliance or adherence with the intervention is not 
considered as an outcome by itself, although good compliance is a prerequisite for 
effectiveness in routine use.39 For example, the number of interventions implemented 
per patient in an IDM programme (Chapter 5) could give some idea about the level 
of compliance. Unfortunately, in our Cochrane review, process outcomes were hardly 
reported (only in 3 of the 26 studies), making it difficult to establish why one interven-
tion was successful or not. Therefore, we recommend that future studies include process 
outcomes so that data on the intensity, processes and organisational changes can be 
linked to the yield of a programme. 
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MOVING FROM EVIDENCE TO PRACTICE
Having studied several integrated care programmes for COPD, we remain somewhat 
puzzled whether IDM for COPD patients is effective in routine practice, or not. Firstly, 
our systematic review demonstrated that an intensive IDM programme of at least three 
months duration is beneficial in more severe COPD patients. By contrast, we found no 
effect of our RECODE programme in milder COPD patients in primary care. Therefore, 
we cannot recommend our programme for primary care. Secondly, despite the lack of 
evidence of our IDM programme, there are several evidence based components in this 
programme (i.e. exercise therapy and smoking cessation), that deserve to be imple-
mented in every general practice, regardless of being delivered in an IDM programme. 
Unfortunately, when moving from evidence to practice, we have experienced several 
barriers that hamper the implementation of these effective components in routine care.
For example, while reimbursement of evidence-based interventions in a study setting is 
usually not a problem, it is essential to drive implementation of programmes in routine 
practice. Although the Dutch government and healthcare insurers propagate better 
integration and substitution of care, their reimbursement policy is not always directed 
towards doing so. In the RECODE study, we experienced that professionals and patients 
felt frustrated and insecure due to sudden changes in reimbursement policies and 
political whims. For example, the cancellation of coverage of smoking cessation therapy 
after one year of implementation had a detrimental influence on motivation to quit 
smoking. Preventive interventions for COPD, such as exercise therapy and nutritional 
support, required a co-payment or an additional healthcare insurance, which is surpris-
ing since expensive drugs, for example biologic therapies, remain fully reimbursed. In 
fact, the level of evidence for the effectiveness of non-pharmacological interventions in 
COPD is generally higher than that for pharmacological treatment.40 As overprescribing 
is obviously a waste of money, this could be saved and reinvested in commissioning 
high-value services such as (community-based) pulmonary rehabilitation.41 Therefore, 
we should aim to invest in robust strategies for increasing referrals to exercise training, 
and encourage people with breathing problems to take exercise rather than to take 
more medicine (if not appropriately prescribed). 
The future will show whether or not IDM programmes are really stimulated and facili-
tated by the insurance companies and the government. Healthcare professionals need 
to focus on strategies that will increase the motivation of patients to commit to elements 
of integrated care (such as an exercise programme or smoking cessation) and to strive 
for evidence-based prescribing of medication. More personalised treatment, in which 
we take into consideration the needs and preferences of patients, and provide them 
with education and support, could be the key to successful long-term implementation. 
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The treatment of Chronic Obstructive Pulmonary Disease (COPD) is difficult due to large 
variation in clinical presentations, underreported symptoms, frequent comorbidities, 
disappointing effects of medical treatment and problems with giving up smoking. 
Treatment is focused on care rather than cure, and consists on improving quality of life 
and daily functioning of patients. In this thesis we explored different aspects of optimal 
COPD care, including optimal medical treatment and self-management. More specifi-
cally, the primary aim was to study the potential role of integrated disease management 
(IDM) programs for COPD, specifically in primary care. 
PART 1: PRIMARY CARE AND COPD MANAGEMENT
In Chapter 2, we studied the external validity of six large pharmaceutically sponsored 
studies that evaluated medical treatment for COPD, and are often reported in guide-
lines. As the majority of COPD patients are treated by general practitioners who use 
those guidelines, we aimed to examine if the patients included in these studies were 
representative to patients seen in primary care. We compared baseline characteristics 
of seven primary care databases (n=3508) from Europe to baseline data of the large 
studies. Overall, patients in the pharmaceutically sponsored studies were younger, 
predominantly male, with worse lung function and worse quality of life scores than the 
patients in routine primary care. In addition, there were large differences in GOLD stage 
distribution and in the number of patients with frequent exacerbations. We concluded 
that the proportion of primary care patients that were eligible for inclusion in a trial 
ranged from 17% to 42%. Thus, large pharmaceutically sponsored trials included se-
lective patient populations, and it is unclear if these results are applicable to patients 
treated in primary care. 
Pulmonary rehabilitation can improve quality of life and exercise capacity, but the 
uptake is low in routine practice due to high costs, low availability and problems with 
adherence to an active lifestyle after the programs have been finished. This has increased 
the interest to develop and test alternative delivery models of PR. In Chapter 3, we 
positioned our hypothesis, which could be the solution for these problems. We assumed 
that if elements of PR programs could be adapted to primary care, the benefits could 
be extended to a larger, and also milder, part of the COPD population. For example, 
COPD patients could be trained in primary care specialised physiotherapy practices, and 
practice nurses could instruct on selfmanagement or smoking cessation. When general 
practitioners and practice nurses are actively involved in these programs, it is reasoned 
lifestyle benefits could be sustainable, even after the program has been finished. Several 
small studies have showed beneficial effects, however there is a need for large cluster 
randomised trials in primary care to demonstrate the effectiveness.
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PART 2: THE EFFECTIVENESS OF INTEGRATED DISEASE MANAGEMENT FOR 
COPD
In Chapter 4 we presented the results of a Cochrane systematic review that evaluated 
the effectiveness of IDM on quality of life, exercise tolerance and exacerbation related 
outcomes (hospitalisations, hospital days). We included 26 studies (n=2997) of moderate 
to high quality, which included 2997 patients of 11 countries, in which IDM was evalu-
ated compared to usual care. On average, patients were 68 years and had a diminished 
lung function (FEV1% predicted 44). Compared with controls, IDM showed significantly 
and clinically relevant improvements in quality of life (CRQ questionnaire mean differ-
ence (MD) 1.02 (95% confidence interval (CI) 0.67-1.36); SGRQ questionnaire MD -3.71 
(95% CI -5.83- -1.59)) and exercise tolerance (6 minute walking distance MD 43.86 (95% 
CI 21.83-65.89)). In addition, hospitalisation days decreased by 4 days and the number 
of patients with at least one hospital admission decreased from 27 to 20 per 100 (OR 
0.68). The number needed to treat in a program to prevent one hospital admission over 
a year period was calculated as 15. Unfortunately, due to heterogeneity between stud-
ies, no further recommendations could be made regarding the ideal composition of a 
program. Subgroup analyses demonstrated the studies incorporating exercise training 
had the largest benefits, compared to studies focusing mainly on exacerbation self-
management. 
Moving from evidence to practice, we aimed to evaluate the attitudes, perceptions and 
experiences of UK healthcare professionals that are highly experienced in providing IDM 
in a COPD multidisciplinary team. In Chapter 5, we presented the results of a cross-
sectional descriptive online survey amongst 69 members of 10 multidisciplinary teams 
in the UK.  Participation was valued as very useful. They reported the meetings served 
1) to optimise management for complex patients; 2) to increase disease-specific knowl-
edge of members; 3) to improve communication between providers across settings and 
disciplines. They acknowledged the meetings could be improved by proper documenta-
tion of derived agreements and more widely information sharing. General practitioners 
were usually not participating in the meetings, although all members expressed a large 
need to include them. 
Self-management programs for exacerbations aim to teach patients to recognise initial 
symptoms, in order to start therapy at an early stage. Although initially regarded as ef-
fective, recently, there is expanded literature published on this topic with mixed results, 
leading to questions if self-management is a safe and effective treatment. In Chapter 6, 
we explored characteristics of negative and positive studies, in order to provide more 
insight for clinicians. Self-management seems to be successful in a subgroup of 40% of 
COPD patients. This subgroup was characterised by being of relatively younger age, liv-
ing with others,  having severe airflow obstruction, and having cardiac comorbidity. 
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We concluded that patients in the negative trials might not be adequately supported. 
Therefore, it is important to involve a case-manager or key-person at place, for example 
a dedicated spouse, friend or family member, which could offer support in making treat-
ment decisions. Hence, it is clear these programmes need to be implemented in daily 
practice only when patients have the capacity for understanding their symptoms. 
The effectiveness of IDM programs in primary care is discussed in the last three chapters. 
In Chapter 7, we presented the long-term results of two Dutch studies: the Bocholtz 
controlled clinical trial and the Kroonluchter implementation project. In both studies, 
multidisciplinary teams were formed and patients received different components of 
IDM based on individualized treatment goals. After 24 months of follow-up, beneficial 
effects on quality of life (Clinical COPD Questionnaire; CCQ) and exercise tolerance (6 
minute walking distance; 6MWD) were still sustained. In patients with a baseline CCQ 
score above 1 and in patients with an MRC dyspnea score above 2, the long-term effect 
on CCQ score was doubled and even tripled, respectively, compared with patients who 
had lower scores. In patients with a baseline 6MWD under 400meters, the 6MWD dif-
ference remained substantially large during two years, with effect sizes exceeding 100 
meters. 
These successful results needed confirmation in a large cluster randomized trial, the 
RECODE study. Design and baseline results of the study are presented in Chapter 8. In 
this pragmatic study, healthcare providers (general practitioners, practice nurses, phys-
iotherapists) in 20 intervention practices learned during a two-day multidisciplinary 
course tips and tricks of applying successful IDM in primary care. During the course, the 
team redesigned the care process and defines responsibilities of different caregivers. 
Practice-tailored feedback reports were provided at baseline, and at 6 and 12 months. 
The team learned the details of an ICT program that supports recording of process and 
outcome measures. Afterwards, they designed a time-contingent individual practice 
plan, agreeing on steps to be taken in order to integrate a COPD IDM program into daily 
practice. The control group continued usual care. Patients were followed up at 6, 9, 12, 
18 and 24 months. The primary outcome was disease-specific health related quality of 
life, as measured with the CCQ. Secondary outcomes were generic health related quality 
of life, self-management, dyspnoea, exacerbation related outcomes, level of physical 
activity, smoking status, and level of integration of care.
The results of the RECODE trial were described in Chapter 9. After 12 months, we 
concluded there was no difference between groups on the CCQ (Mean difference [MD] 
-0.01; 95% CI -0.1-0.08; p=0.8). After 12 months, we found no differences in secondary 
outcomes between groups, except for the PACIC domain ‘follow-up/coordination’ (in-
dicating improved integration of care) (MD 0.15; p=0.01) and proportion of physically 
active patients (MD 10.1; p <0.001). After 24 months, there were no differences in out-
comes, except for the PACIC instrument for ‘follow-up/coordination’. The contradictory 
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findings to earlier positive studies could be explained by differences between interven-
tions (provider- versus patient-targeted), selective reporting of positive trials, or little 
room for improvement in the well-developed Dutch healthcare system. 
In Chapter 10, we reflected on our findings and discussed the implications for routine 
practice. Having studied several integrated care programmes for COPD, we remain 
puzzled whether IDM is potentially effective in routine practice. We concluded that the 
effectiveness of IDM seems highly dependent on the tested interventions, the setting, 
the population and the outcomes chosen. Our Cochrane review demonstrated that an 
intensive IDM program is effective in more severe COPD. Due to a minority of studies in 
milder patients and conflicting results in our studies, it remains less clear whether these 
programs are also effective in primary care populations with a considerable proportion 
of mild and moderate patients. Several elements of IDM have been proven to be more 
or less successful. Exercise training is beneficial, but the effects of exacerbation self-
management and telehealth are less clear. Besides patient-related outcomes, we recom-
mend to include process and compliance outcome measures in studies, so that data 
about the intensity, processes and organisational changes can be linked to the results of 
a program.  Although the Dutch government and healthcare insurers propagate better 
integration and substitution of care, their reimbursement policy is not always directed 
towards doing so. The evidence for effectiveness of non-pharmacological interventions 
is generally higher than for pharmacological treatment. The money that could be saved 
by more evidence-based prescribing of medication could be invested in increased avail-
ability of exercise programs. As healthcare professionals, we need to focus on strategies 
to increase the motivation of our patients. We should try to make treatment plans as 
individual as possible, by adequately informing patients  about their disease and about 







De behandeling van Chronic Obstructive Pulmonary Disease (COPD) is lastig. Hier zijn 
diverse redenen voor: het klinische beeld wisselt sterk tussen patiënten, het effect van 
medicatie is beperkt en patiënten vinden het lastig om te stoppen met roken. COPD is 
niet te genezen en de behandeling is dan ook gericht op het optimaal omgaan met de 
klachten. In dit proefschrift bestudeerden we verschillende aspecten van optimale zorg 
voor COPD patiënten. Meerdere onderdelen van zorg kunnen gecombineerd worden in 
een geïntegreerd zorgprogramma, waarin hulpverleners de zorg op elkaar afstemmen 
en efficiënt samenwerken. Het hoofddoel van dit proefschrift was om een onderbou-
wing te geven van de effectiviteit van zo’n geïntegreerd zorgprogramma voor COPD 
patiënten in het algemeen, maar specifiek in de eerste lijn. Daarnaast werden ook enkele 
specifieke onderdelen van een zorgprogramma (medicatie en zelf-management) uitge-
licht.
DEEL 1: DE EERSTE LIJN EN COPD MANAGEMENT
Medicamenteuze adviezen in richtlijnen voor huisartsen zijn gebaseerd op resultaten 
van grote farmaceutische studies. Het is de vraag of de patiënten die geïncludeerd wer-
den in deze studies ook vergelijkbaar zijn met de patiënten die in de eerste lijn worden 
gezien. Hoofdstuk 2 beschrijft een onderzoek naar de externe validiteit van zes grote 
farmaceutische studies, die veelvuldig geciteerd worden in richtlijnen. We vergeleken 
3508 COPD patiënten uit zeven Europese huisartsdatabases met de patiënten die geïn-
cludeerd waren in deze studies. De studies includeerden overwegend jongere mannen 
met meer pakjaren, veel klachten, een slechtere kwaliteit van leven en meer exacerbaties 
per jaar. Het percentage eerstelijns COPD patiënten dat in aanmerking kwam om deel 
te nemen als proefpersoon in zo’n studie loopt uiteen van 17 tot 48%. Gezien de sterke 
selectie in patiënten populaties, is het onduidelijk of de resultaten van deze studies ook 
toepasbaar zijn op eerstelijns COPD patiënten. 
Longrevalidatie zorgt voor verbeteringen in patiënt-uitkomsten, echter de behandeling 
is duur, er is gebrek aan capaciteit, en patiënten hebben moeite om de levensstijl na 
afloop van het programma te continueren. In Hoofdstuk 3 positioneerden wij in een 
beschrijvende review een hypothese, die een oplossing zou kunnen bieden voor deze 
problemen. Veel van de onderdelen van longrevalidatie kunnen worden aangeboden 
in een geïntegreerd eerstelijns COPD zorgprogramma, zoals bewegingsprogramma’s 
bij fysiotherapeuten, stoppen met roken begeleiding en zelfmanagement bij de 
praktijkverpleegkundige en voedingsadvies bij de diëtiste. Het is belangrijk dat goed 
overleg plaatsvindt met de longarts, en door de huisarts en praktijkverpleegkundige 
actief bij het programma te betrekken en de patiënt in de eigen vertrouwde omgeving 
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te behandelen, is de kans groter dat de positieve veranderingen na het volgen van het 
programma langer beklijven. Enkele kleine studies laten positieve effecten zien van 
dergelijke eerstelijns geïntegreerde zorgprogramma’s, maar een onderbouwing in een 
grote cluster gerandomiseerde trial ontbreekt nog. 
DEEL 2: DE EFFECTIVITEIT VAN GEÏNTEGREERDE ZORGPROGRAMMA’S VOOR 
COPD PATIËNTEN 
In Hoofdstuk 4 beschrijven wij in een Cochrane systematische review de effectiviteit 
van geïntegreerde COPD zorgprogramma’s op kwaliteit van leven, inspanningstole-
rantie en exacerbatie gerelateerde uitkomsten (zoals ziekenhuisopnames). Hiervoor 
analyseerden we alle gepubliceerde artikelen in de medische literatuur. We voegden 
de resultaten van 26 trials samen, van redelijke tot hoge kwaliteit, met in totaal 2997 
deelnemers in 11 landen waarin zo’n multidisciplinaire aanpak werd vergeleken met 
standaardzorg. De patienten waren gemiddeld 68 jaar en hadden een fors verminderde 
longfunctie (voorspeld FEV1 van gemiddeld 44%). COPD patienten die behandeld wer-
den in een zorgprogramma lieten verbeteringen zien op ziekte specifieke kwaliteit van 
leven (CRQ vragenlijst gemiddeld verschil (MD) 1.02 (95% betrouwbaarheidsinterval(BI) 
0.67-1.36); SGRQ vragenlijst MD -3.71 (95% BI -5.83- -1.59)), en inspanningstolerantie 
(6 minuten wandeltest MD 43.86 meter (95% BI 21.83-65.89)). Het percentage mensen 
dat in het ziekenhuis terechtkwam daalde significant van 27 naar 20 per 100 (oddsratio: 
0.68; ‘number needed to treat’: 15), en het aantal opnamedagen nam af met 4 dagen. 
Vanwege klinische heterogeniteit tussen de interventies was het niet mogelijk een 
uitspraak te doen over de ideale samenstelling van een zorgprogramma. Uit subgroep 
analyses bleek daarnaast dat interventies waarbij de nadruk op trainen lag, de grootste 
verbeteringen waarneembaar waren op kwaliteit van leven en inspanningstolerantie, 
vergeleken met studies waarbij de nadruk lag op zelfmanagement. 
Er is geen onderzoek beschikbaar waarin de opvattingen en ervaringen van hulpverle-
ners die een geïntegreerd zorgprogramma verlenen in een multidisciplinair team wordt 
beschreven. Wat vinden zij van het werken in zulke teams, wat bespreken ze, en zijn 
er mogelijkheden tot verbetering? In Hoofdstuk 5 beschrijven wij de resultaten van 
een enquête die is afgenomen onder 69 professionals werkzaam in 10 multidisciplinaire 
COPD teams in Engeland, die al jaren geïntegreerde zorgprogramma’s verlenen. Zij ga-
ven aan dat zij zeer tevreden waren over het werken in zulke teams. Hun wekelijkse 
overleggen dienden om samen tot een behandelplan te komen, om van elkaar te leren, 
en om de communicatie tussen de verschillende professies te verbeteren. Huisartsen 
waren veelal nog niet betrokken bij deze multidisciplinaire teams, maar alle teams 
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gaven aan hier veel behoefte aan te hebben. De overleggen konden verder verbeterd 
worden door de gemaakte afspraken uniform te registeren, en het delen van informatie 
tussen de disciplines te verbeteren. 
Zelfmanagement programma’s voor exacerbaties zijn erop gericht om patiënten begin-
nende symptomen te leren herkennen, zodat door vroegtijdig ingrijpen verergering en 
complicaties kunnen worden voorkomen. De programma’s zijn veelvuldig bestudeerd 
en aanvankelijk met veel enthousiasme ontvangen. Echter, recentelijk zijn enkele grote 
studies verschenen met negatieve resultaten, zoals hogere sterftecijfers in de interven-
tiegroep, waardoor het de vraag is of zelfmanagement programma’s inderdaad effectief 
en veilig zijn. In Hoofdstuk 6 beschrijven wij in een commentaar de eigenschappen van 
zowel positieve als negatieve studies, om op die manier inzicht te bieden in deze vraag-
stelling. Het blijkt dat zelfmanagement niet voor iedereen geschikt en veilig is, maar 
mogelijk effectief kan zijn in 40% van de COPD patiënten, mits voldoende ondersteund 
door een case-manager of voor de patiënt vertrouwd persoon, zoals bijvoorbeeld een 
familielid of vriend. De patiënt kan dan worden gesteund bij moeilijke beslissingen zoals 
wel of niet starten met medicatie voor een mogelijke exacerbatie. Ook zou de case-
manager zelf een vinger aan de pols moeten houden, omdat het bekend is dat COPD pa-
tiënten gewoonlijk te laat of niet aan de bel trekken bij een exacerbatie. De geschiktheid 
van zelfmanagement voor COPD patiënten moet in de praktijk per patiënt zorgvuldig 
worden afgewogen, en alleen worden aangeboden aan patiënten die voldoende inzicht 
hebben in hun ziekte. 
De effectiviteit van geïntegreerde zorg in de eerste lijn wordt besproken in de laatste 3 
hoofdstukken. 
In Hoofdstuk 7 presenteren wij de gecombineerde lange termijn resultaten van een 
gecontroleerde klinische studie (de Bocholtz studie uit Limburg) en een implemen-
tatiestudie (het Kroonluchter programma uit Rotterdam). In beide studies werd een 
multidisciplinair team gevormd en kregen patiënten verschillende onderdelen van zorg 
aangeboden gebaseerd op hun persoonlijke behandeldoelen. Na 24 maanden bleek dat 
de verbeteringen op kwaliteit van leven en inspanningstolerantie die na 12 maanden 
al gemeten waren, gehandhaafd bleven. Bij patiënten met slechtere kwaliteit van le-
ven (CCQ score >1) was het effect zelfs verdubbeld, en bij patiënten met aanzienlijke 
kortademigheid (MRC score >2), was het effect zelfs verdrievoudigd. Bij patiënten met 
beperkte inspanningstolerantie (6 minuten wandeltest < 400 meter), was de verbetering 
in conditie nog steeds meer dan 100 meter na twee jaar.
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Met deze kennis en positieve ervaringen werd de RECODE trial ontworpen; opgezet 
als een grootschalig, cluster gerandomiseerd onderzoek voor de eerste lijn met 24 
maanden follow-up. De opzet van dit onderzoek en de baseline resultaten staan be-
schreven in Hoofdstuk 8. Huisartspraktijken werden gerandomiseerd voor het verlenen 
van een geïntegreerd zorgprogramma dan wel de huidige zorg. Zij namen deel aan 
een tweedaagse nascholing, samen met hun praktijkverpleegkundige, fysiotherapeut 
gespecialiseerd in COPD zorg en eventueel een diëtist. Tijdens de nascholing werden 
alle onderdelen van een geïntegreerd zorgprogramma bijgebracht, en werden de teams 
en patiënten ondersteund door middel van een ICT applicatie (Zorgdraad). De contro-
legroep continueerde de huidige zorg. Patiënten werden gevolgd op 6, 9, 12, 18 and 
24 maanden. De primaire uitkomstmaat was ziekte-specifieke kwaliteit van leven na 12 
maanden, gemeten met de CCQ. De secundaire uitkomstmaten waren kwaliteit van le-
ven, zelfmanagement, kortademigheid, dagelijkse activiteiten, mate van geïntegreerde 
zorg, rookstatus en exacerbaties. 
De resultaten van de RECODE studie staan beschreven in Hoofdstuk 9. Door middel van 
randomisatie kwamen 20 huisartspraktijken (554 patiënten) in de interventiegroep en 
20 huisartspraktijken (532 patiënten) in de controlegroep terecht. Er was geen verschil 
tussen beide groepen op de CCQ na 12 maanden (MD -0.01; 95% BI -0.01-0.08; p=0.08). 
Na 12 maanden waren er geen verschillen tussen beide groepen in de secundaire 
uitkomstmaten, behalve in de mate van coördinatie/follow-up van geïntegreerde zorg, 
zoals gemeten met de PACIC (MD 0.15; p = 0.01). Daarnaast gaf een hoger percentage 
patiënten na 12 maanden aan dat zij meer waren gaan bewegen (MD 10.1; p <0.001). 
Na 24 maanden was alleen de coördinatie en follow-up van geïntegreerde zorg nog 
significant verschillend, zoals gemeten met de PACIC. Onze negatieve bevindingen 
zijn tegenstrijdig met de studies die we evalueerden voor onze systematische review. 
Dit kan verklaard worden door verschillen in interventies (gericht op patiënten of op 
hulpverleners zoals bij RECODE), selectieve rapportage van positieve studie resultaten, 
of weinig ruimte voor verbetering in het al goed ontwikkelde gezondheidszorg systeem 
in Nederland. 
Hoofdstuk 10 bevat de algemene discussie. Na het bestuderen van verschillende 
geïntegreerde zorgprogramma’s, blijven we vertwijfeld achter of deze effectief zijn in 
de dagelijkse praktijk. De opbrengst is niet alleen afhankelijk van gekozen interventie 
en populatie, maar ook van de kwaliteit van de huidige zorg. Uit onze Cochrane review 
blijkt dat geïntegreerde zorgprogramma’s in ieder geval effectief zijn voor patiënten met 
matig ernstig tot zeer ernstig COPD. Er is gebrek aan onderzoek en bewijs in patiënten in 
de eerste lijn die minder ernstig COPD hebben, en onze studies brachten tegenstrijdige 
resultaten. Verschillende onderdelen van geïntegreerde zorg zijn de laatste jaren meer 
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of minder effectief gebleken. Bewegingstherapie zou niet mogen ontbreken, maar voor 
exacerbatie actieplannen en telehealth is minder vaststaand bewijs. Om meer inzicht te 
bieden in waarom de ene interventie wel effectief is en de andere niet, lijkt het zinvol om 
niet alleen patiënt-gerelateerde uitkomsten te meten, maar ook bij te houden hoe de 
compliantie van patiënten en proces veranderingen op organisatie niveau zijn. Alhoewel 
de overheid en zorgverzekeraars (de onderdelen van) geïntegreerde zorgprogramma’s 
sterk aanbevelen, is hun beleid hier niet altijd op gericht. Niet medicamenteuze inter-
venties zoals bewegingstherapie en stoppen met roken zijn voor COPD patiënten effec-
tiever dan medicatie, maar worden niet altijd zonder meer vergoed, hetgeen voor veel 
onrust en gebrek aan motivatie zorgt. Het geld dat zou kunnen worden bespaard door 
kritisch medicatie voor te schrijven, zou kunnen worden besteed aan het vergroten van 
de capaciteit voor preventieve bewegingsprogramma’s. Wij als hulpverleners zouden 
daarnaast veel energie moeten steken in het vergroten van de motivatie van onze COPD 
patiënten. Door patiënten continu te informeren over hun ziekte en mogelijkheden 
voor verbetering, kunnen we de behandeling zo individueel mogelijk maken, en deze 





Er zijn veel mensen die hebben bijgedragen aan de totstandkoming van dit proefschrift. 
In de eerste plaats wil ik alle patiënten bedanken die deelnamen aan de RECODE studie 
en die veel tijd en energie kwijt waren aan de afname van onze vragenlijsten. Daarnaast 
uiteraard alle huisartsen die mee hebben gedaan, en in de interventiegroep ook hun 
praktijkverpleegkundigen, fysiotherapeuten, diëtisten en longartsen die de nascholing 
wilden volgen en aan de slag gingen met de interventie: zonder jullie geen studie en 
daarom heel veel dank. 
Mijn promotoren Pim, Maureen en Jacobijn: heel erg bedankt dat jullie mij gesteund 
hebben en de vrijheid hebben gegeven om het onderzoek te combineren met de oplei-
ding. Dankzij jullie waardevolle input en inzichten heb ik veel geleerd. Niels, als copro-
motor en jouw eerste promovenda was ik verzekerd van een enorm goede begeleiding: 
jouw reactietijd is onvoorstelbaar, ik had mij geen betere copromotor kunnen wensen. 
Erg veel dank voor alle kansen, de gezellige avonden op congressen en de nodige dosis 
humor waarmee we alles konden relativeren. 
Het RECODE team heeft drie jaar lang gezorgd dat onze studie een succes werd. Melinde, 
als mede-promovendus bij RECODE heb ik veel aan je gehad, vooral toen ik de oplei-
ding deed. We vulden elkaar aan en ik heb het samenwerken erg gezellig gevonden, 
vooral tijdens de congressen! Apo, ik bewaar goede herinneringen aan het “bouwen 
van casefinders”; maar gelukkig hoeft het nooit meer. De onderzoeksmedewerkers en 
secretaresses Astrid, Aysun, Wilma, Wilma, Leolien, Anita, en in het bijzonder Irene: dank 
voor alle interviews en jullie tomeloze inzet. Ineke, bedankt voor je hulp aan het base-
line paper. Het team van Zorgdraad en in het bijzonder Coert voor hun bijdrage aan de 
studie en het bouwen van de applicatie. Erwina, heel erg bedankt voor je hulp en inzet 
om bij half Den Haag een spirometrie test af te nemen.
Beste Nynke, met jou een Cochrane review schrijven was geweldig, heel veel dank voor 
alle gezellige uren en dat je me daar zo bij geholpen hebt.
Dear Sarah and Michael, thanks for giving me the opportunity to work with you in 
London, I learned a lot, thanks so much! 
Alle collega’s op de afdeling PHEG: veel dank voor hun betrokkenheid, en in het bijzon-
der mijn mede-promovendi/AIOTHO’s Marjolein, Iris, Annelore, Krista, Antonette, Marije 
en Rosalinde met wie ik het laatste jaar een kamer heb gedeeld. Beste Anne, samen 
hebben we een lang traject gebikkeld (en we zijn nog niet klaar), het was fijn om dat met 
jou te delen. Mede HAIO’s Willemijn, Mascha, Lysbert, Annejet, Muriël, Amy, Margot en 
Jisva: veel dank voor jullie interesse en de gezelligheid.
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Ik ben de SBOH en de Huisartsopleiding Leiden erg dankbaar voor het volgen van een 
AIOTHO traject, en daarnaast Gerard Smit, mijn opleider in het  eerste jaar die het moge-
lijk maakte om de opleiding en onderzoek succesvol te combineren. 
Alle vriendinnetjes en in het bijzonder Cordial Bizar, HW4c en de meiden van Formula: 
veel dank voor de mooie avonden en weekenden. Lieve Dag en Suus, met jullie aan mijn 
zij als paranimf en mede-AGIKO’s maakt het promoveren voor mij extra bijzonder en 
hopelijk wat meer ontspannen, alvast bedankt voor jullie hulp!
Mijn schoonfamilie was altijd enorm betrokken en geïnteresseerd, waar ik heel dankbaar 
voor ben. Lieve oma, ik ben erg blij dat je mijn promotie mag meemaken, deze studie 
zit er weer op! Lieve Fleur en Marc, ondanks dat we alle drie ander werk hebben wordt 
elk succes gevierd op de groepsapp, ik ben blij met zo’n lieve zus en broer die er altijd 
voor me zijn. Lieve mama, jouw steun en betrokkenheid is enorm, heel veel dank. Lieve 
pap, jij bent mijn grote voorbeeld, ik hoop dat ik later zo’n huisarts word als jij. Heel erg 
bedankt allebei dat jullie er altijd voor me zijn. 
Lieve Wout, samen zijn, lekker kletsen en leuke dingen doen zijn de zaken die uiteinde-
lijk het allerleukste zijn en waar ik heel veel van geniet. Ik hoop dat ons nog heel veel 
leuks met veel lachen staat te wachten!  
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